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Zusammenfassung 
Durch Analyse der Subtraktion-cDNA Bibliothek einer humanen Lungentumor 
Zelllinie haben wir ein neues Mitglied der S100 Genfamilie identifiziert und 
charakterisiert, welches S100A14 benannt wurde. Die vollständige cDNA hat eine 
Länge von 1067 bp und kodiert für ein Protein von 104 Aminosäuren, welches die 
S100-spezifische Kalzium-bindende Domäne enthält und die größte Homologie zu 
S100A13 zeigt. Das Gen wird in normalen humanen Epithelien ubiquitär 
exprimiert, zeigt jedoch Expressionsverluste in vielen Tumorzelllinien aus 
unterschiedlichem Gewebe. Im Gegensatz zu Tumorzelllinien ist S100A14 auf 
mRNA- und Proteinebene in vielen humanen Primärtumoren stärker exprimiert, 
unter anderem in Lungen- und Brustkarzinomen. Das Protein ist vorzugsweise in 
der Region der Plasmamembran und im Zytoplasma lokalisiert.  
Das Gen liegt auf Chromosom 1 im Bereich der Bande 1q21, einer Region 
mit hoher chromosomaler Instabilität in Malignomen, in der sich auch mindestens 
16 weitere S100 Gene befinden. Es ist aus vier Exons und drei Introns aufgebaut 
und erstreckt sich über 2165 bp genomischer DNA.  
In der 5´ Region proximal der transkriptionellen Initiationsstelle des S100A14 
Gens wurde mit Hilfe von Deletionsmutationen eine minimale Promoteregion 
identifiziert, die vermutlich zur basalen Promoteraktivität beiträgt. 
Um den Mechanismus der erhöhten S100A14 Expression in Lungen- und 
Brustkarzinomen zu verstehen, haben wir die Effekte des EGF (epidermal growth 
factor) und des TGF-α (transforming growth factor-α) untersucht. Beide Faktoren 
sind Liganden des ERBB Rezeptors und induzieren in der immortalisierten 
bronchialen Epithelzelllinie S100A14 Expression. Unter Verwendung spezifischer 
Inhibitoren konnte gezeigt werden, dass für die EGF-vermittelte transkriptionelle 
Induktion der ERK1/2 Signalweg (extracellular signal-regulated kinase) 
verantwortlich ist und eine de novo Proteinsynthese erfordert. Diese Ergebnisse 
unterstützend konnte immunhistologisch eine signifikante Korrelation zwischen der 
Überexpression von ERBB2 und S100A14 in primären Brustkarzinomen 
nachgewiesen werden. 
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Phorbolester-12-Myristat-13-Acetat (PMA) verstärkte gleichfalls die S100A14 
mRNA Expression in 9442 Zellen, was eine Regulation durch die Protein Kinase C 
(PKC) vermuten lässt. Die PMA-induzierte Expression von S100A14 wird ebenso 
wie die TGF-α/EGF-Induktion durch die Aktivierung des ERK1/2 Signalweges 
vermittelt. 
In Anbetracht der großen Bedeutung der ERK1/2 und PKC Signalwege in der 
Tumorentstehung und Tumorprogression ist zu vermuten, dass S100A14 über die 
aberrante Regulation dieser Signalwege an die maligne Transformation gekoppelt 
ist. 
 
Schlagwörter: S100A14, S100, EGF, TGF-α, PKC, PMA, ERK1/2 
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Abstract 
By analysing a human lung tumour cell line subtraction cDNA library, we have 
identified and characterized a novel member of the human S100 gene family that 
we designated S100A14. The full-length cDNA is 1067 bp and encodes a putative 
protein of 104 amino acids. The predicted protein contains the S100-specific EF-
hand calcium-binding domain and shares the highest sequence homology to 
S100A13. The gene is ubiquitously expressed in normal human tissues of 
epithelial origin, with the highest expression in colon. S100A14 transcript was 
found to be down-regulated in many immortalized and tumour cell lines from 
diverse tissues. In contrast to the tumour cell lines, S100A14 shows up-regulation 
at the mRNA and protein level in many human primary tumours, including lung and 
breast carcinomas. S100A14 protein localizes predominately to the plasma 
membrane and the cytoplasm.  
We localized the S100A14 gene to a region of chromosomal instability on 
human chromosome 1q21, where at least 16 other S100 genes are clustered. We 
subsequently resolved the gene structure of S100A14 in human by demonstrating 
its organization of four exons and three introns spanning a total of 2165 bp of 
genomic sequence. By analysing the proximal 5’ upstream region of the S100A14 
transcription initiation site, we identified the minimal promoter region which 
possibly contributes to the basal activity of the promoter fragment. 
To elucidate mechanisms whereby S100A14 expression is enhanced in lung 
and breast tumours, we studied the effects of epidermal growth factor (EGF) and 
transforming growth factor-α (TGF-α) on its expression. Both are ligands of ERBB 
receptor and induced S100A14 expression in the immortalized bronchial epithelial 
cells. By use of specific inhibitors, we found that EGF-mediated transcriptional 
induction of S100A14 involves extracellular signal-regulated kinase (ERK1/2) 
signalling and requires de novo protein synthesis. In support of these findings, we 
demonstrated by immunohistochemistry a significant correlation between ERBB2 
and S100A14 protein overexpression in primary breast carcinomas. 
Our studies showed that the phorbol ester 12-myristate 13-acetate (PMA) 
increases S100A14 mRNA expression in immortalized bronchial epithelial cells 
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suggesting regulation by protein kinase C (PKC). Similar to TGF-α/EGF induction, 
the PMA-induced S100A14 expression was also mediated by activation of the 
ERK1/2 signalling cascade.  
Considering the importance of the ERK1/2 and PKC signalling pathways in 
tumour development and progression we suggest that it is the aberrant regulation 
of these signalling cascades that couples S100A14 to malignant transformation. 
 
Keywords: S100A14, S100, EGF, TGF-α, PKC, PMA, ERK1/2 
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1 Introduction 
1.1 Multi-Step Progression of Tumours 
Several lines of evidence indicate that tumorigenesis in humans is a multi-step 
process, formally analogous to Darwinian evolution, in which a succession of 
genetic and epigenetic changes, each conferring a different type of growth 
advantage, leads to the progressive conversion of normal cells into cancer cells 
(Nowell, 1976). The accumulation of genetic changes liberates neoplastic cells 
from the homeostatic mechanisms that govern normal cell proliferation. 
Observations of human cancers and animal models implicate a limited number of 
molecular pathways, the disruption of which contributes to most cancers. In 
humans, at least four to six distinct somatic mutations are required to reach this 
state (Renan, 1993; Kinzler et al., 1996).  
Several properties are shared by most of human tumours: self-sufficiency in 
growth signals, insensitivity to growth-inhibitory signals, evasion of programmed 
cell death (apoptosis), limitless replicative potential, sustained angiogenesis, and 
tissue invasion and metastasis (Hanahan and Weinberg, 2000). Each of these 
novel capabilities acquired during tumour development represents the successful 
breaking of an anti-cancer defense mechanism applied by cells and tissues. 
Molecular studies have identified three groups of genes, which are frequently 
deregulated in cancer: 
1. proto-oncogenes, which are activated by mutations and become 
oncogenes. Their acquired oncogenic functions lead to uncontrolled 
cellular growth and proliferation. 
2. tumour-suppressor genes, which normally negatively regulate cell growth 
and proliferation preventing the development of tumour. Loss or 
mutational inactivation of these genes leads to the deregulation of cell 
cycle progression as well as other intracellular processes resulting in 
cancer progression. 
3. genes responsible for maintaining the genomic integrity and genes 
encoding the DNA-repair system. Loss of function of these genes results 
in a genetic instability that is characteristic of tumour cells. 
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Development of gene-expression profiling as well as advances in tumour 
diagnosis revealed, however, a striking conceptual inconsistency in the prevailing 
multi-step model of tumour progression (Bernards and Weinberg, 2002). Gene-
expression pattern of metastatic tumour cells is often strikingly similar to that of the 
cells confined to the primary tumour mass from which they were derived. Equally 
relevant are other studies in which the gene-expression profiles of the dominant 
populations of breast-cancer cells within a primary tumour mass have been used 
to predict, with 90% accuracy, whether the tumour will remain localized or whether 
the patient will experience metastases and disease relapse.  
Based on these findings, it is suggested that a subset of the mutant alleles 
acquired by incipient tumour cells early in tumorigenesis confer not only the 
selected replicative advantage, but also, later in tumorigenesis, the tendency to 
metastasize. This tendency will become manifest only much later in tumour 
progression, in the context of yet other mutations that have struck the genomes of 
descendant cells. 
This reasoning has important implications. First, genes and genetic changes 
specifically and exclusively involved in orchestrating the process of metastasis do 
not exist. Instead, it is the particular combination of genes that enables cells to 
create primary tumour mass that also empowers them to become metastatic. 
Second, because important components of the genotype of metastasis are already 
implanted in cells relatively early in tumorigenesis, even relatively small primary 
tumour cell populations may already have the ability to dispatch metastatic cells to 
distant sites in the body. 
Moreover, several independent lines of evidence seem to support the idea 
that tumorigenesis is governed not only by the tumour cells per se, but also by the 
microenvironment (Chang and Werb, 2001). For example, tumour-associated 
fibroblasts can direct tumour progression (Olumi et al., 1999), and endothelial cells 
foster tumour angiogenesis (Carmeliet and Jain, 2000). Inflammatory cells might 
also promote tumour development, as shown by studies on skin tumorigenesis in 
K14-HPV16 transgenic mice that lack mast cells or metalloproteinase-9 (Coussens 
et al., 1999; Coussens et al., 2000). 
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1.2 The S100 Protein Family  
Calcium (Ca2+) functions as a universal second messenger that plays a regulatory 
role in a great variety of cellular processes such as memory and transmission of 
nerve impulses, muscle contraction, secretion, cell motility and volume regulation, 
cell growth and differentiation, gene expression, cross-talk between different 
enzyme systems, apoptosis, and necrosis (Berridge et al., 2000). The Ca2+ 
signalling networks are composed of many molecular components including the 
large family of Ca2+-binding proteins characterized by the EF-hand structural motif 
(Kawasaki et al., 1998). Certain members, notably calbindin D28k and 
parvalbumin, serve as cytosolic Ca2+ buffers, whereas others, such as calmodulin, 
troponin C, and the S100 proteins, are Ca2+-dependent regulatory proteins.  
S100 proteins represent the largest subgroup within the EF-hand protein 
family. They have received increasing attention in recent years due to their 
association with various human pathologies including cancer, neurodegenerative 
disorders, inflammation, and cardiomyopathy (Heizmann et al., 2002). Moreover, 
they have been of value in the diagnosis of these diseases. Twenty-two members 
have been identified so far. Unlike the ubiquitous calmodulin, most of them show 
cell- and tissue-specific expression.  
S100 proteins are small (10 to 12 kDa) acidic proteins that form homo- and 
heterodimers. They are characterized by a pair of helix-loop-helix (the EF-hand) 
motifs connected by a central hinge region. The two EF-hand structural motifs 
display different affinities for calcium. The C-terminal EF-hand contains the 
canonical Ca2+-binding loop consisting of 12 amino acids. The N-terminal EF-hand 
consists of 14 amino acids and is specific for S100 proteins. Upon Ca2+ binding 
S100 proteins undergo a conformational change required for target recognition 
and binding. Generally, the dimeric S100 proteins bind four Ca2+ per dimer. 
Besides Ca2+, a number of S100 proteins bind Zn2+ with a wide range of affinities. 
For S100B, S100A5, and S100A13 Cu2+ binding was reported (Nishikawa et al., 
1997; Schäfer et al., 2000; Mandinova et al., 2003).  
Another distinguishing feature of S100 proteins is that individual members 
are localized within specific cellular compartments from which some of them re-
locate upon Ca2+ or Zn2+ activation (Davey et al., 2001). A signalling event is thus 
transduced in a temporal and spatial manner by specific targeting for each S100 
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protein. Furthermore, some S100 proteins are secreted from cells acting in a 
cytokine-like manner. The individual members are believed to utilize distinct 
pathways (ER-Golgi route, tubulin- or actin-dependent) for their translocation/ 
secretion into the extracellular space (Hsieh et al., 2002). S100B and S100A12 
specifically bind to the surface receptor RAGE (receptor for advanced glycation 
endproduct) – a multiligand member of the immunoglobulin superfamily (Schmidt 
et al., 2000). The extracellular levels of S100B thereby play a crucial role in that 
nanomolar concentrations of S100B have trophic effects on cells whereas 
pathological levels (as found in Alzheimer’s patients) induce apoptosis (Huttunen 
et al., 2000). 
Characteristic of the S100 protein family is that most S100 genes form a 
cluster on human chromosome 1q21, a region frequently involved in chromosomal 
rearrangements and deletions in human cancers (Schäfer et al., 1995; Weterman 
et al., 1996; Gendler et al., 1990).  
S100 proteins were recently found to be reliable diagnostic markers for 
hypoxic brain damage and for monitoring the outcome after cardiac arrest (S100B; 
Böttiger et al., 2001), acute myocardial infarction (S100A1; Kiewitz et al., 2000), 
amyotrophic lateral sclerosis (S100A6; Hoyaux et al., 2000), for the classification 
of astrocytomas and glioblastomas (Camby et al., 2000; Camby et al., 1999), 
melanoma metastasis formation (S100B; Krähn et al., 2001), as prognostic 
indicators for gastric cancer (S100A4; Yonemura et al., 2000), laryngeal (S100A2; 
Lauriola et al., 2000) and esophageal squamous cell carcinomas (S100A4; 
Ninomiya et al., 2001), and for breast cancer (Platt-Higgins et al., 2001).  
1.2.1 Genomic Organization and Chromosomal Localization of S100 Genes 
The structural organization of S100 genes is highly conserved both within an 
organism and in different species (Heizmann et al., 2002). A typical S100 gene 
consists of three exons whereby the first exon carries exclusively 5’ untranslated 
sequences. The second exon contains the ATG translation start codon and codes 
for the N-terminal EF-hand, and the third exon encodes the carboxy-terminal 
canonical EF-hand. Presently, 16 S100 genes are found in a tight gene cluster on 
human chromosome 1q21 within a genomic region of 260 kb (Fig. 1).  
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Fig. 1 The S100 gene cluster on human chromosome 1q21. Genes located in 
the cluster region are indicated as well as two commonly used genomic markers 
(D1S1664 and D1S2346). p and q indicate the short and the long arm of the 
chromosome, respectively. 
Four additional S100 genes are found on other human chromosomes: Xp22 
(calbindin-D9K), 21q22 (S100B), 4p16 (S100P) and 5 (S100Z). Within the gene 
cluster, epidermal differentiation genes as well as a gene of unknown function 
called NICE2 interrupt the S100 genes. Furthermore, there are three proteins 
encoded in 1q21 that carry in the N-terminus an S100-like domain, namely 
trichohyalin, profilaggrin, and C1 or f10. The small distances between the genes 
on the chromosome and the phylogenetic tree indicate that S100 genes most likely 
originate from late gene duplication events. It is interesting that the clustered 
organization of the human genes seems to be evolutionarily conserved, at least in 
the mouse. In other species, S100 genes are less well characterized.  
1.2.2 Biological Functions 
S100 proteins generally are involved in a large number of cellular activities such 
as signal transduction, cell differentiation, regulation of cell motility, transcription 
and cell cycle progression. Such activities can be expected since S100 proteins 
are thought to modulate the activity of target proteins in a Ca2+- (and possibly also 
in a Zn2+- and Cu2+-) dependent manner, thereby transferring the signal from the 
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second messenger. Therefore, understanding the biological function of S100 
proteins will crucially depend on the identification of their target proteins. During 
the last decade, a large number of such possible interactions have been described 
involving enzymes, cytoskeletal elements as well as transcription factors.  
Apart from these intracellular functions, some S100 proteins like 
S100A8/S100A9, S100B, S100A4 and probably others can be secreted from cells, 
as noted above, and exibit cytokine-like extracellular functions. These include 
chemotactic activities related to inflammation (S100A8/A9 and A12), neurotrophic 
activities (S100B), and angiogenic effects (S100A4 and S100A13). In all cases, 
the mechanisms of secretion as well as the nature of high affinity surface 
receptors remain largely unknown. One candidate receptor to mediate at least 
some of the described extracellular functions is the RAGE, which is activated upon 
binding of S100A12, S100A13, S100P, and S100B (Hofmann et al., 1999; 
Huttunen et al., 2000; Arumugam et al., 2004; Hsieh et al., 2004). It is currently not 
known whether RAGE is a universal S100 receptor. 
Generation of animal models has been initiated to study the physiological 
significance of S100 proteins. Ectopic overexpression in the mouse has been 
described for S100B and S100A4. In the case of S100B, enhanced expression in 
the brain led to hyperactivity associated with an impairment of hippocampal 
function (Gerlai and Roder, 1995). In contrast to this mild phenotype, expression of 
S100A4 in oncogene-bearing transgenic mice can induce metastasis of mammary 
tumours, suggesting that S100A4 plays an important role in the acquisition of the 
metastatic phenotype (Ambartsumian et al., 1996; Davies et al., 1996). 
Inactivation through homologous recombination in mouse embryonic stem 
cells has been demonstrated for S100B, S100A8, and S100A1. While inactivation 
of S100B has no obvious consequences for life (Xiong et al., 2000), S100A8 null 
mice die via early resorption of the mouse embryo (Passey et al., 1999), a result 
that suggests a role for this protein in prevention of maternal rejection of the 
implanting embryo. S100A1 null mice have significantly reduced responses to 
acute and chronic hemodynamic stress that are associated with reduced cardiac 
calcium sensitivity (Du et al., 2002). 
Since S100 proteins can form homo- and heterodimers and usually more 
than one S100 protein is expressed in a given cell type, functional redundancy or 
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compensatory mechanisms might explain the lack of phenotype observed in some 
animal models.  
1.2.3 Association with Human Diseases 
Several S100 proteins are closely associated with human diseases (Table 1). 
 
Table 1 S100 proteins: functions and association with human diseases 
Protein Postulated functions Disease associatio
S100A1  Regulation of cell motility, muscle contraction, phosphorylation, Ca2+-release channel, transcription  Cardiomyopathies 
S100A2 Tumour suppression, nuclear functions, chemotaxis Cancer, tumour suppression
S100A3 Hair shaft formation, tumour suppression, secretion, and extracellular functions Hair damage, cancer 
S100A4 Regulation of cell motility, secretion and extracellular functions, angiogenesis Cancer (metastasis) 
S100A5 Ca
2+, Zn2+, and Cu2+-binding protein in the CNS and other tissues; 
unknown function Not known 
S100A6 Regulation of insulin release, prolactin secretion, Ca
2+ 
homeostasis, tumour progression  
Amyotrophical lateral 
sclerosis 
S100A7  S100A7-fatty acid binding protein complex regulates differentiation of keratinocytes Psoriasis, cancer 
S100A8/ 
S100A9 
Chemotactic activities, adhesion of neutrophils, myeloid cell 
differentiation, apoptosis, fatty acid metabolism 
Inflammation, wound 
healing, cystic fibrosis 
S100A10 Inhibition of phospholipase A2, neurotransmitter release, in connection with annexin II regulates membrane traffic, ion currents Inflammation 
S100A11  
Organization of early endosomes, inhibition of annexin I function, 
regulation of phoshorylation, physiological role in keratinocyte 
cornified envelope  
Skin diseases, ocular 
melanoma 
S100A12 Host-parasite interaction, differentiation of squamous epithelial cells and extracellular functions 
Mooren's ulcer (autoimmune 
disease), inflammation 
S100A13 
Regulation of FGF-1 and synaptotagmin-1 stress-induced release; 
involved in the formation of Cu2+-dependent IL-1α:S100A13 
heterotetramer that facilates the export of both proteins 
Angiogenesis, vascular 
response to injury 
S100A15 unknown Psoriasis 
S100A16 unknown Malignant transformation 
S100B 
Cell motility, proliferation, inhibition of microtubule assembly, 
transcription, regulation of nuclear kinase, extracellular functions, 
e.g. neurite extension  
Alzheimer’s disease, Down 
syndrome, melanoma, 
amyotrophic lateral 
sclerosis, epilepsy 
S100P Function in the placenta Malignant transformation 
S100Z Function in spleen and leukocytes Aberrrant in some tumours 
Calbindin 
D9K Ca
2+ buffer and Ca2+ transport Vitamin D deficiency, abnormal mineralization 
  
A few S100 proteins have been proposed to play important roles in tumour 
progression and suppression and are recognized as potential tumour markers. 
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The association of S100 proteins with cancer development originates in the finding 
that the evolutionary conserved gene cluster on human chromosome 1q21 is 
implicated in gene rearrangements during tumour development. As discussed 
below, up-regulation in tumours has been reported for S100A1, S100A4, S100A6, 
S100A7, S100A8, S100A9, S100A10, S100A16, S100B, and S100P, whereas 
S100A2 and S100A11 have been postulated to be tumour suppressor genes. 
S100A1 and S100B are overexpressed in human cancers and have been 
suggested to play a role in the hyperactivation of Ndr kinase in melanomas 
(Millward et al., 1998). Inhibition of p53 activity by S100B could be one 
mechanism, whereby overexpressed S100B is involved in neoplastic 
transformation. Blood levels of S100B are used to monitor malignant melanomas 
(Krähn et al., 2001). 
S100A4 has been implicated in invasion and metastasis. The prognostic 
significance of its selective expression in various cancers has been exploited. In 
gastric cancer the opposite expression of S100A4 in relation to a tumour 
suppressor E-cadherin was found to be a powerful aid in histological typing and in 
evaluating the metastatic potential/prognosis of patients with this type of cancer 
(Yonemura et al., 2000). It was also demonstrated that extracellular S100A4 could 
act as an angiogenic factor and might induce tumour progression via an 
extracellular route stimulating angiogenesis (Kriajevska et al., 2002). 
S100A5 has been postulated to be a marker of recurrence in WHO grade I 
meningiomas (Hancq et al., 2004). 
S100A6 has been found overexpressed in human pancreatic 
adenocarcinomas (Logsdon et al., 2003) as well as in intrahepatic tumours, where 
it was activated by TNF-α and NFκB (Joo et al., 2003). 
S100A7 (psoriasin) expression has been associated with psoriasiform 
hyperplasia, tumour progression in breast cancer and a worse prognosis in 
estrogen receptor-negative invasive ductal breast carcinomas (Emberley et al., 
2003) as well as with gastric tumours (El-Rifai et al., 2002). In addition, S100A7 is 
a potential tumour marker for non-invasive follow-up of patients with urinary 
bladder squamous cell carcinoma (Ostergaard et al., 1999). 
The two calgranulins – S100A8 and S100A9 – are differentially expressed at 
sites of acute and chronic inflammation. Recent reports, however, indicate that 
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they are also overexpressed during skin carcinogenesis (Gebhardt et al., 2002), in 
poorly differentiated lung adenocarcinomas (Arai et al., 2001), gastric tumours 
(El-Rifai et al., 2002), and at the invasive margin of colorectal carcinomas (Stulik et 
al., 1999). 
S100P expression has been noted in various cancer cell lines. It is 
associated with cellular immortalization in breast cancer cell lines (Guerreiro et al., 
2000). In colon cancer cell lines, its expression is elevated in doxorubicin-resistant 
cells (Bertram et al., 1998). S100P is expressed in prostate cancer, where its 
expression is androgen-sensitive (Averboukh et al., 1996) and in pancreatic 
adenocarcinoma, where its expression has been localized to the neoplastic 
epithelium of pancreas (Logsdon et al., 2003). Furthermore, it was found that 
S100P expression correlates with decreased survival in patients with lung cancer 
(Beer et al., 2002). 
S100A10 is an annexin 2 protein ligand and a key plasminogen receptor of 
the extracellular cell surface that is overexpressed in esophageal squamous cell 
carcinomas (Zhi et al., 2003), renal cell carcinomas (Teratani et al., 2002), and 
gastric tumours (Rifai et al., 2002). It was shown that S100A10 stimulates the 
conversion of plasminogen to plasmin on the tumour cell surface thereby 
contributing to the increased invasiveness of tumour cells (Zhang et al., 2004). 
The recently identified S100A16 is up-regulated at the transcriptional level in 
tumours of the bladder, lung, thyroid gland, pancreas, and ovary (Marenholz and 
Heizmann, 2004). 
By contrast, S100A2 is markedly down-regulated in breast tumour biopsies 
and can be re-expressed in mammary carcinoma cells by 5-azadeoxycytidine 
treatment (Wicki et al., 1997). A prognostic significance of S100A2 in laryngeal 
squamous-cell carcinoma has also been found allowing discrimination of high and 
low risk patients in the lymph-node negative subgroup to provide better therapy 
(Lauriola et al., 2000). Using DNA array technology, S100A2 was identified as 
differentially expressed in normal versus tumorigenic human bronchial epithelial 
cells (Feng et al., 2001). 
A role for S100A11 as a tumour suppressor protein was postulated. This was 
based on its down-regulation in immortalized versus normal cells (Sakaguchi et 
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al., 2000) and the observation that microinjection of an anti-S100A11 antibody into 
normal confluent quiescent cells induced DNA synthesis (Sakaguchi et al., 2003). 
1.3 Aim of This Work 
The primary aim of the study was to identify novel tumour-associated genes with 
potential application in the detection or treatment of cancer. The starting point was 
a collection of partial cDNA clones of yet unknown genes from a suppression 
subtractive hybridization (SSH) cDNA library preferentially representing genes that 
were down-regulated in the small cell lung carcinoma cell line as compared to 
normal human bronchial epithelial cells. 
An unknown human transcript was selected for further characterization in 
view of its differential expression in tumour cell lines and in primary tumours, as 
well as its homology to a protein family known to be associated with 
tumorigenesis. 
I aimed to elucidate the rationale for the differential expression of the gene in 
tumours as well as to evaluate its potential clinical relevance. A further intention 
was to shed light on the mechanism of regulation of the gene in order to determine 
its association with malignant transformation. 
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2 Materials and Methods 
2.1 Materials 
2.1.1 Chemicals 
All chemicals used in this work were purchased from Roche Diagnostics GmbH, 
Mannheim, Germany; Calbiochem, CA, USA; Sigma-Aldrich Chemie GmbH, 
Munich, Germany; Sigma, MS, USA; Biozym Diagnostik GmbH, Oldendorf, 
Germany; Merck, Darmstadt, Germany; Serva Electrophoresis GmbH, Heidelberg, 
Germany; R&D Systems Inc., MN, USA. 
Milli-Q 18.2 MΩ · cm water was used in all procedures if required. 
2.1.2 Kits 
 
5’-RACE Kit BD Biosciences, CA, USA 
BEGM Bullet Kit Clonetics, San Diego, CA, USA 
ChemMate Detection Kit DAKO, Glostrup, Denmark 
Developer RP X-OMAT EX Eastman Kodak Company, NY, USA 
Dual-Luciferase Reporter Assay System Promega, WI, USA 
ECL Western Blotting Detection Kit Amersham Pharmacia Biotech, Freiburg, Germany 
Endofree Plasmid Maxiprep Kit Qiagen GmbH, Hilden, Germany 
ExpressHyb solution  BD Biosciences, CA, USA 
FastTrack 2.0 Kit for Isolation of mRNA Invitrogen, CA, USA 
Fixer RP X-OMAT LO Eastman Kodak Company, NY, USA 
Megaprime DNA Labelling System Amersham Pharmacia Biotech, Buckinghamshire, UK 
Opti-MEM I Reduced Serum Medium  Invitrogen, CA, USA 
Plasmid Mini and Maxi Kit Qiagen GmbH, Hilden, Germany 
Protease Inhibitors Cocktail Roche Diagnostics GmbH, Mannheim, Germany 
QIAquick PCR Purification Kit Qiagen GmbH, Hilden, Germany 
QIAquick Nucleotide Removal Kit Qiagen GmbH, Hilden, Germany 
Qiaquick Gel Extraction Kit Qiagen GmbH, Hilden, Germany 
Rapid Ligation Kit Roche Diagnostics GmbH, Mannheim, Germany 
SequaGel XR National Diagnostics, GE, USA 
Thermoscript RT-PCR System Invitrogen, CA, USA 
Thermo-Sequenase Fluorescent-
Labeling Cycle-Sequencing Kit 
Amersham Pharmacia Biotech, Buckinghamshire, UK 
TRIzol Invitrogen, CA, USA 
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2.1.3 Materials 
Hybond-N membrane  Amersham Pharmacia Biotech, Buckinghamshire, UK 
Hybond-N+ membrane Amersham Pharmacia Biotech, Buckinghamshire, UK 
Hybond-P PVDF membrane  Amersham Pharmacia Biotech, Buckinghamshire, UK 
Kodak X-ray Film NEN Life Science Products, MA, USA 
Hybond Hyperfilm Amersham Pharmacia Biotech, Buckinghamshire, UK 
Human Multiple Tissue Northern (MTN) 
Blot 
BD Biosciences, CA, USA 
Cancer Profiling Array BD Biosciences, CA, USA 
Metaphases of normal human 
lymphocytes 
Vysis, IL, USA 
 
2.1.4 Enzymes 
Ampli Taq DNA Polymerase Perkin Elmer, MA, USA 
Calf Intestinal Alkaline Phosphatase (CIAP)  Promega, Mannheim, Germany 
Restriction Endonucleases: BamHI, XbaI, KpnI, 
SacI, PstI, XhoI, SalI, NotI, EcoRI 
Promega, Mannheim, Germany 
 
2.1.5 Antibodies  
Anti-β-actin Sigma-Aldrich, Inc., MS, USA 
Anti-AKT Cell Signalling Technology, Inc., MA, USA 
Anti-ER Novocastra, Newcastle, UK 
Anti-ERBB2 DAKO, Glostrup, Denmark 
Anti-c-JUN Cell Signalling Technology, Inc., MA, USA 
Anti-Ki-67 Dianova, Hamburg, Germany 
Anti-p38 Cell Signalling Technology, Inc., MA, USA 
Anti-Phospho-AKT (Ser473) Cell Signalling Technology, Inc., MA, USA 
Anti-Phospho-HSP27 (Ser82) Cell Signalling Technology, Inc., MA, USA 
Anti-Phospho-c-JUN (Ser63) Cell Signalling Technology, Inc., MA, USA 
Anti-Phospho-p38 (Thr180/Tyr182) Cell Signalling Technology, Inc., MA, USA 
Anti-Phospho-p44/42 MAPK (Thr202/Tyr204) Cell Signalling Technology, Inc., MA, USA 
Anti-Phospho-SAPK/JNK (Thr183/Tyr185) Cell Signalling Technology, Inc., MA, USA 
Anti-PR DAKO, Glostrup, Denmark 
Anti-S100A14 affinity-purified A. Pietas, Charité, Berlin, Germany 
Anti-SAPK/JNK Cell Signalling Technology, Inc., MA, USA 
Anti-pan-Ras BD Biosciences, CA, USA 
Anti-α-tubulin Monosan, Sanbio b.v., Netherlands 
Anti-V5 Invitrogen, CA, USA 
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FITC(DTAF)-Conjugated Goat Anti-Mouse IgG 
(H + L)  
Jackson ImmunoResearch Laboratories, 
Baltimore, MD, USA 
FITC(DTAF)-Conjugated Goat Anti-Rabbit IgG 
(H + L)  
Jackson ImmunoResearch Laboratories, 
Baltimore, MD, USA 
Horseradish Peroxidase-Conjugated Rabbit Anti-
Mouse  
DAKO, Glostrup, Denmark 
Horseradish Peroxidase-Conjugated Goat Anti-
Rabbit 
Amersham Pharmacia Biotech, 
Buckinghamshire, UK 
 
2.1.6 Mammalian Cell Lines 
HBE Normal human bronchial epithelial cells; Clonetics, San Diego, CA, USA 
SAE Normal human small-airway epithelial cells; Clonetics, San Diego, CA, USA 
H378 SCLC; ATCC, Rockville, MD,USA 
H82 SCLC; ATCC, Rockville, MD, USA 
COLO 677 SCLC; German Collection of Microorganisms and Cell Cultures, 
Braunschweig, Germany 
H446 SCLC; ATCC, Rockville, MD, USA 
CPC-N SCLC; German Collection of Microorganisms and Cell Cultures, 
Braunschweig, Germany 
DMS-79 SCLC; ATCC, Rockville, MD, USA 
H209 SCLC; ATCC, Rockville, MD, USA 
DMS-114 SCLC; ATCC, Rockville, MD, USA 
H187 SCLC; ATCC, Rockville, MD, USA 
N417 SCLC; ATCC, Rockville, MD, USA 
H526 SCLC metastatic; ATCC, Rockville, MD, USA 
COLO 668 Brain metastasis of SCLC; German Collection of Microorganisms and Cell 
Cultures, Braunschweig, Germany 
SHP77 Large cell variant of SCLC; ATCC, Rockville, MD; German Collection of 
Microorganisms and Cell Cultures, Braunschweig, Germany 
COLO 699 ADC; German Collection of Microorganisms and Cell Cultures, Braunschweig, 
Germany 
DV-90 ADC; German Collection of Microorganisms and Cell Cultures, Braunschweig, 
Germany 
H322 ADC; ATCC, Rockville, MD, USA 
D51 ADC; I. Petersen, Charité, Berlin, Germany 
D54 ADC; I. Petersen, Charité, Berlin, Germany 
D117 ADC; I. Petersen, Charité, Berlin, Germany 
H125 ADC; ATCC, Rockville, MD, USA 
H23 ADC; ATCC, Rockville, MD, USA 
A549 ADC; German Collection of Microorganisms and Cell Cultures, Braunschweig, 
Germany 
H2228 ADC; ATCC, Rockville, MD, USA 
H2030 ADC; ATCC, Rockville, MD, USA 
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H157 SCC; ATCC, Rockville, MD, USA 
H2170 SCC; ATCC, Rockville, MD, USA 
H226 SCC mesothelioma; ATCC, Rockville, MD, USA 
A427 Lung Ca; German Collection of Microorganisms and Cell Cultures, 
Braunschweig, Germany 
BEN Lung Ca, lymph node metastasis; German Collection of Microorganisms and 
Cell Cultures, Braunschweig, Germany 
D97 LCLC; I. Petersen, Charité, Berlin, Germany 
HBE4-E6/E7 HBE immortalized with E6 and E7 genes of HPV-16; ATCC, Rockville, MD, 
USA 
9442  
(BET-1A) 
HBE immortalized with SV40 early region; ATCC, Rockville, MD, USA 
BEAS-2B HBE immortalized with SV40 early region; ATCC, Rockville, MD, USA 
YP44 HBE immortalized with SV40 early region; kindly provided by Dr. Cheng, 
Cancer Institute, Beijing, China 
HMEC Normal human mammary epithelial cells; Clonetics, San Diego, CA, USA 
HMEB HMEC immortalized with telomerase and SV40 early region; kindly provided 
by Dr. B. Weinberg, Whitehead Institute for Biomedical Research, 
Massachusetts Institute of Technology, USA 
MCF-10A Spontaneously immortalized mammary epithelial cells; kindly provided by 
Dr. A. Gontarewicz, Charité, Berlin, Germany  
MCF-7 Breast Ca; kindly provided by Dr. A. Gontarewicz, Charité, Berlin, Germany 
SK-BR-3 Breast Ca; kindly provided by Dr. A. Gontarewicz, Charité, Berlin, Germany 
MDA-MD-231 Breast Ca; kindly provided by Dr. A. Gontarewicz, Charité, Berlin, Germany 
HT-29 Colon Ca; kindly provided by Dr. K. Jürchott, Charité, Berlin, Germany 
SW-480 Colon Ca; kindly provided by Dr. K. Jürchott, Charité, Berlin, Germany 
HCT-116 Colon Ca; kindly provided by Dr. K. Jürchott, Charité, Berlin, Germany 
CaCo-2 Colon Ca; kindly provided by Dr. K. Kölble, Charité, Berlin, Germany 
WiDr Colon Ca; kindly provided by Dr. K. Kölble, Charité, Berlin, Germany 
Lovo Colon Ca; kindly provided by Dr. A. Siegert, Charité, Berlin, Germany 
CX-2 Colon Ca; kindly provided by Dr. A. Siegert, Charité, Berlin, Germany 
HRT-18 Colon Ca; kindly provided by Dr. A. Siegert, Charité, Berlin, Germany 
HEP-2 Head and neck Ca; kindly provided by J. Möller, Charité, Berlin, Germany 
D36-1/95 Head and neck Ca; I. Petersen, Charité, Berlin, Germany 
D36-2/95 Head and neck Ca; I. Petersen, Charité, Berlin, Germany 
D6/95 Head and neck Ca; I. Petersen, Charité, Berlin, Germany 
D3/02 Head and neck Ca; I. Petersen, Charité, Berlin, Germany 
D40/97 Head and neck Ca; I. Petersen, Charité, Berlin, Germany 
IMR-90 Fetal lung fibroblasts; kindly provided by Dr. A. Gontarewicz, Charité, 
Berlin, Germany 
HAKAT Immortalized keratinocytes; kindly provided by Dr. N. Fusenig, DKFZ, 
Heidelberg, Germany 
HEK 293 Human embryonic kidney epithelial cells; kindly provided by 
Dr. A. Gontarewicz, Charité, Berlin, Germany 
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COS-7 African green monkey kidney fibroblasts; kindly provided by Dr. I. Nazarenko, 
Charité, Berlin, Germany 
RAW 264.7 Mouse macrophagoid immortalized cells; ATCC, Rockville, MD, USA 
L-cells Mouse fibroblasts; ATCC, Rockville, MD, USA 
L-Wnt 3 cells Mouse fibroblasts transfected with Wnt-3A; ATCC, Rockville, MD, USA 
C57MG Mouse mammary epithelial cells, kindly provided by Dr. R. Nusse, Stanford 
University School of Medicine, USA 
 
2.1.7 E. coli Strain 
One Shot TOP10F’ F’{lacIqTn10(TetR)} mcrA∆(mrr-hsdRMS-mcrBC) 
Φ80lacZ∆M15 deoR recA1 endA1 
Invitrogen, CA, USA 
 
2.1.8 RNA Samples from Mammalian Cell Lines 
H596 Lung Ca; Cancer Profiling Array, BD Biosciences, CA, USA 
DU 145 Prostate Ca; kindly provided by Dr. A. Gontarewicz, Charité, Berlin, Germany 
PC-3 Prostate Ca; kindly provided by Dr. A. Gontarewicz, Charité, Berlin, Germany 
Kato III Metastasis of gastric Ca; kindly provided by Dr. A. Gontarewicz, Charité, Berlin, 
Germany 
EJ Bladder Ca; kindly provided by Dr. A. Gontarewicz, Charité, Berlin, Germany 
HeLa Cervical Ca; kindly provided by Dr. A. Gontarewicz, Charité, Berlin, Germany 
Daudi Burkitt’s lymphoma; Cancer Profiling Array, BD Biosciences, CA, USA 
K562 Chronic myelogenous leukemia; Cancer Profiling Array, BD Biosciences, CA, USA 
HL-60 Promyeolocytic leukemia; Cancer Profiling Array, BD Biosciences, CA, USA 
MOLT-4 Lymphoblastic leukemia; Cancer Profiling Array, BD Biosciences, CA, USA 
Raji Burkitt’s lymphoma; Cancer Profiling Array, BD Biosciences, CA, USA 
G361 Melanoma; Cancer Profiling Array, BD Biosciences, CA, USA 
SKOV-3 Ovarian Ca; kindly provided by Dr. A. Gontarewicz, Charité, Berlin, Germany 
OVCAR-3 Ovarian Ca; kindly provided by Dr. A. Gontarewicz, Charité, Berlin, Germany 
HT 1080 Fibrosarcoma; kindly provided by Dr. A. Gontarewicz, Charité, Berlin, Germany 
ROSE 199 Rat ovarian surface epithelial cells; kindly provided by Dr. A. Gontarewicz, Charité, 
Berlin, Germany 
ROSE A2/1 Rat ovarian surface epithelial cells transfected with KRas; kindly provided by 
Dr. A. Gontarewicz, Charité, Berlin, Germany 
ROSE A2/5 Rat ovarian surface epithelial cells transfected with KRas; kindly provided by 
Dr. A. Gontarewicz, Charité, Berlin, Germany 
208F Immortalized rat fibroblasts; kindly provided by Dr. A. Gontarewicz, Charité, Berlin, 
Germany 
FE-8 HRAS-transformed derivative of 208F; kindly provided by Dr. A. Gontarewicz, 
Charité, Berlin, Germany 
IR-4 208F cells transfected with IPTG-inducible Ras; kindly provided by 
Dr. A. Gontarewicz, Charité, Berlin, Germany 
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2.1.9 Tissue Specimens 
Tumour specimens used in this study include xenografts of the following lung 
cancer cell lines transplanted subcutaneously into immunodefficient mice: CPC-N, 
H526, H446, H82, H209, N417 (SCLC); Colo 668 (brain metastasis of SCLC); D54 
(adenocarcinoma), and D97 (LCLC). They were obtained from experiments 
conducted by Prof. Dr. I. Petersen on tumorigenicity of various human cultured 
lung cancer cell lines in nude mice (unpublished results). These specimens were 
shock frozen in liquid nitrogen and stored at -80°C until RNA extraction. 
Normal human colon tissue and tumour tissue specimens used in the 
immunohistochemical analysis were obtained from surgical resections at the 
Department of Surgery of the Charité Hospital at the Humboldt University Berlin. 
Operation specimens were transferred to the Institute of Pathology within 1 hour 
after surgical removal. Generally, no adjuvant radiotherapy or chemotherapy was 
applied before surgery. These specimens were shock frozen in liquid nitrogen and 
stored at -80°C until RNA extraction. 
2.1.10 Plasmids and Expression Constructs 
S100A14-V5 The expression construct was generated by PCR-amplification of the 
ORF of the S100A14 cDNA using H1043for-tr and H1043rev-tr 
primers. The amplified fragment of 316-bp was ligated into the BamHI 
and XbaI sites of the pcDNA3.1/V5 vector. 
pcDNA3.1/V5 Invitrogen, CA, USA 
D1-4 human S100A14 
genomic construct 
The human S100A14 genomic construct was generated by cloning of 
the 3173-bp positive fragment (hybridizing with S100A14 coding 
region, intron 2, and 3 in Southern blot analysis) produced by BamHI 
digestion of the PAC clone D11609 into pBluescript II KS(+) phagemid 
vector. 
pBluescript II KS(+) 
phagemid vector  
Stratagene, La Jolla, Canada 
H1043 The DKFZp404H1043 clone containing the human full-length 
S100A14 cloned in pSPORT1 vector, was provided by RZPD, 
Heidelberg, Germany. 
H1043(-)0.5/10  The human full-length S100A14 expression construct was generated 
by subcloning from the H1043 clone by restriction digestion with NotI 
and XbaI. 
pGL3-Basic  The firefly luciferase reporter vector lacking eukaryotic promoter and 
enhancer elements upstream of the firefly luciferease gene. 
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pRL-TK The Renilla luciferase reporter vector containing the herpes simplex 
virus thymidine kinase promoter region upstream of Renilla luciferase 
gene. 
p500-luc The p500-luc luciferase reporter vector was generated by restriction 
digestion with KpnI (multiple cloning site) and SacI (endogenous 
restriction site; position 496 bp in D1-4) of the S100A14 genomic 
construct D1-4. The fragment of 495-bp was ligated into the 
compatible restriction sites of the pGL3-Basic firefly luciferase reporter 
vector.    
p300-luc The p300-luc luciferase reporter vector was generated by restriction 
digestion with PstI (endogenous restriction site; position 192 bp in 
D1-4) of the p500-luc fragment. The resulting PstI-SacI (-313 bp to -
12 bp) restriction fragment was amplified by PCR using the 
oligonucleotides Prom2b-for and Prom2b-rev. The amplified fragment 
of 300-bp was ligated into KpnI and SacI sites of the pGL3-Basic 
firefly luciferase reporter vector. 
p250-luc The p250-luc luciferase reporter vector was generated by restriction 
digestion with PstI (endogenous restriction site; position 192 bp in 
D1-4) of the p500-luc fragment. The resulting PstI (the multiple 
cloning site)- PstI (-573 bp to -313 bp) restriction fragment was 
amplified by PCR using the oligonucleotides Prom1b-for and Prom1b-
rev. The amplified fragment of 192-bp was ligated into KpnI and SacI 
sites of the pGL3-Basic firefly luciferase reporter vector. 
p2A-luc The p2A-luc deletion construct was created by PCR-amplification of 
the fragment (-313 bp to -269 bp) of the p300-luc, using prom2A-for 
and prom2A-rev primers. The amplified fragment of 51-bp was ligated 
into the KpnI and SacI sites of the pGL3-Basic firefly luciferase 
reporter vector. 
p2B-luc The p2B-luc deletion construct was created by PCR-amplification of 
the fragment (-313 bp to -206 bp) of the p300-luc, using prom2A-for 
and prom2B-rev primers. The amplified fragment of 107-bp was 
ligated into the KpnI and SacI sites of the pGL3-Basic firefly luciferase 
reporter vector. 
p2C-luc The p2C-luc deletion construct was created by PCR-amplification of 
the fragment of the p300-luc (-208 bp to -12 bp) using prom2C-for and 
prom2C-rev primers. The amplified fragment of 196-bp was ligated 
into the KpnI and SacI sites of the pGL3-Basic firefly luciferase 
reporter vector 
EGFP (enhanced green 
fluorescent protein) 
BD Biosciences, San Diego, TX, USA 
p65/Flag The p65 expression vector containing p65 full-length cDNA fused with 
Flag epitope, was a generous gift from Dr. C. Scheidereit, MDC, 
Berlin, Germany.  
pcDNA3/Flag The empty vector pcDNA3/Flag was a generous gift from 
Dr. C. Scheidereit (MDC, Berlin, Germany). 
pCR2.1 TA Cloning 
Vector 
Invitrogen, Groningen, Netherlands 
m-S100A14 The IMAGp998M1311375Q3 clone containing the mouse full-length 
S100A14 cDNA cloned in pCMV-SPORT6 phagemid vector, was 
provided by RZPD (Berlin, Germany). 
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2.1.11 Oligonucleotides  
IRD-labelled oligonucletides were purchased from MWG-Biotech, Ebersberg, 
Germany. Non-labelled oligonucleotides were purchased from BioTeZ GmbH, 
Berlin-Buch, Germany. 
 
Oligonucl. Labelling Sequence 
Prom1b-for  5’– TTA GGG GTA CCC CCC AGG CAG GCT TGA GTG – 3’ 
Prom1b-rev  5’– TTA TAT CGA GCT CGT GCA GGG CAG GGA AGG – 3’ 
Prom2b-for  5’– TAG GGG TAC CCC TGC AGT TCG CCA GGG C – 3’ 
Prom2b-rev  5’– GCG ACC ACG AGC TCA GCT CTT ATA CCT G – 3’ 
18S-for  5’– GGG GAG GTA GTG ACG AA – 3’ 
18S-rev  5’– ACA AAG GGC AGG GAC TT – 3’ 
Prom2A-for  5’– TTA GGG GTA CCC CTG CAG TTC GCC AGG GCC – 3’ 
Prom2A-rev  5’– TTA TAT CGA GCT CGA CTT CGA GAC CTC ATG GG – 3’ 
Prom2B-rev  5’– TTA TAT CGA GCT CGG ATC AGC ATG CAG AGT CAC – 3’ 
Prom2C-for  5’– TTA GGG GTA CCC CTG CTG ATC GGA GGC CAG – 3’ 
Prom2C-rev  5’– TTA TAT CGA GCT CGA GCT CTT ATA CCT GGG GG – 3’ 
GAPDH-for  5’– GAA CGG GAA GCT TGT CAT CA – 3’ 
GAPDH-rev  5’– GTA GCC AAA TTC GTT GTC ATA C – 3’ 
mA14-for  5’– ATG GGA CAG TGT CGG TCA – 3’ 
mA14-rev  5’– TCA GCT CCG AGT AAC AGG – 3’ 
pGL3basic-f IRD800 5’– CTA GCA AAA TAG GCT GTC CC – 3’ 
pGL3basic-r IRD800 5’– CTT TAT GTT TTT GGC GTC TTC CA – 3’ 
exon1 for  5’– CTC AGC GGC TGC CAA CAG – 3’ 
exon2 for  5’– CAG TGT CGG TCA GCC AAC – 3’ 
exon3 for  5’– GAA CTT TCA CCA GTA CTC CG – 3’ 
D1-4prom-for  5’– CAT GAG GTC TCG AAG TCC – 3’ 
D1-4prom-rev  5’– CAG CTC ACC TGA GCT CAG – 3’ 
H1043for-2  5’– TCA TGC CGA GCA ACT GTG G – 3’ 
H1043rev-2  5’– GCC TCT CCA GCT TCA CAC T – 3’ 
H1043for-3  5’– GCT GCC AAC AGA TCA TGA – 3’ 
H1043rev-3  5’– TTG GCT GAC CGA CAC TGT – 3’ 
H1043 f  5’– CAA CAG AAC TCT CAC CAA AG – 3’ 
H1043 r  5’– TCC AGA GGG AGT TCT CAG T – 3’ 
H1043 i1 for  5’– GGC TGC CAA GTA AGG AAA C – 3’ 
H1043 i1 rev  5’– TCA TGA TCT GCT TAG AGG AG – 3’ 
H1043 i2 for  5’– AAC GCA GAG GTG GGC TCA T – 3’ 
H1043 i2 rev  5’– CTG AGC ATC CTG AGG GCA G – 3’ 
H1043 i3 for  5’– TCT CAT GCC GGT ATG GAC – 3’ 
H1043 i3 rev  5’– CCA CAG TTG CTC TGA GGG – 3’ 
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H1043for-tr  5’– CGG GAT CCC GCA CCA TGG GAC AGT GTC GG – 3’ 
H1043rev-tr  5’– GCT CTA GAG CGT GCC CCC GGA CAG GCC T – 3’ 
GPS1  5’– AGG CCT CTC CAG CTT CAC ACT CTT G – 3’ 
NGPS1  5’– CAA CAG AAC TCT CAC CAA AG – 3’ 
NGPS2  5’– GCC TCT CCA GCT TCA CAC T – 3’ 
D1-4 T7-1 IRD800 5’– AGG CTG CTG CAA TAG CAG – 3’ 
D1-4 T7-2 IRD800 5’– TCT AAG CAG ATC ATG AGC – 3’ 
D1-4 T7-3 IRD800 5’– CAT CTC ATG CCG GTA TGG – 3’ 
H1043 M13 IRD800 5’– TGA GGT CAG ATC TCA GAA C – 3’ 
H1043 T7 IRD800 5’– CCT ACT TAT AAA CTC CCT A – 3’ 
pcDNA3.1R IRD800 5’– CCT CGA CTG TGC CTT CTA – 3’ 
pcDNA3.1R-2 IRD800 5’– TAG AAG GCA CAG TCG AGG – 3’ 
M13 IRD800 5’– GTA AAA CGA CGG CCA G – 3’ 
M13R IRD800 5’– CAG GAA ACA GCT ATG AC – 3’ 
T7 IRD800 5’– TAA TAC GAC TCA CTA TAG GG – 3’ 
 
2.2 Methods 
2.2.1 Bacterial Culture 
2.2.1.1 Routine Culturing and Storage Conditions 
E.coli cultures were routinely grown at 37°C on Luria Bertani (LB) agar or in the LB 
broth, containing Ampicillin (50 µg/ml) or Kanamycin (25 µg/ml).  
For long-term storage, a fresh overnight culture was prepared as follows: 
bacteria were streaked onto an agar plate containing the selective antibiotic, and 
incubated at 37°C overnight. Individual bacterial colonies were picked into Greiner 
tubes (Greiner Bio-One, Germany) containing 3 ml LB broth, and incubated for 
14-16 hours at 37°C with shaking at 160 rpm. Then 800 µl of 2 x bacteria storage 
medium and 800 µl of bacterial culture were added into the storage tube. The vials 
were immediately transferred to -70°C and stored until use. To recover a bacteria 
culture, a small amount of the frozen stock was inoculated into 3 ml LB broth, 
containing the appropriate antibiotic, and incubated overnight at 37°C with shaking 
at 160 rpm. 
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2 x Bacteria storage medium 
8.25 g K2HPO4*3H2O 
1.80 g KH2PO4 
0.45 g Na-citrate*2H2O 
0.09 g MgSO4*7H2O 
5.90 g (NH4)2SO4 
35.75 ml 87% Glycerol 
sterile H2O was added to a final volume of 500 ml and the medium was filter-
sterilised under sterile conditions. 
1 x LB broth 
1% Bacto tryptone 
0.5 % Bacto yeast extract 
1% NaCl 
1 x LB agar 
LB broth with 1.5% Bacto agar 
To prepare agar plates, the LB agar was cooled to ~50°C, appropriate antibiotics 
were added and 15 ml of LB agar per 100-mm plate were poured. For 
β-galactosidase assay, LB agar plates were prepared with 80 µg/ml X-gal 
(5-bromo-4-chloro-3-indol-β-D-galactopyranisode) and 20 mM IPTG (isopropyl-I-
thio-β-D-galactopyranisode). IPTG was prepared in sterile water, and X-gal in 
dimethylformamide (DMF). 
2.2.1.2 Transformation 
Chemically competent TOP10F’ E.coli were thawed on ice and mixed gently. The 
cells were transformed with an aliquot of 2 µl of the ligation reaction and incubated 
for 30 min on ice. Next, the cells were incubated for 30 sec in the 42°C water bath 
and placed on ice. 250 µl of pre-warmed SOC medium (Invitrogen) were added, 
the vials were placed horizontally and shaken at 220 rpm and 37°C for 1 hour in a 
rotary shaker incubator. Finally, 50 and 200 µl of each transformed culture were 
spread on separate LB agar plates containing 50 µg/ml ampicilin and incubated 
overnight at 37°C.  
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Individual transformants were selected for plasmid miniprep DNA isolation by 
Plasmid Mini Kit and analysed by restriction endonuclease digestion and 
sequencing. The plates were sealed with parafilm and stored at 4°C for up to four 
weeks. 
2.2.2 Culturing of Mammalian Cells 
2.2.2.1 Routine Culturing  
Mammalian cell lines were maintained at 37°C and 95% humidity in the presence 
of 5% CO2. Cells were typically grown in T-75 flasks and 100-mm dishes (BD 
Biosciences). 
The cell lines used in this study were cultivated in the following media: 
Cell line Medium 
HBE BEGM 
SAE SAGM 
HBE-E6/E7 BEGM 
9442 (BET-1A) BEGM 
BEAS-2B BEGM 
YP44 BEGM 
H378 RPMI + 10% FCS 
H82 RPMI + 10% FCS 
COLO 677 RPMI + 10% FCS 
H446 RPMI + 10% FCS 
CPC-N McCoys + 10% FCS 
DMS-79 RPMI + 10% FCS 
H209 RPMI + 10% FCS 
DMS-114 Waymouth's + 10% FCS 
H187 RPMI + 10% FCS 
N417 RPMI + 10% FCS 
H526 RPMI + 10% FCS 
COLO 668 RPMI + 10% FCS 
SHP77 RPMI + 10% FCS 
COLO 699 RPMI + 10% FCS 
DV-90 RPMI + 10% FCS 
H322 RPMI + 10% FCS 
D51 Leibovitz 15 medium (L-15) + 10% FCS + 1% glutamine 
D54 L-15 + 10% FCS + 1% glutamine 
D117 L-15 + 10% FCS + 1% glutamine 
H125 RPMI + 10% FCS 
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H23 RPMI + 10% FCS 
A549 F12/Ham + 10% FCS 
H2228 RPMI + 10% FCS 
H2030 RPMI + 10% FCS 
H157 RPMI + 10% FCS 
H2170 RPMI + 10% FCS 
H226 RPMI + 10% FCS 
A427 RPMI + 10% FCS 
BEN Dulbecco modified Eagle’s medium (DMEM) + 10% FCS + 2 
mM glutamine + 4.5 g/l glucose 
D97 L-15 + 10% FCS + 1% glutamine 
HMEC MEBM 
HMEB MEBM + G418 (0.4 mg/ml) + hygromycine (0.1 mg/ml) + 
puromycine (1 ng/ml) 
MCF 10A DMEM:F12 HAM + 5% horse serum + 10 µg/ml insulin + 5 
µg/ml hydrocortisone + 20 ng/ml EGF + 100 ng/ml cholera toxin 
MCF-7 DMEM + 10% FCS + 2 mM glutamine 
SK-BR 3 DMEM + 10% FCS + 2 mM glutamine 
MDA MD 231 DMEM + 10% FCS + 2 mM glutamine 
HT-29 L-15 + 10% FCS + 1% glutamine 
SW-480 L-15 + 10% FCS + 1% glutamine 
HCT-116 L-15 + 10% FCS + 1% glutamine 
CaCo-2 RPMI + 10% FCS 
WiDr RPMI + 10% FCS 
Lovo DMEM + 10% FCS + 2 mM glutamine + 4.5 g/l glucose 
CX-2 RPMI + 10% FCS 
HRT-18 RPMI + 10% FCS 
HEP-2 RPMI + 10% FCS 
D36-1/95 L-15 + 10% FCS + 1% glutamine 
D36-2/95 L-15 + 10% FCS + 1% glutamine 
D6/95 L-15 + 10% FCS + 1% glutamine 
D3/02 L-15 + 10% FCS + 1% glutamine 
D40/97 L-15 + 10% FCS + 1% glutamine 
IMR-90 DMEM + 20% FCS + 2 mM glutamine 
HAKAT DMEM + 10% FCS + 2 mM glutamine 
HEK 293 DMEM + 10% FCS + 2 mM glutamine + 4.5 g/l glucose 
COS-7 DMEM + 10% FCS + 2 mM glutamine 
RAW 264.7 DMEM + 10% FCS + 2 mM glutamine + 4.5 g/l glucose 
L-cells DMEM + 10% FCS + 2 mM glutamine + 4.5 g/l glucose 
L-Wnt 3 cells DMEM + 10% FCS + 2 mM glutamine + 4.5 g/l glucose + G418 
(400 µg/ml) 
C57MG DMEM + 10% FCS + 2 mM glutamine + 4.5 g/l glucose + 10 
µg/ml insulin 
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For sub-culturing of the cells, the medium was removed, and the cells were rinsed 
once with 1 x PBS buffer. Then, the buffer was removed and 2 ml of trypsin-EDTA 
solution was added per 75-cm2 culture flask. The cells were incubated for a few 
minutes at 37°C until they detached. Then, 8 ml of a fresh culture medium was 
added, aspirated, and dispensed into new culture flasks. Fresh medium was 
added every 2 to 3 days. 
Trypsin-EDTA 10 x stock solution (Biochrom AG) contained 0.5% Trypsin 
and 0.2% EDTA. For use in cell culture, the solution was diluted 1:10 with PBS, 
filter-sterilized, and frozen at -20°C in 80 ml aliquots. Before use, an aliquot was 
thawed in a water bath at 37°C and used as described above. 
10 x PBS 
2 g/l KCl 
2 g/l KH2PO4 
21.6 g/l Na2HPO4*7 H2O 
pH was adjusted to 7.4 
2.2.2.2 Freezing and Thawing Procedure 
Following tripsinization, the cells were transferred into a 15 ml Falcon tube and 
centrifuged at 1 000 x g for 5 min at room temperature. The cell pellet was 
resuspended in 1 ml of storage medium, transferred into a cryo-tube and placed in 
a cryo-container with isopropanol. The cells were kept at -70°C for 24 hours to 
allow them to freeze slowly. After this time, they were stored in liquid nitrogen. 
Storage medium consisted of the respective cell culture medium supplemented 
with 5% DMSO. 
Thawing of cells was performed quickly in a 37°C water bath for ~2 min. 
Then, the cells were transferred immediately into a culture flask containing pre-
warmed culture medium. The next day, the medium was replaced with the fresh 
one to remove traces of DMSO.   
2.2.2.3 Cell Treatments  
For the treatment with EGF, TGF-α, and TNF-α, 9442 (BET-1A) cells were grown 
to ~70% confluence in regular medium (BEBM) supplemented with growth factors 
(BEGM) for 3 days. After this time, subconfluent cultures were treated with 
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50 ng/ml of human recombinant EGF, 20 ng/ml of human recombinant TGF-α, and 
25 ng/ml of human recombinant TNF-α without medium change, cultured for the 
indicated times, and harvested. The growth and treatment of cells as well as the 
RNA and protein extraction were performed at least 3 independent times. 
For the stimulation with medium, BEBM medium was supplemented with a 
double set of growth factors (BEGM; we refer to this as “stimulation medium”). 
After 3 days of incubation in regular culture medium, the medium was replaced 
with the “stimulation medium” and cells were cultured for the indicated times and 
harvested.  
To determine the kinetics of MAPK pathways stimulation, 9442 cells were 
grown in regular medium for 3 days and then stimulated for various periods of time 
(5, 15, 30, 60, 90, 120 min) with “stimulation medium”.  
In order to determine the effective drug concentration, 9442 cells were grown 
in regular medium for 3 days and then preincubated for 1 hour with 10 µM 
AG1478, 20 µM U0126, 40 µM SB203580, 40 µM SP600125, 40 µM LY294002, 
respectively, without medium change. Next, the cells were stimulated with 
“stimulation medium” for the optimal time course determined from the stimulation 
kinetics studies. The drug concentrations were chosen based on maximal 
suppressive efficacy and minimal cell toxicity. Stock solutions of 15.8 mM AG1478, 
10 mM U0126, 25 mM SB203580, and 22.7 mM SP600125 were prepared in 
DMSO, and 50 mM LY294002 in 100% ethanol. As a control, cells were treated 
with the vehicle, DMSO or ethanol, respectively. 
For inhibition studies, 9442 cells were incubated for 12 hours (RNA analysis) 
and 24 hours (protein analysis) with EGF or TGF-α without medium change, in the 
presence or absence of the inhibitors, which were added 1 hour prior to treatment 
with the growth factors. 
To inhibit protein synthesis, cells were pretreated for 1 hour with 
cycloheximide (2-10 µg/ml) before adding EGF. Stock solution of 100 mg/ml 
cycloheximide was prepared in DMSO. 
Protein kinase C (PKC) was induced by treatment with phorbol 12-myristate 
13-acetate (PMA; 10 nM and 100 nM) for the indicated times. Inhibition of PKC 
was carried out by preincubating cells for 1 hour with a broad PKC inhibitor 
bisindolylmaleimide I (5 µM) before stimulation with PMA or EGF. Stock solutions 
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of 2 mg/ml PMA and 3 mM bisindolylmaleimide I were prepared in 100% ethanol 
and DMSO, respectively. Control plates were treated with the vehicle. 
For the treatment with thapsigargin, cells were preincubated with the 
stimulation buffer containing 1 mM CaCl2 for 10 min (Davey et al., 2001). Then, 
0.5 µM thapsigargin was added and the cells were incubated for 15 and 30 min at 
37°C, fixed and immunostained for the endogenous S100A14 protein. Stock 
solution of 1.5 mM thapsigargin was prepared in DMSO. Control incubations were 
performed with DMSO as the vehicle. For Zn2+ treatment, cells were incubated 
with 40 µM of ZnCl2 for 15 and 30 min at 37°C. 
Stimulation buffer 
140 mM NaCl 
5 mM KCl 
1 mM MgCl2 
10 mM Glucose 
10 mM HEPES 
1 mM CaCl2 
H2O was added and the solution was filter-sterilised. 
 
Lung tumour cell lines (H525, COLO 668, COLO 667, H157, SHP-77, D117, H23, 
N417) were treated with 20 µM 5-aza-2’-deoxycytydine for 5 days and processed 
for RNA. Stock solution of 10 mM 5-aza-2’-deoxycytydine was prepared in 
1 x PBS, pH 6.0. 
Stimulation of HEK 293 and Lovo cells with EGF and TNF-α was performed 
24 hours after the transfection with p2C promoter construct, following 24 hours 
incubation in serum-containing, or serum-free medium. Cells were incubated for 6, 
12, and 24 hours in the presence or absence of EGF and TNF-α and harvested 
after indicated times.  
2.2.2.4 Transfection of Mammalian Cells  
Cationic lipid-mediated transfection was employed as a method of introducing 
DNA into cells. 
A total of 6 x 104 cells/well of the H157, A549, and COS-7 cells were seeded 
in 6-well plates a day before transfection. The cells were transfected with 0.8 µg 
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(H157), 1.9 µg (COS-7), and 3.8 µg (A549) of S100A14-V5 construct using 5.2 µl 
of Lipofectin reagent (Invitrogen, MD, USA), 6 µl, and 12 µl of LipofectAMINE 
reagent (Invitrogen, MD, USA), respectively. Transfection was performed 
according to the following protocol: for each transfection, DNA and 
Lipofectin/LipofectAMINE were diluted into separate aliquots (200 µl) of Opti-MEM 
I Reduced Serum Medium (Invitrogen). Diluted Lipofectin Reagent was allowed to 
stand at room temperature for 30 min. The two solutions were then combined, 
mixed gently and incubated at room temperature for 15 min (Lipofectin) or 45 min 
(LipofectAMINE) for lipid-DNA complexes formation. The cells were washed once 
with Opti-MEM, then 800 µl of Opti-MEM was added per well and the cells were 
overlaid with lipid-DNA complexes. Cells were then incubated for 5 hours at 37°C 
in a CO2 incubator. After this time, DNA-lipid containing medium was replaced with 
growth medium. Cells were assayed for gene expression 48 hours after 
transfection.  
To control the transfection efficiency, cells were transfected with an EGFP 
plasmid (enhanced green fluorescent protein) and viewed 48 hours after 
transfection using inverted microscope equipped with UV-lamp. The number of 
green fluorescent cells was visually estimated. Mock-transfected cells were used 
as negative controls. 
2.2.3 Preparation, Enzymatic Manipulation and Analysis of DNA 
2.2.3.1 Mini-Preparation of Plasmid DNA 
Mini-preparation of plasmid DNA was performed with Qiagen Plasmid Miniprep Kit 
according to the manufacturer’s recommendations. For isolation of ~15 µg of 
plasmid DNA, 3 ml overnight culture of E.coli in LB medium was prepared. DNA 
was eluted in 15 µl of the elution buffer (EB; 10 mM Tris-HCl, pH 8.5) and stored at 
-20°C.   
2.2.3.2 Large-Scale Preparation of Plasmid DNA 
For large-scale plasmid isolation, the Qiagen Plasmid Maxiprep Kit was used. 
Plasmid DNA preparations for transfection experiments were performed with 
Qiagen Endofree Plasmid Maxiprep Kit. Plasmid DNA was isolated according to 
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the supplier’s manual. A 150 ml (Qiagen Plasmid Maxiprep Kit) or 100 ml (Qiagen 
Endofree Plasmid Maxiprep Kit) E.coli overnight culture was prepared for each 
experiment. The pellet was resuspeded in a volume of EB buffer that the final 
concentration of DNA was ~1.0-1.5 µg/µl.  
2.2.3.3 Measurement of DNA Concentration 
Concentration of DNA was measured using a GeneQuant II RNA/DNA 
spectrophotometer (Pharmacia Biotech). Typical OD 260/280 ratios were ~1.7-1.8. 
2.2.3.4 Digestion of DNA with Restriction Endonucleases 
Digestion of DNA with restriction endonucleases was performed according to the 
recommendations of the manufacturer. For the digestion of 1-2 µg of DNA, 10 U of 
enzyme were added with an appropriate buffer in a final volume of 20 µl. 
Reactions were incubated for 14-16 hours.  
For cloning experiments, the digested DNA was subsequently separated in 
agarose gel, excised from the gel, and purified with QIAquick Gel Extraction Kit. 
Alternatively, QIAquick PCR Purification Kit was used to purify PCR-amplified 
fragments with incorporated restriction sites. An additional purification step for 
DNA was included for cloning experiments. The DNA was precipitated with 0.5 
volumes of 4 M NaAc, pH 5.2 and 2.5 volumes of cold 100% ethanol, and 
incubated for 1 hour at -20°C. For PCR-amplified and subsequently digested DNA 
fragments, Pellet Paint Co-Precipitant (Novagen) was included in the precipitation 
reaction. Then, the solution was centrifuged at 14 000 x g and 4°C for 30 min, the 
pellet was washed with 1 ml 70% ethanol, and centrifuged a second time at 
14 000 x g and 4°C for 5 min. Finally, the pellet was shortly air-dried and 
resuspeded in 10 µl of EB buffer.  
2.2.3.5 Vector Dephoshorylation 
To exclude self-ligation of the vector DNA, the protruding 5’-end of the vector was 
dephosphorylated with calf intestinal alkaline phosphatase (CIAP). The reaction 
was performed according to the recommendations of the supplier. One unit of 
CIAP was diluted for immediate use in 1 x CIAP Reaction Buffer and incubated 
with the vector DNA at 37°C for 30 minutes. After that time, another aliquot of 
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diluted CIAP was added and the incubation was continued at 37°C for additional 
30 minutes. The reaction was stopped by incubation at 75°C for 15 minutes. The 
dephosphorylated DNA was then purified by QIAquick PCR Purification Kit 
followed by DNA precipitation. 
2.2.3.6 DNA Ligation 
Ligation of DNA fragments into plasmid vectors was performed with Rapid DNA 
Ligation Kit. Experiments were performed according to the protocol of the supplier. 
A maximum of 200 ng of total DNA (vector + insert) at the molar ratios of vector 
DNA to insert DNA 1:2 and 1:5 were used. The reactions were incubated for 5 min 
at room temperature and then placed on ice. To determine the efficiency of 
ligation, 5 µl of the reaction mix were run on an agarose gel and visualised with 
ethidium bromide.   
2.2.3.7 Polymerase Chain Reaction (PCR) 
Amplification of DNA was performed according to the following protocol: 
Template DNA 25.0 ng – 0.5 µg 
10 x PCR buffer (including 15 mM MgCl2) 2.50 µl 
dNTP mix (each 10 nM) 1.00 µl 
5’- and 3’- oligonucleotide primers 1.00 µl (each) 
AmpliTaq DNA polymerase (1U) 0.25 µl 
H2O filled up to 25.0 µl 
 
For amplification of DNA fragments from PAC genomic clone, 5% DMSO was 
added to the reaction. 
Typical cycling profiles were programmed in Primus 96 Plus Thermal Cycler 
(MWG-Biotech) as follows: 
Denaturation of double-stranded DNA 95°C 30 sec 
Annealing of oligonucleotides to the 
template DNA 
Ta 30 sec 
Elongation 72°C 30/60 sec 
30 cycles 
Extension 72°C 5 min  
Chilling 4°C up to 1 h  
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Annealing temperatures were calculated using the formula: Ta = Tm - 2°C, where 
Tm is the melting temperature of the primers used for amplification. Tm of each 
oligonucleotide primer was calculated as follows: Tm = 4 x (G + C) + 2 x (A + T), 
where G – guanine, C – cytosine, T – thymine, A – adenine. 
2.2.3.8 Purification of PCR-Amplified Fragments of DNA  
Purification of PCR-amplified DNA fragments was performed with QIAquick PCR 
Purification Kit according to the supplier’s protocol. Purified PCR fragments were 
controlled by agarose gel electrophoresis. 
2.2.3.9 Sequencing 
Sequencing analysis was performed on a LI-COR automated DNA sequencer 
(MWG-Biotech) using fluorescent primers labelled with the tricarbocyanine dye 
IRD800 at their 5’-end. 
Gel components were pre-mixed the following way: 
30 ml Sequagel XR (Biozym) 
7.5 ml Sequagel-buffer (Biozym) 
150 µl 10% Ammonium persulfate (APS) 
15 µl TEMED 
and polymerised for 1 hour. 
Cycle sequencing reactions were done using the Thermo-Sequenase 
Fluorescent-Labeling Cycle-Sequencing Kit according to a protocol of the supplier. 
The reactions were pre-mixed the following way: 
4 µl H2O 
4 µl plasmid DNA (100-300 ng/µl) 
4 µl IRD800-labelled primer (2 pmol/µl) 
to a total reaction volume of 12 µl. 
The pre-mix was distributed in four tubes, 3 µl in each, and 1.3 µl of Thermo-
Sequenase DNA Polymerase and Termination Mix A/C/G/T was added to each 
tube. 
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The following parameters were used for a cycle-sequencing: 
30 sec 95°C  
15 sec Ta 30 cycles  
1 min 70°C  
Each reaction was stopped with 4 µl of a Stop/Loading Buffer. Samples were then 
analysed by electrophoresis or stored at -20°C. 
The reaction tubes were heated for 5 min at 70°C to denature the samples. 
Then 1.3 µl/well was loaded onto sequencing gel, and run overnight. Data were 
analysed using a LI-COR user program. 
2.2.3.10 Electrophoretic Separation of DNA 
Gel electrophoretic separation of DNA was performed in 1 to 2% agarose gels run 
at 30 to 80V with 0.5 x TBE as a running buffer. Samples were diluted in 
6 x Loading Dye (Promega) and loaded on gels containing 0.1 µg/ml ethidium 
bromide for visualisation.  
10 x TBE 
108 g Tris-base 
55 g Boric acid 
40 ml 0.5 M EDTA, pH 8.0 
adjusted with H2O to 1 l 
2.2.3.11 Elution of DNA Fragments from a Gel 
For elution of DNA fragments from agarose gels, the QIAquick Gel Extraction Kit 
was used. DNA fragments were excised from the gel on UV light and handled as 
recommended by the manufacturer. DNA was eluted in 30 µl of EB buffer, purified, 
and concentrated by ethanol precipitation.  
2.2.3.12 Southern Blot Analysis 
For Southern blot analysis, DNA samples were loaded onto a 1% agarose gel and 
run at 50V for 4 hours or overnight. Following electrophoresis, the gel was 
processed for blotting by depurination, denaturation, and neutralization. The gel 
was rinsed in H2O between each step. 
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For depurination, the gel was placed in 0.25 M HCl and agitated gently for 15 min. 
Then, the gel was submerged in denaturation buffer (0.5 M NaOH/1.5 M NaCl) 
and incubated for 45 min with gentle agitation. To neutralize the gel, it has been 
submerged in neutralization buffer (0.5 M Tris-HCl/1.5 M NaCl) and incubated for 
30 min with gentle agitation. Then, the neutralization solution was replaced with 
the fresh one and incubated for further 30 min.  
The DNA was transferred from the gel onto the Hybond-N+ membrane by 
vacuum transfer using the Vacuum blotter (Model 785, BIO-RAD) for 90 min. 10 x 
SSC was used as a transfer buffer. The membrane was pre-wetted with H2O and 
then submerged for 5 min in transfer buffer. Following the transfer, the membrane 
was rinsed for 5 min in 2 x SSC, air-dried, and cross-linked by UV exposure at 
120 000 microjoules/cm2. The membrane was wrapped in plastic foil and stored at 
4°C until use.  
DNA probes were labelled with [α-32P] dCTP by random oligonucleotide 
priming using Megaprime DNA Labeling System, according to the manufacturer’s 
recommendations. Typically, 25 ng of labelled probe was used for each 
hybridization. Unincorporated nucleotides were removed using QIAquick 
Nucleotide Removal Kit, according to the protocol of the supplier. Subsequently, 
the radioactively labelled probe was denatured at 98°C for 5 min and quickly 
placed on ice. 
Prehybridization and hybridization were carried out in glass tubes in a 
commercial hybridization oven. The membrane was placed RNA-side-up in a 
hybridization tube, ~5 ml of pre-warmed ExpressHyb solution were added and it 
was prehybridized with rotation at 60°C for 30 min. Following prehybridization, the 
denaturated probe was added into the hybridization solution and the incubation 
was continued at 60°C overnight.  
The next day, the blot was rinsed quickly in 2 x SSPE/0.1% SDS wash 
solution. Then, the washing solution was replaced with the fresh one and 
incubated with rotation for 1 hour at room temperature. After that time, the solution 
solution was replaced with 0.1 x SSPE/0.1% SDS wash solution and incubated 
with rotation for 1 hour at 60°C. After the final wash, the membrane was 
immediately covered with plastic wrap and mounted. Autoradiography was 
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performed by exposition to Kodak X-ray film at -70°C in a cassette with two 
intensifying screens.  
For re-probing the membrane, the probe was stripped from the membrane by 
incubation with shaking for 10 min in 0.5% SDS solution pre-warmed to 80-100°C. 
The membrane was then covered with plastic wrap and stored at 4°C until use. 
20 x SSC 
3 M NaCl 
0.3 M Natrium citrate 
20 x SSPE 
3.6 M NaCl 
0.2 M Natrium phosphate 
0.02 M EDTA, pH 8.0 
pH was adjusted to 7.7, H2O was added to a final volume of 1 liter and the solution 
was autoclaved. 
2.2.3.13 Cancer Profiling Array Analysis 
Cancer Profiling Array (BD Biosciences) consists of SMART-amplified cDNA from 
241 tumour and corresponding normal tissues from individual patients, along with 
eight negative and positive controls (yeast total RNA; yeast tRNA; E.coli DNA; 
human Cot-1 DNA; poly(A); ubiquitin cDNA; human genomic DNA). Samples on 
the array are normalized to four different housekeeping genes: ubiquitin, 23-kDa 
highly basic protein, β-actin, and glutamase dehydrogenase. The array also 
includes the following human cancer cell lines: HeLa; Burkitt’s lymphoma, Daudi; 
chronic myelogenous leukemia K562; promyelocytic leukemia HL-60; melanoma 
G361; lung carcinoma A549; lymphoblastic leukemia MOLT-4; colorectal 
adenocarcinoma SW480, and Burkitt’s lymphoma, Raji. 
The 369-bp PCR fragment of the human S100A14 cDNA, corresponding to 
the complete protein coding region, was used as a hybridization probe. The probe 
was prepared using H1043f and H1043r primers.  
Hybridization was performed according to the manufacturer’s recommen-
dations and as described above for Southern blot, except for the following 
modifications: the array membrane was prehybridized in 15 ml of prewarmed 
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ExpressHyb solution with 1.5 mg yeast tRNA at 65°C for 2 hours. The 
radioactively labelled cDNA probe was mixed with 100 µg of yeast tRNA, 
denatured at 98°C for 10 min, and hybridized to the array at 65°C overnight. 
Following exposure to a phosphor screen for 14 hours and 7 hours, the array was 
scanned with the GS-250 Molecular Imager (BIO-RAD, Munich, Germany) at a 
800-µm resolution. The results were quantified using the Molecular Analyst 
Software Version 1.4 by applying a grid to the image to measure the intensity of 
the hybridization signal of every spot. After background subtraction, the image was 
normalized using all spots on the membrane as reference points. The threshold 
values for up- and down-regulation were chosen based on careful inspection of 
tumour/normal intensity ratios for all the spots on the membrane (intensity ratio >2 
for up-regulation and <0.5 for down-regulation).  
2.2.3.14 Fluorescence in situ Hybridization (FISH) Analysis 
The FISH analysis was performed by Ms. N. Deutschmann (Institute of Pathology, 
Berlin, Germany) as described by Lichter and Ried (Godsen, 1994). The DNA from 
the genomic PAC clones I22230, A12752, and D11609 was purified with Qiagen 
Maxi Kit and labelled by nick-translation with biotin-16-dUTP (Roche). Next, 
hybridization on metaphases of normal lymphocytes was performed. Images were 
captured with a cooled charge-coupled device camera (Photometrics, Tucson, 
Arizona) and processed using a custom made program (Karyomed, KaryoMedics, 
Germany). 
2.2.3.15 5’ Rapid Amplification of cDNA Ends (5’ RACE) 
The 5’-end of the S100A14 cDNA was determined with 5’ RACE Kit according to 
the supplier’s manual, using poly(A) RNA from normal colon tissue. The gene-
specific primers for 5’ RACE included GPS1, NGPS1, and NGPS2. The PCR 
products were cloned into the pCR2.1 TA Cloning Vector and 24 clones were 
sequenced. 
2.2.4 Dual-Luciferase Reporter Assay 
Human embryonic epithelial kidney cells HEK 293 were plated in 6-well plates at 
1.5 x 105 cells/well a day before transfection. The cells were transfected for 
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6 hours using a transfection mixture consisting of 200 µl of Opti-MEM, 4 µl of 
LipofectAMINE, 1 µg of Firefly luciferase reporter constructs driven by the 
S100A14 promoter fragments, and 0.1 µg of pRL-TK Renilla luciferase reporter 
vector as an internal control for transfection efficiency.  
For co-transfection experiments, cells were transfected with a total of 1 µg 
DNA, consisting of a mixture of 0.5 µg of the p2C-luc plasmid and 0.5 µg of the 
expression vector encoding wild type p65. Where necessary, “empty” vector for 
p65 (pcDNA3Flag) or pGL3-Basic vector were included to maintain constant 
amounts of DNA.  
The assays for firefly and Renilla luciferase activity were performed using the 
Dual-Luciferase Reporter Assay Kit (Promega), as recommended by the 
manufacturer. Forty-eight hours after transfection, the cells were washed once 
with 1 x PBS and cell lysates were prepared by passive lysis in 250 µl of freshly 
prepared 1 x passive lysis buffer (Promega). Firefly and Renilla luciferase activities 
were assayed in 20 µl of cell lysate pre-dispensed into 5-ml Sarstedt tubes, 
followed by sequential autoinjection of 25 µl LAR II and Stop&Glo reagents using 
the Lumat LB9507 luminometer fitted with automatic injection system (Berthold 
Technologies, Germany). The luminometer was programmed to perform a 
2-second per measurement delay, followed by a 10-second measurement period 
for each reporter assay. 
Luciferase read-out was obtained from triplicate transfections and averaged. 
Firefly luciferase activity was normalized to the Renilla luciferase activity, and the 
results were expressed as relative luciferase activity.  
2.2.5 Preparation and Analysis of RNA 
2.2.5.1 RNA Preparation 
Total RNA from cultured cells was isolated using TRIzol (Invitrogen). Cells growing 
on 100-mm dishes were washed once with pre-cooled 1 x PBS and lysed by 
adding 2 ml of TRIzol reagent and passing the cell lysate several times through a 
pipette. Then the lysed cells were scraped off with a sterile cell scraper (Sarstedt) 
and transferred to 11-ml Sarstedt tubes. The samples were then extracted with 
0.4 ml of chloroform (0.2 ml chloroform per 1 ml of TRIzol reagent) by inversion 
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mixing. Phase separation was achieved by placing the samples at room tempe-
rature for 5 min, and centrifuging at 9 000 x g and 4°C for 20 min. The aqueous 
layer was mixed with 1 ml of isopropanol (0.5 ml isopropanol per 1 ml of TRIzol 
reagent) to precipitate the RNA. Samples were incubated at room temperature for 
10 min, then centrifuged at 10 000 x g and 4°C for 10 min. The RNA pellet was 
washed with 2 ml of 80% ethanol (1 ml ethanol per 1 ml of TRIzol reagent), and 
centrifuged at 7 500 x g and 4°C for 5 min. The pellet was air-dried, resuspended 
in DEPC-treated water, and the RNA was quantified using a GeneQuant II 
RNA/DNA spectrophotometer (Pharmacia Biotech). The concentration of RNA was 
adjusted to ~1.0-1.5 µg/µl. Typical OD 260/280 ratios were ~1.4-1.5. To assess 
the integrity of the RNA preparations, a test formaldehyde-agarose gel 
electrophoresis was performed.  
Tissue samples were homogenized in 4 ml of TRIzol reagent using a power 
homogenizer (MICRA). The homogenized samples were incubated at room 
temperature for 5 min and followed the standard RNA extraction procedure as 
outlined above.  
Poly(A) RNA was isolated using FastTrack 2.0 Kit (Invitrogen) according to 
the recommendations of the manufacturer. 
DEPC-treated H2O 
1 l H2O 
1 ml Diethylpyrocarbonate (DEPC) 
The solution was stirred on a magnetic stirrer overnight in a fume hood and 
autoclaved the next day. 
2.2.5.2 Electrophoretic Separation of RNA 
A 10-µg aliquot of total RNA was size-fractionated on 1% denaturing agarose gel 
in the presence of 2.2 M formaldehyde.  
To denature the RNA sample, a denaturation reaction was set up:  
RNA 10.0 µg 
10 x MOPS 1.0 µl  
Formaldehyde 3.5 µl 
Formamide 10.0 µl 
10 x Gel-loading buffer 2.0 µl 
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The RNA solution was incubated for 10 min at 55°C and then quickly chilled on 
ice. After loading, the gel was run in 1 x MOPS electrophoresis buffer at 50V for 
~5 hours, visualised and photographed on a UV transilluminator. 
Denaturing agarose gel 
1 g Agarose  
72.2 ml of DEPC-treated H2O 
agarose was disolved by boiling in a microwave oven and cooled to ~50°C. In a 
chemical fume hood, 10 ml of 10 x MOPS electrophoresis buffer and 17.8 ml of 
formaldehyde were added and the gel was casted. 
10 x MOPS 
0.2 M MOPS 
50 mM Sodium acetate 
10 mM EDTA, pH 8.0 
pH was adjusted to 7.0 with NaOH 
10 x Gel-loading buffer 
500 µl Formamide 
2 µl EDTA, pH 8.0 
5 µl Ethidium bromide 
0.1% w/v Bromophenol blue  
2.2.5.3 Northern Blot Analysis 
Electrophoretically separated RNA was transferred from gel onto Hybond-N 
membrane by upward capillary transfer. Prior to the transfer, the gel was rinsed 
with H2O. The membrane was prepared for the transfer by immersing in 10 x SSC 
for 5 min and the gel was placed on a solid support in an inverted position. Then, 
the membrane was placed on the top of the gel, followed by 6 pieces of Whatman 
3MM papers and a stack of paper towels. A glass plate was put on it and weighted 
down with a 500-g weight. The transfer occurred overnight in 20 x SSC buffer. The 
next day, the membrane was immersed for 5 min in 2 x SSC, air-dried, and cross-
linked by UV irradiation. If not used immediately, the membrane was stored at 4°C.  
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The radioactive labelling of the probe, hybridization, washing of the blots, and 
stripping of radiolabelled probes were carried out as described for Southern blot 
analysis (Section 2.2.3.12). Following modifications to the protocol were 
introduced for Northern blot analysis: the hybridization temperature was 64°C and 
the membrane washing times were 40 min. All the washing steps were performed 
with solutions prepared with DEPC-treated H2O. As a hybridization probe, the PCR 
fragment of the human S100A14 cDNA corresponding to the complete protein 
coding region was used. To confirm equal RNA loading and transfer, the 180-bp 
fragment of the mouse 18S cDNA that cross-hybridizes with human 18S RNA was 
used. 
Typically, the blots were exposed to a phosphor screen for different time 
periods and scanned with the GS-250 Molecular Imager (BIO-RAD, Munich, 
Germany) at a 200-µm resolution. The results were quantified using the Molecular 
Analyst Software Version 1.4. Alternatively, if autoradiography was performed, the 
autoradiographs were scanned to quantify the intensity of the radiographic bands 
using a scanning laser BIO-RAD Laboratories Imaging Densitometer Model 
GS-670 and densitometry was performed. 
2.2.5.4 Reverse Transcriptase-PCR (RT-PCR) Analysis 
For the detection and expression analysis of the S100A14 mRNA, the 
THERMOSCRIPT RT-PCR System (Invitrogen) was applied. First, cDNA 
synthesis was performed using 3 µg of total RNA primed with gene-specific primer 
H1043-rev and control gene primer GAPDH-rev. The RNA was reverse-
transcribed at 55°C for 1 hour according to the manufacturer’s recommendations. 
The reaction was terminated by heating at 85°C for 5 min. In the second step, 
PCR amplification was carried out using 2 µl of the cDNA synthesis reaction and 
primed with gene specific primers designed from open reading frame: ex1-for or 
ex3-for, and H1043-rev. A control PCR reaction for GAPDH was performed in 
parallel using the primer pair: GAPDH-for and GAPDH-rev. Amplification resulted 
in DNA fragments of 249-bp (ex1-for and H1043-rev), 425-bp (ex1-for and 
H1043-rev), and 800-bp (GAPDH-for and GAPDH-rev). PCR products were 
analysed on a 1.2% agarose gel and viewed on UV light. 
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2.2.6 Analysis of Proteins 
2.2.6.1 Protein Isolation from Mammalian Cells 
For protein isolation, cells were washed twice with cold 1 x PBS and lysed with 
denaturing hypotonic lysis buffer on ice. The lysed cells were scraped off the 
plates, transferred into 1.5-ml Eppendorf tubes, and incubated with shaking for 
10 min at 95°C. Then, the protein samples were aliquoted and stored at -20°C. 
Denaturing hypotonic lysis buffer 
1% SDS 
10 mM Tris-HCl, pH 7.5 
2 mM EDTA, pH 8.0 
2.2.6.2 Subcellular Fractionation 
Cells were washed twice with cold 1 x PBS and lysed in hypotonic lysis buffer 
(1.2 ml per 100-mm plate) for 10 min. The cell lysate was homogenized in a pre-
cooled Dounce homogenizer by repeated strokes and centrifuged for 10 min at 
2 700 x g to pellet the nuclei using a Sorvall SA-600 rotor. The nuclear pellet was 
resuspended in a volume of 50 µl of 2 x SDS sample buffer. 
The postnuclear supernatant was transferred into Beckman tubes (13 x 
15 mm) and centrifuged for 30 min at 60 000 x g and 4°C to pellet the membranes 
using a Beckman TLN 100.3 rotor. The crude membranes were resuspended in a 
volume of 100 µl of 2 x SDS sample buffer. 
The postmembrane supernatant was further fractionated by methanol/ 
chloroform precipitation to recover cytoplasmic proteins. Four ml methanol were 
added to the postmembrane supernatant, then 1 ml chloroform was added and 
mixed, then 3 ml of H2O were added and mixed. The solution was centrifuged at 
15 000 x g for 15 min at 4°C. The upper phase was discarded, and 6 ml methanol 
were added, mixed and centrifuged again at 15 000 x g for 15 min at 4°C. The 
pellet was dried and resuspended in 100 µl of 2 x SDS sample buffer. 
Following dissolving of the pellets in 2 x SDS sample buffer, samples were 
incubated with shaking for 10 min at 95°C, centrifuged for 5 min at 14 000 x g, and 
stored at -20°C until use.  
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The resulting fractions were tested for their enrichment in soluble, membrane, and 
nuclear fractions by Western blotting with anti-α-tubulin, anti-pan RAS, and anti-
phospho-c-JUN antibodies, respectively.  
Hypotonic lysis buffer 
10 mM Tris-HCl, pH 8.0 
0.1 mM DTT 
1 mM PMSF 
1 tab/10 ml protease inhibitor Complete tabs (Roche) 
2 x SDS sample buffer 
120 mM Tris-HCl, pH 6.8 
200 mM DTT 
4% w/v SDS 
10% w/v Glycerol 
0.002% w/v Bromophenol blue  
2.2.6.3 Determination of Protein Concentration 
Protein content was determined by colorimetric amido-black method as described 
by Schaffner and Weissmann (1973). 
A standard curve for bovine serum albumine (BSA) was created by preparing 0.5, 
0.75, 1, 2, 4, 8, and 10-µg duplicate dilutions of 200 mg/ml stock solution of BSA.  
Then, 1 µl of protein standards (applied in duplicates) and 1 µl of protein 
sample were applied to the nitrocelulose membrane (Schleicher & Schüll). The 
membrane was placed in 0.1% amido-black for 1 min and then washed 
extensively with shaking using freshly prepared destaining solution. The destaining 
solution was replaced several times till the membrane was completely destained. 
The protein spots were cut out, put into Eppendorf tubes, and 800 µl of elution 
solution were added. The tubes were placed in an Eppendorf shaker and shaken 
for 30 min. 
Absorbance of standards and protein samples was measured at 630 nm in 
disposable 1.5 ml semi-micro cuvettes (Brand) using Biochrom 4060 software in 
UV-Visible Spectrophotometer (Pharmacia LKB). Protein concentration was 
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determined by plotting absorbance of the protein samples against the standard 
curve using Microsoft Excel program. 
Destaining solution 
90 ml Methanol 
2 ml Acetic acid 
8 ml H2O 
Elution solution 
50 ml Ethanol 
10 µl 0.5 M EDTA, pH 8.0 
0.5 ml 5 M NaOH 
49.5 ml H2O 
2.2.6.4 One-Dimensional SDS Gel Electrophoresis (PAGE) 
Protein samples were separated by polyacrylamide gel electrophoresis (PAGE) 
using the standard Laemmli method.  
Protein samples were mixed with 1 volume of 2 x SDS sample buffer and 
denatured for 5 min at 95°C. Equal amounts of proteins were loaded onto 12% gel 
and run ~4 hours at 65V in 1 x running buffer using Mini-PROTEAN 3 Cell 
electrophoresis tank (BIO-RAD). Protein separation was controlled by running a 
Prestained Broad Range Protein Marker (BIO-RAD). 
Separating gel: 10 ml of 12% gel 
3.35 ml H2O 
2.5 ml 1.5 M Tris-HCl, pH 8.8 
4.0 ml 30% Acrylamide/Bisacrylamide 
100 µl 10% SDS  
50 µl APS 
10 µl TEMED 
Stacking gel: 5 ml of 4% gel 
3.05 ml H2O 
1.25 ml 0.5 M Tris-HCl, pH 6.8 
0.66 ml 30% Acrylamide/Bisacrylamide 
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50 µl 10% SDS  
50 µl APS 
10 µl TEMED 
5 x running buffer 
15.1 g/l Tris-base 
72.0 g/l Glycine 
5.0 g/l SDS 
An alternative protocol was used for S100A14 gel electrophoresis. Protein 
samples were mixed with 1 volume of 2 x tricine sample buffer and denatured for 
5 min at 95°C. Equal amounts of proteins were loaded onto 15% Tris-tricine gel 
and run in 1 x cathode (upper tank) and 1 x anode (lower tank) electrophoresis 
buffer for ~1 hour at 35V and ~5 hour at 50V.  
2 x Tricine sample buffer 
2.0 ml 0.5 M Tris-HCl, pH 6.8 
2.4 ml Glycerol 
4.2 ml 20% SDS 
0.31 g DTT 
0.02% w/v Coomassie blue 
adjusted with H2O to 10 ml 
Separating gel: 10 ml of a 15% gel 
1.66 ml H2O 
3.32 ml 3 M Tris-HCl, pH 8.45 
1.06 ml Glycerol 
3.75 ml 40% Acrylamide/Bisacrylamide 
150 µl 20% SDS  
50 µl APS 
10 µl TEMED 
Stacking gel: 5 ml of 4% gel 
2.71 ml H2O 
1.66 ml 3 M Tris-HCl, pH 8.45 
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0.5 ml 40% Acrylamide/Bisacrylamide 
75 µl 20% SDS 
50 µl APS 
10 µl TEMED 
Cathode electrophoresis buffer 
12.11 g/l Tris-base 
17.92 g/l Tricine 
1 g/l SDS 
stored at 4°C 
Anode electrophoresis buffer 
24.22 g Tris-base 
diluted to 1 l with H2O, adjusted to pH 8.9, and stored at 4°C 
2.2.6.5 Western Blot Analysis 
Following electrophoresis, the stacking gel was discarded, and the separating gel 
was submerged in transfer buffer for 20 min. During that time, PVDF membrane 
(Amersham) was activated in methanol for 11 sec, washed in H2O for 5 min, and 
equilibrated in transfer buffer for 10 min. On a semidry transfer unit (Peqlab 
Biotechnology GmbH) 6 sheets of Whatman paper pre-wetted in transfer buffer, 
the PVDV membrane, the gel, and 6 sheets of pre-wetted Whatman paper were 
assembled. The protein transfer proceeded for 45 min at 200 mA.  
Transfer efficiency was controlled by Coomassie blue staining of the gel for 
30 min, followed by destaining and visualisation. After the transfer, the membrane 
was washed briefly in TBST buffer and blocked for 1 hour in 10 ml of blocking 
buffer at room temperature with shaking on a rotor platform. After the blocking 
procedure, the membrane was washed 3 x 5 min in 20 ml TBST, and incubated 
overnight with the primary antibody in 5% BSA solution (5% BSA in TBST) at 4°C. 
The next day, the membrane was washed 3 x 10 min in 20 ml TBST, and 
incubated with the corresponding secondary antibody for 1 hour. The membrane 
was washed again 3 x 10 min in TBST, and the immunocomplexes were detected 
with an Enhanced Chemiluminescence Kit (ECL, Amersham), as recommended by 
the supplier. 
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For S100A14 detection, the membranes were incubated with the primary antibody 
for 2 hours in blocking buffer at room temperature. 
For re-probing, the membranes were incubated in stripping buffer for 30 min 
at 70°C and washed 3 x 10 min in TBST. The membranes were subsequently 
blocked in blocking buffer and immunoblotted with a primary antibody as outlined 
above. 
Primary antibodies, corresponding secondary antibodies, and their dilutions 
Primary antibody Dilution Secondary antibody Dilution 
Anti-β-actin 1:10 000 Peroxidase-conjugated rabbit anti-
mouse 
1:5000 
Anti-AKT 1:1000 Peroxidase-conjugated goat anti- 
rabbit 
1:5000 
Anti-c-JUN 1:1000 Peroxidase-conjugated goat anti- 
rabbit 
1:5000 
Anti-p38 1:1000 Peroxidase-conjugated goat anti- 
rabbit 
1:5000 
Anti-Phospho-AKT (Ser473) 1:1000 Peroxidase-conjugated goat anti- 
rabbit 
1:5000 
Anti-Phospho-HSP27 (Ser82) 1:1000 Peroxidase-conjugated goat anti- 
rabbit 
1:5000 
Anti-Phospho-c-JUN (Ser63) 1:1000 Peroxidase-conjugated goat anti- 
rabbit 
1:5000 
Anti-Phospho-p38 
(Thr180/Tyr182) 
1:1000 Peroxidase-conjugated goat anti- 
rabbit 
1:5000 
Anti-Phospho-p44/42 MAPK 
(Thr202/Tyr204) 
1:1000 Peroxidase-conjugated goat anti- 
rabbit 
1:5000 
Anti-Phospho-SAPK/JNK 
(Thr183/Tyr185) 
1:1000 Peroxidase-conjugated goat anti- 
rabbit 
1:5000 
Anti-S100A14 affinity-purified 1:2700 Peroxidase-conjugated goat anti- 
rabbit 
1:5000 
Anti-SAPK/JNK 1:1000 Peroxidase-conjugated goat anti- 
rabbit 
1:5000 
Anti-pan-RAS 1:800 Peroxidase-conjugated rabbit anti-
mouse 
1:5000 
Anti-α-tubulin 1:5000 Peroxidase-conjugated rabbit anti-
mouse 
1:5000 
Anti-V5 1:5000 Peroxidase-conjugated rabbit anti-
mouse 
1:5000 
 
Transfer buffer 
5.81 g Tris-base 
2.93 g Glycine 
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1.875 ml 20% SDS 
200 ml Methanol 
H2O was added to 1 l 
TBST 
10 ml 1 M Tris-base, pH 8.0 
30 ml 5 M NaCl 
500 µl Tween-20 
H2O was added to 1 l 
Coomassie blue staining solution 
50% v/v Methanol 
0.05% v/v Coomassie blue R-250 
10% v/v Acetic acid 
40% H2O 
Coomassie blue destaining solution 
5% v/v Methanol 
7% v/v Acetic acid 
88% H2O 
Blocking buffer 
5% Non-fat dry milk (Difco, Becton Dickinson, MD, USA) in TBST 
Stripping buffer 
25 ml Tris-HCl, pH 6.7 
20 ml 20% SDS 
1.4 ml 14.3 M β-Mercaptoethanol 
H2O was added to 200 ml 
2.2.7 S100A14 Antibody Generation 
The anti-S100A14 polyclonal antibody was raised by immunizing two rabbits with 
the NH2 – CEAAKSVKLERPVRGH – COOH peptide located in the C-terminus of 
S100A14 protein (Eurogentec, Belgium). Animals were immunized four times at 
2-weeks intervals by subcutaneous injection of 50-100 µg of peptide in an 
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emulsion with KLH. The titer of the antiserum was determined by ELISA using 
100 ng of the antigen peptide. A dilution of maximally 1:1000 (antiserum SA1349) 
is possible for the detection of 4 µg of the antigen peptide. The antibody was 
affinity-purified with the antigen peptide using standard methods (Eurogentec, 
Belgium).  
Potential cross-reactivity of the antibody with other S100 family members 
was examined by Western blot using recombinant S100 proteins: S100A1, 
S100A2, S100A3, S100A4, S100A5, S100A6, S100A8, S100A9, S100A12, 
S100A13, S100B, and a protein extract from HBE cells as a positive control. The 
recombinant proteins were kindly provided by Prof. Dr. C. Heizmann (University of 
Zürich, Switzerland) and Dr. C. Kerkhoff (University of Münster, Germany). No 
cross-reactivity with any S100 protein tested was detected confirming that the 
C-terminal peptide used for rabbit immunisation is indeed S100A14-specific (data 
not shown). 
2.2.8 Immunofluorescence Analysis 
For immunofluorescence analysis, cells were seeded and grown on 18 x 18 mm 
glass cover slips. After fixation with freshly prepared 3% paraformaldehyd in 
1 x PBS for 15 min at room temperature, cells were permeabilized with 0.2% 
Triton X-100 for 2 min, washed 3 x 5 min with 1 x PBS and incubated for 1 hour in 
blocking buffer (10% FCS in 1 x PBS).  
The S100A14 affinity-purified antibody was diluted 1:2000, and anti-V5 
antibody 1:200 in blocking buffer. Cover slips were incubated with the primary 
antibodies for 2 hours at room temperature, then washed 3 x 5 min in PBS, and 
incubated with the secondary antibodies for 1 hour. Fluorescein isothiocyanate 
(FITC)-conjugated goat anti-mouse IgG (H + L) antibody at 1:200 and FITC-
conjugated goat anti-rabbit antibody at 1:200 were used. Nuclei were stained with 
4,6-diamidino-2-phenylindole (DAPI) (Sigma, Steinheim, Germany) for 5 min. 
Cover slips were then washed with PBS, air-dried, and mounted on glass slides 
with DABCO anti-fade reagent (Merck, Darmstadt, Germany). They were 
examined using Leica confocal laser-scanning microscope (Jena, Germany).  
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2.2.9 Immunohistochemistry 
Immunohistochemical staining of tissue sections was performed by Ms. B. Thews, 
Ms. K. Witkowski, and Ms. K. Petri at the Immunohistochemistry Laboratory of the 
Institute of Pathology, Charité in Berlin.  
Paraffin-embedded archive material was retrieved from the files of the 
Institute of Pathology of the Charité University Hospital. One-µm sections were cut 
from the blocks, mounted on superfrost slides (Menzel-Gläser, Germany) or 
ChemMate Capillary Cap Microscope slides (DAKO), dewaxed with xylene and 
gradually hydrated. Antigen retrieval was performed by pressure cooking in 0.01 M 
citrate buffer for 5 min. The primary antibody was incubated at room temperature 
for 30 min. The biotinylated secondary antibody reagent of the ChemMate 
Detection Kit (DAKO, Denmark), that reacts equally well with rabbit and mouse 
immunoglobulins, was applied as recommended by the supplier. Detection took 
place by indirect streptavidin-biotin method with alkaline phosphatase as the 
reporting enzyme according to the manufacturer’s instructions. Chromogen-Red 
(ChemMate Detection Kit) served as chromogen, afterwards the slides were briefly 
counterstained with haematoxylin and aquaeously mounted. 
Primary antibodies, corresponding secondary antibodies, and their dilutions  
Primary antibody Dilution Secondary antibody 
Anti-S100A14 1:1000 ChemMate biotinylated goat anti-rabbit 
Anti-ERBB2 1:1000 ChemMate biotinylated goat anti-rabbit 
Anti-Ki-67 1:1000 ChemMate biotinylated goat anti-mouse 
Anti-ER 1:100 ChemMate biotinylated goat anti-mouse 
Anti-PR 1:500 ChemMate biotinylated goat anti-mouse 
 
Specificity of the S100A14 antibody was verified by incubating tissue sections with 
pre-immune serum, demonstrating completely negative staining. 
Immunostained slides were analysed under a Zeiss Axioskop light 
microscope and scored after the entire slide had been evaluated. The 
immunohistochemical evaluation was performed by Prof. Dr. I. Petersen.  
In order to analyse the expression level of S100A14, we introduced a 
semiquantitative scoring system consisting of four different staining patterns to 
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distinguish between positive and negative staining. The highest positive score has 
been assigned to score 3, where the entire tissue shows strong positive staining. 
Moderately positive staining represents score 2. Score 1 was assigned to 
borderline positive staining of the protein and score 0 represents the complete 
negative staining (Fig. 2). 
Score 0 Score 1
Score 2 Score 3  
Fig. 2 The scoring system used for immunohistochemical analysis of 
S100A14. Examples shown are lung tumour tissue spots stained with anti-S100A14 
antibody. The four different scores used are indicated. 
ERBB2 immunostaining was evaluated using the method employed by the 
HercepTest (DAKO) according to the degree and the proportion of plasma 
membrane staining. ERBB2 expression was negative for a score of 0 to 1+. 
A score of 0 was defined as no staining or plasma membrane staining in less than 
10% of tumour cells. A score of 1+ comprised faint or partly stained plasma 
membrane in more than 10% of tumour tissue. Tumours with scores of 2 or 
greater were considered to be positive for ERBB2 overexpression. A score of 2+ 
was defined as weak to moderate complete plasma membrane staining in more 
Materials and Methods  48 
 
 
than 10% of tumour cells. A score of 3+ was interpreted as strong, complete 
plasma membrane staining in more than 10% of tumour cells. 
2.2.10 Tissue Microarrays (TMA) Generation 
Tissue microarrays containing normal human tissues, as well as breast and lung 
tumours were generated by Dr. Y. Yongwei and Ms. N. Deutschmann. The normal 
human tissue array consisted of 29 tissue samples, the lung tumour array 
consisted of 150 tissue samples, and the breast tumour array was composed of 
146 tissue samples. All the tissue samples were derived from randomly selected 
patients who underwent surgical resections performed at the Department of 
Surgery, University Hospital Charité between 2000 and 2002.  
Suitable areas for tissue retrieval were marked on standard haematoxylin-
eosin (HE) sections. Then, tissue cylinders with a diameter of 1.0 or 0.6 mm were 
punched out of the paraffin block and transferred into a recipient array block using 
a manual tissue arrayer purchased from Beecher Instruments (Woodland, USA). 
The tissue array was cut in 1-µm sections without any sectioning aid like adhesive 
tapes or additionally coated slides. 
Limitations of the tumour material and slide damages were the main reasons 
for the missing specimens on the tissue microarray slides. Tissue spots with 
heterogeneous expression patterns for S100A14 were subsequently examined by 
whole tissue section immunohistostaining. 
2.2.11 Statistical Analysis 
The Fisher’s exact test for categorical variables was used to compare 
immunohistochemical results for S100A14 with other immunohistochemical 
markers and clinicopathologic characteristics. All analysis were two-tailed, and the 
criterion of significance was set at p < 0.05. The statistical analysis was 
undertaken using the SPSS statistical package (Version 11.5). 
2.2.12 Bioinformatics 
Blast analysis was performed to search for homologies at the nucleotide level and 
for pairwaise sequence alignments (National Center for Biotechnology Information, 
http://www.ncbi.nlm.nih.gov/BLAST). Recognition sites for restriction enzymes 
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were identified with the Webcutter program at the Web address 
http://www.firstmarket.com/cutter/cut2.html. S100A14 promoter region was 
analysed by TRANSFAC 4.0 (http://www.transfac.gbf.de/TRANSFAC), using the 
MatInspector V2.2 program. Parameters for MatInspector were set for 1.0 core 
similarity (a 4-nt highly conserved sequence) and 0.85 matrix similarity, employing 
the vertebrates matrix group. ClustalW 1.8 program was used for multiple 
alignments of DNA sequences (http://www.ebi.ac.uk).  
The ExPASy nucleotide translation tool (Swiss Institute of Bioinformatics, 
http://www.expasy.ch/tools/dna.html) was applied to translate cDNA in all six 
possible open reading frames. Sequence homologies at the amino acid level were 
determined with the EMBnet-CH Blast program and potential posttranslational 
modification sites with the PROSITE program (all the programs are available at the 
ExPASy Molecular Biology Server). Hydrophobicity analysis based on the method 
of Kyte and Doolittle was performed using the program ProtScale at the ExPASy 
Molecular Biology Server. Protein secondary structure was predicted with the 
PSIpred V2.0 (University College London, UK http://bioinf.cs.ucl.ac.uk/psipred). 
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3 Results 
3.1 Identification of the Human S100A14 cDNA 
3.1.1 Screening of SSH cDNA Libraries 
To identify new potential cancer diagnostic or therapeutic targets, suppression 
subtractive hybridization (SSH) transcript profiling was performed between normal 
human cultured bronchial epithelial cells (HBE) and the metastatic small cell lung 
carcinoma cell line H526 (Difilippantonio et al., 2003). 
The quality of the SSH library was confirmed by Northern blot analysis, 
indicating that 69% (236/342) of the clones were differentially expressed in the 
tumour cell line. In an initial evaluation we used a limited panel of cell lines 
including HBE cells, as well as lung tumour cell lines 2170, H526, and D51, 
representing the three major subtypes (squamous cell carcinoma, adeno-
carcinoma, and small cell lung carcinoma). Thirty-one cDNAs scored as 
differentially expressed in at least two of the tumour cell lines were analysed more 
extensively on an extended panel of cell lines including small airway epithelial cells 
(SAE), four immortalized HBE cells, and 32 lung cancer cell lines. The DNA 
sequences of isolated cDNA fragments were then determined and compared with 
those deposited in the GenBank database.  
Based on our interest in further examining those transcripts with no homology 
to any known gene, 6 partial cDNAs representing transcripts that were abundantly 
expressed in normal lung epithelial cells but were absent or under-represented in 
the majority of lung tumour cell lines were selected for further analysis. These 
cDNA fragments were sent to the German Resource Center of the Human 
Genome Project (RZPD, Heidelberg, Germany) for screening of human cDNA 
libraries enriched in full-length cDNAs. Three of those cDNA fragments 
represented the same unknown gene. Screening of the human lung, trachea, and 
primary keratinocyte cDNA libraries yielded 13 positive clones out of which 9 were 
confirmed positive by Southern blot analysis. Out of 5 clones containing the 
longest inserts determined by NotI/SalI-restriction digest, clones DKFZp404H1043, 
DKFZp404B1018, and DKFZp719J2437 were identified as candidate full-length 
cDNA clones. Clone DKFZp404H1043 (designated H1043) with cDNA insert of 
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1057 bp was chosen for further characterization. The insert size was in 
accordance with the transcript size estimated by Northern blot analysis.  
On the nucleotide level no homology to any known gene was found. Analysis 
of the predicted protein sequence revealed an S100-specific EF-hand Ca2+-binding 
domain as well as a high homology to the S100A13 calcium-binding protein. 
Therefore, we designated the transcript S100A14 and submitted it to the NCBI 
GenBank database under Accession No NM_020672 (LocusID LOC57402).  
To verify the full-length cDNA sequence of S100A14 we performed 5’ RACE 
on human colon cDNAs since this organ showed the most abundant expression of 
the transcript in our Northern blot analysis. It provided additional 5’ UTR sequence, 
not present in the H1043 clone. The predominant cDNA product was 1067 bp in 
length. 
3.1.2 Sequence Analysis of S100A14 cDNA 
The cDNA was predicted to contain an open reading frame (ORF) of 104 amino 
acids (nt 109-423), a 5’ untranslated region (UTR) of 108 bp, and a 3’ UTR of 
644 bp. The putative ATG initiation codon was embedded in a strong Kozak 
consensus sequence (CACCATGG) (Kozak, 1996) and was preceded by an in-
frame stop codon. A polyadenylation signal (nt 1028-1033) and a poly(A)-tail 
beginning after nucleotide 1053 oriented the fragment and provided further 
evidence for the predicted ORF. The nucleotide sequence and the predicted open 
reading frame of S100A14 are shown in Fig. 3. 
Computer-assisted analysis of the deduced amino acid sequence revealed 
an S100-specific EF-hand Ca2+-binding domain at the N-terminus (aa 33-45) 
consisting of 13 amino acids. The second putative canonical EF-hand motif has 
been deduced from the secondary structure and hydrophobicity analysis of the 
protein. It contained only 2 out of 6 conserved residues (Asp76 and Glu80) and 
might start at Gly72 ending at Ser83. In addition, the protein was predicted to 
contain a N-glycosylation site (aa 75-78), a protein kinase C phosphorylation site 
(aa 94-96), 5 casein kinase II phosphorylation sites (aa 16-19, 42-45, 73-76, 
77-80, 83-86), and a N-myristoylation site (aa 2-7). 
The calculated molecular weight of S100A14 is 11 662 Da and the isoelectric 
point is 4.99. Protein secondary structure analysis indicated two helix-loop-helix 
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structural motifs characteristic of calcium-binding sites. There was an extended 
hydrophilic loop at the extreme N-terminus in contrast to other S100 family 
members. 
 
             CTCCTGTCTTGTCTCAGCGGCTGCCAACAGATCATGAGCCATCAGCTC 48
 CTCTGGGGCCAGCTATAGGACAACAGAACTCTCACCAAAGGACCAGACACAGTGAGCACC 108 
 ATGGGACAGTGTCGGTCAGCCAACGCAGAGGATGCTCAGGAATTCAGTGATGTGGAGAGG 168
1  M  G  Q  C  R  S  A  N  A  E  D  A  Q  E  F  S  D  V  E  R 
 GCCATTGAGACCCTCATCAAGAACTTTCACCAGTACTCCGTGGAGGGTGGGAAGGAGACG 228
21  A  I  E  T  L  I  K  N  F  H  Q  Y  S  V  E  G  G  K  E  T 
 CTGACCCCTTCTGAGCTACGGGACCTGGTCACCCAGCAGCTGCCCCATCTCATGCCGAGC 288
41  L  T  P  S  E  L  R  D  L  V  T  Q  Q  L  P  H  L  M  P  S 
 AACTGTGGCCTGGAAGAGAAAATTGCCAACCTGGGCAGCTGCAATGACTCTAAACTGGAG  348
61  N  C  G  L  E  E  K  I  A  N  L  G  S  C  N  D  S  K  L  E   
 TTCAGGAGTTTCTGGGAGCTGATTGGAGAAGCGGCCAAGAGTGTGAAGCTGGAGAGGCCT  408
81   F  R  S  F  W  E  L  I  G  E  A  A  K  S  V  K  L  E  R  P   
 GTCCGGGGGCACTGAGAACTCCCTCTGGAATTCTTGGGGGGTGTTGGGGAGAGACTGTGG 468
101  V  R  G  H  *  
 GCCTGGAGATAAAACTTGTCTCCTCTACCACCACCCTGTACCCTAGCCTGCACCTGTCCT 528
 CATCTCTGCAAAGTTCAGCTTCCTTCCCCAGGTCTCTGTGCACTCTGTCTTGGATGCTCT  588
 GGGGAGCTCATGGGTGGAGGAGTCTCCACCAGAGGGAGGCTCAGGGGACTGGTTGGGCCA 648
 GGGATGAATATTTGAGGGATAAAAATTGTGTAAGAGCCAAAGAATTGGTAGTAGGGGGAG 708
 AACAGAGAGGAGCTGGGCTATGGGAAATGATTTGAATAATGGAGCTGGGAATATGGCTGG 768
 ATATCTGGTACTAAAAAAGGGTCTTTAAGAACCTACTTCCTAATCTCTTCCCCAATCCAA 828
 ACCATAGCTGTCTGTCCAGTGCTCTCTTCCTGCCTCCAGCTCTGCCCCAGGCTCCTCCTA 888
 GACTCTGTCCCTGGGCTAGGGCAGGGGAGGAGGGAGAGCAGGGTTGGGGGAGAGGCTGAG 948
 GAGAGTGTGACATGTGGGGAGAGGACCAGCTGGGTGCTTGGGCATTGACAGAATGATGGT 1008
 TGTTTTGTATCATTTGATTAATAAAAAAAAATGAAAAAAGTGAAAAAAAAAAAAAAAAA 1067
 
Fig. 3 Nucleotide and deduced amino acid sequence of the human S100A14 
gene. The predicted start codon and polyadenylation signal are underlined. An 
asterisk indicates the putative stop codon. Numbers to the left correspond to the 
single-letter amino acid sequence. Numbers to the right correspond to the nucleotide 
sequence. 
The deduced protein of S100A14 shares 68% similarity and 38% identity to 
S100A13 (Accession No Q99584) being the closest human match. Significant 
similarity was also found with S100A4 (62% similarity; 30% identity), S100A2 (60% 
similarity; 30% identity), S100A10 (58% similarity; 31% identity), and S100A9 
(55% similarity; 34% identity), as illustrated in Fig. 4. Furthermore, in the 
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SwissProt database we identified an apparent mouse orthologue, 1110013O05RIK 
protein (Accession No Q9D2Q8), showing 97% similarity (93% identity) using the 
human S100A14 amino acid sequence as a query. A comparison between the 
S100A14 cDNA and RIKEN 1110013O05 (1110013O05Rik) cDNA (GenBank 
Accession No NM_025393) revealed 87% identity. 
S100A14  MGQCRSANAEDAQEFSDVERAIETLIKNFHQYS-VEGGKETLTPSELRDLVTQQLPHLMP  59
RIK      MGQCRSANAEDAQEFSDVERAIETLIKNFHKYS-VAGKKETLTPAELRDLVTQQLPHLMP  59
S100A13  ---------MAAEPLTELEESIETVVTTFFTFARQEGRKDSLSVNEFKELVTQQLPHLLK  51
S100A4   -------------MACPLEKALDVMVSTFHKYSGKEGDKFKLNKSELKELLTRELPSFLG  47
S100A2   -------------MCSSLEQALAVLVTTFHKYSCQEGDKFKLSKGEMKELLHKELPSFVG  47
S100A10  --------------PSQMEHAMETMMFTFHKFAGDKG--Y-LTKEDLRVLMEKEFPGFLE  43
S100A9   ----------MTCKMSQLERNIETIINTFHQYSVKLGHPDTLNQGEFKELVRKDLQNFLK  50
  
S100A14  ----SNCGLEEKIANLGSCNDSKLEFRSFWELIGEAAKSVKLER--PVRGH--------- 104
RIK      ----SNCGLEEKIANLGNCNDSKLEFGSFWELIGEAAKSVKMER--PVTRS--------- 104
S100A13  ----DVGSLDEKMKSLDVNQDSELKFNEYWRLIGELAKEIRKKKDLKIRKK---------  98
S100A4   KR-TDEAAFQKLMSNLDSNRDNEVDFQEYCVFLSCIAMMCNEFFEGFPDKQPRKK----- 101
S100A2   EK-VDEEGLKKLMGNLDENSDQQVDFQEYAVFLALITVMCNDFFQGCPDR-P--------  97
S100A10  NQ-KDPLAVDKIMKDLDQCRDGKVGFQSFFSLIAGLTIACNDYFVVHMKQKGKK------  96
S100A9   KENKNEKVIEHIMEDLDTNADKQLSFEEFIMLMARLTWASHEKMHEGDEGPGHHHKPGLG 110
  
S100A14  ----     
RIK      ----     
S100A13  ----     
S100A4   ----     
S100A2   ----     
S100A10  ----     
S100A9   EGTP 114  
Fig. 4 Alignment of the predicted amino acid sequences of the human 
S100A14 and the mouse orthologue 1110013O05RIK with the most homologous 
S100 family members. Homology is represented by shading of the amino acid 
identities. Identical amino acid residues are indicated as black boxes whereas similar 
amino acids are indicated as gray boxes. 
3.2 Expression Profile in Tumour Cell Lines, Normal, and Neoplastic 
Tissues 
3.2.1 S100A14 mRNA Level in Tumour Cell Lines 
To characterize S100A14 expression in tumour cell lines from other tissues we 
extended the expression analysis to normal human cultured mammary epithelial 
cells, four immortalized epithelial cell lines, and 31 different human tumour cell 
lines as well as ten mouse and rat cell lines. The complete list of the examined cell 
lines is given in Table 2 and Table 3. 
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Table 2 Expression of S100A14 mRNA in human cancer cell lines. S100A14 
transcript level was examined by Northern blot and RT-PCR analysis. The expression 
level was determined by semiquantitative scoring as follows: (+++) strong expression, 
(++) moderate expression, (+) weak expression, (RT-PCR) transcript not detectable by 
Northern blot but detected by RT-PCR, (–) negative expression. The tumour cell lines 
histopathology: SCLC, small cell lung cancer; ADC, adenocarcinoma; SCC, squamous 
cell carcinoma; LCLC, large cell lung cancer; Ca, carcinoma. 
Cell lines Histopathology S100A14 
HBE Normal human bronchial epithelial cells +++ 
SAE Normal human small-airway epithelial cells +++ 
H378 SCLC – 
H82 SCLC – 
COLO 677 SCLC RT-PCR 
H446 SCLC – 
CPC-N SCLC – 
DMS-79 SCLC + 
H209 SCLC RT-PCR 
DMS-114 SCLC – 
H187 SCLC RT-PCR 
N417 SCLC – 
H526 SCLC metastatic – 
COLO 668 Brain metastasis of SCLC – 
SHP77 Large cell variant of SCLC – 
COLO 699 ADC – 
DV-90 ADC + 
H322 ADC + 
D51 ADC RT-PCR 
D54 ADC RT-PCR 
D117 ADC – 
H125 ADC – 
H23 ADC – 
A549 ADC RT-PCR 
H2228 ADC RT-PCR 
H2030 ADC – 
H157 SCC – 
H2170 SCC + 
H226 SCC mesothelioma – 
H596 Lung Ca – 
D40/97 Lung Ca + 
A427 Lung Ca – 
BEN Lung Ca, lymph node metastasis – 
D97 LCLC – 
HBE-E6/E7 HBE immortalized with HPV-16 ++ 
9442 (BET-1A) HBE immortalized with SV40 early region ++ 
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BEAS-2B HBE immortalized with SV40 early region ++ 
YP44 HBE immortalized with SV40 early region ++ 
DU 145 Prostate Ca – 
PC-3 Prostate Ca – 
HMEC Normal human mammary epithelial cells ++ 
HMEB HMEC immortalized with telomerase and SV40 + 
MCF-10A Spontaneously immortalized mammary epithelial cells ++ 
MCF-7 Breast Ca – 
SK-BR-3 Breast Ca – 
MDA-MD-231 Breast Ca – 
Kato III Metastasis of gastric Ca ++ 
HT-29 Colon Ca + 
SW-480 Colon Ca – 
HCT-116 Colon Ca + 
CaCo-2 Colon Ca ++ 
WiDr Colon Ca + 
Lovo Colon Ca +++ 
CX-2 Colon Ca + 
HRT-18 Colon Ca ++ 
EJ Bladder Ca – 
HeLa Cervical Ca – 
Daudi Burkitt’s lymphoma – 
K562 Chronic myelogenous leukemia – 
HL-60 Promyeolocytic leukemia – 
MOLT-4 Lymphoblastic leukemia – 
Raji Burkitt’s lymphoma – 
G361 Melanoma – 
SKOV-3 Ovarian Ca – 
OVCAR-3 Ovarian Ca + 
HT 1080 Fibrosarcoma – 
HEP-2 Head and neck Ca – 
D36-1/95 Head and neck Ca + 
D36-2/95 Head and neck Ca + 
D6/95 Head and neck Ca + 
D3/02 Head and neck Ca – 
IMR-90 Fetal lung fibroblasts – 
HAKAT Immortalized keratinocytes + 
HEK 293 Human embryonic kidney epithelial cells – 
 
The S100A14 mRNA is most abundant in cells cultured from normal human 
epithelial cells, but is absent from the vast majority of cancer-derived cell lines. 
Interestingly, most of the immortalized human cell lines also show significant 
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S100A14 mRNA expression. The S100A14 mRNA level is relatively high in most 
of the colon tumour cell lines. We did not detect S100a14 in any mouse or rat cell 
line examined using a mouse S100a14 cDNA sequence as a hybridization probe.  
 
Table 3 Expression of S100A14 mRNA in other mammalian cell lines 
Cell lines Histopathology S100a14 
COS-7 Monkey kidney fibroblasts – 
RAW 264.7 Mouse macrophagoid immortalized cells – 
L-cells Mouse immortalized fibroblasts – 
L-Wnt 3 cells L-cells transfected with Wnt-3A – 
C57MG Mouse mammary epithelial cells – 
ROSE 199 Rat ovarian surface epithelial cells – 
ROSE A2/1 ROSE 199 cells transfected with KRas – 
ROSE A2/5 ROSE 199 cells transfected with KRas – 
208F Immortalized rat fibroblasts – 
FE-8 HRas-transformed derivative of 208F – 
IR-4 208F cells transfected with IPTG-inducible Ras – 
 
3.2.2 Expression Profile in Normal Human Tissues   
We examined the expression pattern and transcript size of S100A14 in normal 
human tissues by Northern blot hybridization using a cDNA probe corresponding 
to the complete protein coding region. The transcript of approximately 1.1 kb was 
expressed most abundantly in colon (Fig. 5A). Moderate levels of S100A14 mRNA 
were detected in thymus, kidney, liver, small intestine, and lung. A very low 
expression level was detected in heart where a slightly longer transcript of 
approximately 1.35 kb was observed. No expression could be detected in brain, 
skeletal muscle, spleen, placenta, and peripheral blood leukocytes. Additionally, 
S100A14 was expressed in normal breast, ovary, prostate, rectum, stomach, 
thyroid, and uterus as determined by hybridization to the Cancer Profiling Array 
(Fig. 5B). 
To confirm the mRNA expression data, we analysed a panel of normal 
human tissues by immunohistochemistry using a polyclonal anti-S100A14 
antibody raised in rabbit. The S100A14 protein expression was predominantly 
associated with various epithelia as well as gland cells (Table 4). The expression 
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pattern was virtually consistent with the S100A14 mRNA expression in normal 
human tissues. The exceptions were brain and placenta, showing a weak 
expression of S100A14 protein, in contrast to the absence of the transcript in 
Northern blot analysis. 
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Fig. 5 Expression of the S100A14 mRNA in normal human tissues. A: A 
human 12-lane Multiple Tissue Northern Blot (BD Biosciences) containing 2 µg 
poly(A)+ RNA in each lane was hybridized with a 32P-labelled S100A14 cDNA probe. 
β-actin was assayed as a loading control. B: Expression of S100A14 mRNA in 
additional normal human tissues examined by hybridization to the Cancer Profiling 
Array (BD Biosciences). 
These results suggest that there is a very low S100A14 expression in these 
tissues and a not sufficient sensitivity of Northern blot to detect low abundant 
transcripts. 
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Table 4 Expression of the S100A14 protein in normal human tissues 
Tissue S100A14 Expression 
Pancreas Islet cells, endocrine pancreas 
Spleen Negative 
Breast Mammary gland cells 
Smooth muscle Muscle fibres weakly positive 
Skeletal muscle Negative 
Salivary glands Salivary gland cells, exocrine salivary glands 
Gall bladder Basal cytoplasm of goblet cells 
Thyroid Follicular epithelium  
Kidney Tubular epithelium 
Tonsille Squamous epithelium 
Appendix Epithelium 
Lung Pneumocytes 
Uterus Apical epithelium, stroma cells and smooth muscle weakly positive 
Prostate Epithelium, stroma cells and smooth muscle weakly positive 
Stomach Epithelium, gland cells weakly positive 
Parathyroid gland Epithelium 
Placenta Trophoblast cells weakly positive 
Colon Epithelium 
Testis Spermatocytes and stroma cells weakly positive 
Small intestine Epithelium 
Heart Cardiac muscle fibres weakly positive 
Cervix Suprabasal cells of squamous epithelium, basal cells weakly positive 
Liver Hepatocytes, bile duct epithelium 
Brain Ganglia cells 
Skin Squamous epithelium, hair follicles, sweat glands 
Endothelium Weakly positive 
 
3.2.3 S100A14 mRNA Level in Tumour Tissues 
Since S100A14 mRNA was not expressed in most of the tumour-derived cell lines, 
we hypothesized that its expression might be suppressed also in primary tumour 
tissue. To examine its expression in primary tissue we applied a commercially 
available Cancer Profiling Array, which contains cDNAs from 241 tumours and 
corresponding normal tissues from individual patients. This analysis, however, 
revealed a varied expression of the gene in different tumours (Fig. 6A). Significant 
overexpression was detected in ovary (78.6%), breast (62%), and uterus (45.2%) 
tumour tissues. Also lung (38.1%), prostate (25%), and thyroid gland (16.7%) 
tumours showed up-regulated levels of S100A14 transcript. In contrast, marked 
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underexpression was found in kidney (70%), rectum (50%), and colon (40%) 
tumours and to lesser extent in stomach tumours (18.5%). The expression status 
in cervix, small intestine and pancreas tumours could not be evaluated because of 
the limited number of samples available on the array. The schematic presentation 
of S100A14 expression in normal and tumour tissues is shown in Fig. 6B. 
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Fig. 6 Expression profile of S100A14 in human tumours. A: The Cancer 
Profiling Array containing SMART-amplified cDNA from tumour (T) and corresponding 
normal (N) tissues from individual patients was hybridized with 32P-labelled S100A14-
specific probe. Hybridization to ubiquitin cDNA (top and bottom) and E.coli DNA 
(middle) is shown on the right side of the array. Human cancer cell lines (no 
detectable signal) are spotted on the right. B: The schematic presentation of S100A14 
expression in normal and tumour tissues determined by hybridization to the Cancer 
Profiling Array. Data are expressed as percentage of up-regulated, down-regulated 
and normal samples and normalized to all spots on the membrane to correct for RNA 
quantity and integrity. The grey bars represent normal expression level, the black and 
white bars denote up-regulated and down-regulated expression, respectively. Signal 
intensities were quantified after several exposure times to compensate for differences 
in mRNA expression between different organs. 
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3.2.4 S100A14 Protein Expression in Lung Tumours and Association with 
Clinicopathological Factors 
Our transcript expression analysis in primary tumour tissues suggested that 
S100A14 is not a simple suppressor of tumour cell growth as might have been 
concluded from the cell line model system. It is possible that its altered expression 
is a result of, or otherwise associated with, tumour progression. To shed light on 
the association of S100A14 protein with malignant transformation and to verify the 
RNA expression data we used immunohistochemistry to investigate its expression 
in tumour tissues. 
S100A14 protein was examined in 120 histological sections of human lung 
cancer and 10 specimens of normal human lung epithelium. The cohort of tumour 
samples included 62 cases of adenocarcinoma (51.7%) and 58 cases of 
squamous cell carcinoma (SCC) (48.3%). The small number of samples precluded 
a separate analysis of large cell lung cancer (LCLC) tumour specimens. We 
observed a low cytoplasmic S100A14 staining in normal lung epithelium (score 0 
to 1+; Fig. 7). Therefore, we approved a scoring of 2+ and 3+ as indicative of 
protein overexpression for our analysis. Scores 0 or 1+ were considered as 
physiologically normal expression.  
Normal lung tissue Lung squamous cell carcinoma  
Fig. 7 S100A14 protein is overexpressed in primary lung tumour tissue in 
comparison to normal lung tissue. Immunohistochemical staining of S100A14 
protein in tissue sections of normal lung pneumocytes (left, indicated by an arrow) and 
lung squamous cell carcinoma (right). Specimens were stained with an anti-S100A14 
antibody. Photographs were taken with a 40x objective. 
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Positive staining was assessed not only as the degree of staining intensity but also 
as the proportion of cells with staining of both plasma membrane and cytoplasm 
as compared with those of cytoplasmic staining alone.  
S100A14 immunoreactivity in tumour tissue scored positive in 68.3% 
(82/120) of cases thus validating its up-regulation in this tumour type (Fig. 7). The 
S100A14 staining was restricted to the cancerous epithelial cells of the tissue. 
Next, S100A14 expression was analysed in relation to clinicopathological criteria. 
No significant correlation was found between S100A14 positivity and gender, age, 
histological subtype, tumour size, number of positive lymph nodes, and histological 
grade. 
We found that 57.3% (47/82) of S100A14-overexpressing lung tumours 
displayed cytoplasmic and membranous expression relative to exclusively 
cytoplasmic S100A14 staining in normal lung epithelium (p = 0.006; Fig. 8).  
Normal lung tissue Squamous cell carcinoma  
Fig. 8 S100A14 localizes to plasma membrane in lung tumour tissue. 
Immunohistochemical analysis of S100A14 protein in sections of normal bronchial 
epithelial cells (left) and lung squamous cell carcinoma (right). Panels show high 
power microscopy (magnification, 40x), demonstrating cytoplasmic staining of 
S100A14 in normal bronchial epithelial cells (left, indicated by an arrow) and distinct 
plasma membrane-associated staining of S100A14 in lung carcinoma cells (right). 
Moreover, we observed a significant association (p = 0.048) between higher-grade 
tumours (grade 3) and S100A14 subcellular distribution. 50% (27/54) of high-
grade tumours displayed S100A14 protein localized both to the cytoplasm and the 
plasma membrane. Another relation was found between lung tumour histology and 
subcellular distribution of S100A14. Cytoplasm and plasma membrane-localized 
S100A14 staining was associated with 61.8% (34/55) of SCC (p = 0.02) compared 
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to 38.2 % (20/58) of adenocarcinoma tumours, the latter detecting predominantly 
cytoplasmic S100A14 (65.5%; 38/58). S100A14-negative tumours were not 
included in the statistical analysis of the subcellular distribution of S100A14. These 
results are summarized in Table 5. 
Table 5 Association of S100A14 protein expression in lung tumours with 
clinicopathological factors 
Parameter S100A14 positive/total p 
memb.+cytopl. 
positive/total p 
S100A14 overexpression 68.3% (82/120)    
Membranous+cytoplasmic 57.3% (47/82) < 0.01   
High grade   50% ( 27/54) 0.048 
Histological subtype     
     Adenocarcinoma   38.2% (20/58)  
     Squamous cell carcinoma   61.8% (34/55) < 0.01 
 
 
3.2.5 S100A14 Protein Expression in Breast Tumours and Association with 
Clinicopathological Factors 
A significant up-regulation of S100A14 mRNA in breast tumours prompted us to 
investigate this tumour type by immunohistochemistry. We examined S100A14 
protein expression in 93 breast tumour samples, 14 lymph node metastases and 
10 normal mammary epithelia. In our cohort of breast tumours were 77 invasive 
ductal carcinomas (IDC), 14 invasive lobular carcinomas (ILC) and 2 cases of 
mixed type (IDC+ILC).  
Normal mammary epithelium stained rather weakly for S100A14 protein with 
cytoplasm-localized staining (score 1+; Fig. 9). Therefore we applied the same 
scoring as for lung tumours, i.e. scores 0 to 1+ were considered as normal 
physiological expression, whereas scores of 2+ and 3+ were assessed as positive 
and indicative of protein overexpression. S100A14 positivity was detected in 
68.8% (64/93) of breast tumour samples and 71.4% (10/14) of lymph node 
metastases (Fig. 9). Clinical relevance of S100A14-overexpressing tumours was 
investigated only in IDC cases due to small sample number of other tumour 
subtypes. No significant correlation with gender, age, histological subtype, tumour 
size, number of positive lymph nodes or histological grade was observed.  
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Normal breast tissue Intraductal breast carcinoma  
Fig. 9 S100A14 protein is up-regulated in primary breast carcinoma relative to 
normal breast tissue. Immunohistochemical analysis of S100A14 protein in normal 
breast ductal epithelial cells (left) and ductal carcinoma epithelial cells (right). 
Specimens were stained with an anti-S100A14 antibody. Photographs were taken with 
a 20x objective. 
Interestingly, we found a significant correlation between a high S100A14 level and 
ERBB2 overexpression (p = 0.04). 82.9% (29/35) of ERBB2-overexpressing 
tumours (score 2+ and 3+) had up-regulated S100A14 expression as well 
(Fig. 10). To further substantiate this finding, we separately examined 31 ERBB2-
overexpressing breast tumours of score 3+. We found that 90.3% (28/31) of 
ERBB2-positive tumours were also S100A14-positive.  
ERBB2-positive breast carcinoma S100A14-positive breast carcinoma  
Fig. 10 S100A14 overexpression correlates with ERBB2 overexpression in 
primary breast tumours. Immunohistochemical analysis of a section of a breast 
ductal carcinoma specimen stained both with anti-ERBB2 antibody (left) and (the 
same section) with anti-S100A14 antibody (right). Photographs were taken with a 40x 
objective. 
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Oestrogen receptor-α (ER-α) negativity was also significantly associated with 
elevated levels of S100A14 (p = 0.024). 87.5% (21/24) of ER-α-negative tumour 
specimens were S100A14-positive. Moreover, a significant association to 
increased tumour cells proliferation index (MIB) was observed (p = 0.033). 100% 
(11/11) of tumours assessed as highly proliferating (60-100% of actively 
proliferating cells) stained positively for S100A14.  
Also in this case the subcellular distribution of S100A14 was related to 
S100A14 protein abundance. 79.7% (59/74) of S100A14-overexpressing tumours 
displayed prominent plasma membrane and cytoplasmic localization of S100A14 
(p < 0.01) relative to 34.8% (8/23) of low-expressing tumours showing 
predominantly cytoplasmic staining (65.2%; 15/23). In contrast to this tumour cell 
plasma membrane localization, normal human breast epithelial cells showed solely 
diffuse cytosolic S100A14 expression (Fig. 11). For the statistical analysis of 
subcellular localization of S100A14 we omitted the S100A14-negative samples. 
These results are summarized in Table 6.  
Normal breast tissue Intraductal breast carcinoma  
Fig. 11 S100A14 localizes to plasma membrane in breast cancer tissue. 
S100A14 immunostaining in sections of normal breast ductal epithelial cells (left) and 
breast ductal carcinoma sections (right). Panels show high power microscopy 
(magnification, 40x), demonstrating cytoplasmic staining of S100A14 in normal breast 
ductal epithelial cells (left, indicated by an arrow) and plasma membrane-associated 
staining of S100A14 in breast carcinoma cells (right). 
Our transcriptional and protein analysis demonstrated that expression of S100A14 
in primary tumours differed from that in cell line model; the gene was significantly 
overexpressed in multiple lung and breast tumour samples. Nevertheless, our data 
also confirmed the differential expression of the gene in a wide range of primary 
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tumours as well as its potential clinical relevance with regard to the positive 
correlation with ERBB2 overexpression in breast tumours. Therefore, we decided 
to further characterize the gene and the molecular determinants of its regulation.  
Table 6 Association of S100A14 protein expression in breast tumours with 
clinicopathological factors 
Parameter S100A14 positive/total p 
S100A14 overexpression 68.8% (64/93)  
ERBB2 overexpression 82.9% (29/35) 0.04 
ER-α negativity 87.5% (21/24) 0.024 
MIB 100 % (11/11) 0.033 
Membranous+cytoplasmic 79.7% (59/74) < 0.01 
  
3.2.6 S100A14 is not Re-Expressed Following Growth of Human Cancer Cell 
Lines Transplanted into Mice  
To determine if the absence of S100A14 in the vast majority of cultured tumour 
cell lines could be due to differences between the cell model system and the 
primary tissue, we examined 9 mouse xenograft tumours of human cultured lung 
cancer cell lines. They represented the following histopathological types: SCLC 
(CPC-N, H526, H446, H82, H209, N417), brain metastasis of SCLC (Colo 668), 
adenocarcinoma (D54), and LCLC (D97). These cell lines do not express 
endogenous S100A14 in Northern blot analysis. 
RT-PCR analysis did not reveal re-expression of the S100A14 transcript in 
the majority of the examined xenografts (Fig. 12).  
S100A14
GAPDH
CL MT CL MT CL MT CL MT CL MT CL MT CL MT CL MT CL MT
D97 CPC-N N417 H446 Colo 668 H526 D54 H82 H209
 
Fig. 12 S100A14 is not re-expressed in lung cancer cell line xenografts from 
nude mice. Nine S100A14-negative human lung cancer cell lines (CPC-N, H526, 
H446, H82, H209, N417, Colo 668, D54, and D97) were transplanted subcutaneously 
into immunodefficient mice. Mouse xenograft tumours (MT) and the respective lung 
cancer cell lines (CL) were examined by RT-PCR. GAPDH was used as a loading 
control. 
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An enhanced S100A14 mRNA expression was clearly present only in the D54 
xenograft tumour as compared with the corresponding cell line. A very weak 
mRNA expression was detected in the H82 cell line and the corresponding 
xenograft as well as in the D97 cell line. A modest mRNA expression was 
observed in the H209 cell line and a weak expression in the corresponding 
xenograft. 
3.3 Subcellular Localization of the S100A14 Protein  
In an attempt to achieve a better understanding of the biology of the S100A14 
protein, we examined its subcellular localization by immunfluorescence. Initially, 
we expressed the protein as carboxyl-terminal fusion of V5-epitope, and 
determined expression of the fusion protein after transient transfection by confocal 
laser-scanning microscopy. H157, A549, and COS-7 cells were chosen for their 
absence of S100A14 transcript in Northern blot analysis. 
Distinct subcellular localizations were detected in all analysed cell lines. 
Immunoreactivity was observed in the cytoplasm with a higher expression around 
the nucleus in A549 and COS-7 cells (Fig. 13A, B). H157 cells displayed a 
pronounced immunoreactivity in the perinuclear area (Fig. 13C). Control 
incubation with mock-transfected cells was completely negative (Fig. 13D). 
Expression of the protein was also confirmed by Western blot analysis (Fig. 13E). 
To confirm that the localization studies performed with epitope-tagged protein 
corresponded to the subcellular distribution of endogenous protein, we applied the 
polyclonal antibody against the endogenous S100A14 protein. Patterns of 
subcellular distribution and expression of S100A14 protein were examined in 
immortalized lung cells (9442, 2078), colon tumour (Caco-2, HCT-116, Lovo, 
WiDr), and lung tumour (H322) cells.  
9442 and 2078 cells displayed strong plasma membrane immunoreactivity of 
sharp and clear pattern with the exception of cell protrusions where more diffuse 
staining was observed (Fig. 14A, B). Additionally, a very weak and diffuse 
cytoplasmic S100A14 staining was detectable. This staining pattern is consistent 
with our analysis of fractionated proteins in 9442 cells (see below).  
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Fig. 13 Cellular localization of S100A14-V5 protein in human lung tumour and 
COS-7 cells. A: A549 (lung tumour), B: COS-7 (monkey kidney fibroblasts), and C: 
H157 (lung tumour) cells were transiently transfected with the S100A14-V5 expression 
vector. Forty-eight hours after transfection immunofluorescent analysis was performed 
using confocal laser scanning microscopy. Cells were examined for localization of 
S100A14-V5 after indirect staining with monoclonal anti-V5 primary antibody and anti-
mouse FITC-conjugated secondary antibody. Magnification using 60x oil immersion 
objective. D: Control incubation with mock-transfected cells was completely negative. 
E: Expression of the protein was confirmed by immunoblotting analysis. Vector-
transfected cells were used as a negative control. Equal loading was determined by 
immunoblotting with anti-β-actin antibody. 
Moreover, strong S100A14 expression was observed in actively proliferating cells 
(Fig. 14C). Interestingly, staining of distinct vesicles of unknown origin was also 
observed in these cells (Fig. 14D). H322 and HCT-116 cells, which grow in 
colonies, expressed S100A14 in similar patterns (Fig. 14E, F). Immunofluorescent 
staining in these cells revealed distinct immunoreactivity at cell junctions with 
occasionally stronger plasma membrane expression relative to neighbouring cells 
indicating a heterogeneous expression. Weak and diffuse cytoplasmic staining 
was also observed. In contrast, Caco-2 cells had diffuse rather than sharp staining 
at cell junctions and moderately strong and homogenous cytosol immunoreactivity 
(Fig. 14G). Prominent membranous staining was observed in Lovo cells with 
focally stronger expression (Fig. 14H). Overall staining was low in WiDr cells 
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showing heterogenous expression at cell junctions (data not shown). Control 
incubation with preimmune serum was completely negative (Fig. 14I). 
2078 9442
9442
A
D
CB
9442
E
H322
F
HCT-116
Caco-2 Lovo Control
G H I
 
Fig. 14 Subcellular localization of the endogenous S100A14 protein in 
immortalized lung cells, and lung and colon tumour cells. Immunofluorescence 
microscopy of A: 2078, B, C, D: 9442 (immortalized lung epithelial cells), E: H322 
(lung tumour), F: HCT-116, G: Caco-2, and H: Lovo. Cells were fixed and stained with 
the polyclonal anti-S100A14 antibody and with the secondary anti-rabbit FITC-
conjugated antibody. Magnification using 60x oil immersion objective. I: Control 
incubation with preimmune serum was completely negative. 
To verify the data obtained by immunofluorescence, we fractionated whole-cell 
extracts into membrane and soluble components. Soluble and crude membrane 
fractions of 9442 cells were prepared by hypotonic lysis, Dounce homogenization, 
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and differential centrifugation. Western blot analysis with anti-S100A14 antibody 
revealed that S100A14 was predominantly associated with the membrane fraction, 
whereas only very little S100A14 protein was detected in the soluble form 
(Fig. 15). These data indicate that the cells endogenously expressing S100A14 
preferentially target the protein to the plasma membrane. 
α-tubulin RAS
S100A14
CY ME
 
Fig. 15 The S100A14 protein is distributed through the cytoplasmic and 
membranous fractions of 9442 cells. Total proteins from 9442 cells were 
fractionated. For SDS-PAGE, 80 µg of protein extract from each fraction was used for 
loading. Immunoblotting was performed with a polyclonal anti-S100A14 antibody. The 
specific S100A14 band was detected in the cytoplasmic (CY) and membranous 
fraction (ME). α-tubulin and RAS were assayed as loading controls for cytoplasmic 
and membranous fraction, respectively. 
It was of interest to determine whether divalent cations could affect the subcellular 
localization of S100A14. To characterize the dependence of the subcellular 
distribution of S100A14 on the intracellular Ca2+ and Zn2+ levels, we treated 9442, 
2078, Caco-2, WiDr, Lovo, HCT-116, and H322 cells with thapsigargin in 
conjunction with 1 mM CaCl2 as well as with ZnCl2. Thapsigargin increases 
intracellular Ca2+ levels by blocking endoplasmic reticulum calcium pumps. We 
observed predominantly plasma membrane anti-S100A14 staining under all 
conditions tested, with no detectable alterations in distribution pattern.  
3.4 Genomic Organization and Chromosomal Localization of the S100A14 
Gene 
Most of the human S100 genes are clustered on the chromosome 1q21, a region 
which is frequently involved in chromosomal rearrangements and deletions in 
human cancers. In order to identify the mechanisms of abnormal S100A14 
expression in tumours we sought to determine its genomic structure and 
localization.  
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To obtain S100A14 genomic sequence data, human RPCI 1,3-5 PAC blood 
genomic libraries (RZPD) were screened with the purified insert of the full-length 
cDNA clone of human S100A14 (H1043). We obtained 18 positive clones that we 
re-screened by PCR using several cDNA-derived primer pairs: H1043f, 
H1043ex1f, H1043ex2f, H1043ex3f, and H1043r. 
We identified three candidate positive clones, RPCIP704 I22230Q2A, 
RPCIP704 A12752Q2, and RPCI P704 D11609Q2 (designated I22230, A12752, 
and D11609), and subjected them to a second screening by PCR to confirm their 
positive status. Following assembly of the genomic sequence of S100A14 based 
on the Celera’s human genome-unassembled fragments database (Venter et al., 
2001), we designed the following PCR primers located in the flanking region of the 
exon/intron junctions of the relevant putative introns: H1043i1for, and H1043i1rev; 
H1043i2for, and H1043i2rev; H1043i3for, and H1043i3rev. The three genomic 
PAC clones were confirmed positive by this screening. Southern blot analysis 
revealed an approximately 3-kb region of overlap among the three clones that 
were positive for hybridization with the S100A14 cDNA and intronic probes 
(Fig. 16A). The restriction enzyme-digested fragments covering that region were 
subcloned and sequenced to identify the genomic organization of S100A14 
(Fig. 16B).  
In total, we obtained 3173 bp of continuous genomic sequence. In addition to 
the genomic locus of the S100A14 gene, it included part of the putative 5’ 
upstream promoter sequence and the 3’ downstream region of the gene. It was 
consistent with the compiled sequence identified in Celera’s human genome-
unassembled fragments database using S100A14 cDNA as a query. The 
sequence was submitted to GenBank under Accession No AF426828.  
Comparison of the genomic and cDNA sequence revealed that the gene 
spanned 2165 bp. It was organized in four exons and three introns (Fig. 17). 
Exon 1 is untranslated, exon 2 contains the translation initiation codon and the 
putative N-myristoylation site, and exon 3 codes for the N-terminal EF-hand motif. 
The latter exon contains the C-terminal EF-hand motif and the translation 
termination codon followed by 630 bp of 3’-untranslated sequence. All the 
intron/exon boundaries confirmed to the GT-AG rule (Table 7). 
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Fig. 16 Southern blot analysis of the genomic PAC clones positive for 
S100A14. Southern blot analysis of the candidate S100A14-positive clones, 
RPCIP704 I22230Q2A, RPCIP704 A12752Q2, and RPCI P704 D11609Q2. A: 
Restriction analysis with BamHI, XbaI, KpnI, XhoI, and SalI restriction endonucleases 
revealed a ~3-kb region of overlap (rectangle) among the three clones that were 
positive for hybridization with the S100A14 cDNA and intronic probes. B: The BamHI-
digested fragments covering that region (rectangles) were subcloned and sequenced. 
Genomic PAC clone K11781, which was negative by PCR, was assayed as a negative 
control. λHindIII-digested DNA was used as a molecular size marker. 
We also identified a candidate TATAA box, lacking the third and fourth adenosine 
residues (Bucher, 1990), 26 bp upstream from the transcription initiation site 
determined by RACE. No other consensus promoter sequences were identified in 
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the entire 5’ region sequenced, suggesting that the 5’-end of the cDNA sequence 
is in fact the major initiation site for the gene. 
1 2 3 4
 
Fig. 17 Genomic structure of the human S100A14. Schematic representation of 
the exon/intron organization. Boxes represent exons, and intervening lines represent 
introns. The hatched region within the boxed exons denotes the coding sequence.  
Sequence analysis of the entire genomic locus of S100A14 did not reveal any 
CpG island. This was in accordance with our DNA hypermethylation analysis in 
8 lung cancer cell lines. Treatment with 5-aza-2‘-deoxycytidine (20 µM) did not 
induce re-expression of the gene either. 
A search for repetitive elements revealed AluY subfamily repeat of 283-bp 
(nt 2450-2732) located near the polyadenylation site as well as (TG)n and (GA)n 
simple repeats in the putative promoter region.  
We verified the human S100A14 genomic sequence by Southern blot 
hybridization to examine the possibility of deletion or gross rearrangement in the 
gene. The 1628-bp (SacI; spanning all introns and coding exons) and 500-bp 
(EcoRI; spanning exon 3 and part of exon 4) bands were found to be informative 
for the verification of the assembly. Using the cDNA sequence that covers the 
coding region of S100A14 as a probe for the hybridization, we observed the same 
restriction pattern for each enzyme in both S100A14-negative and S100A14-
positive tumour cells. A single band was detected in digests of 25 tumour cell lines 
(Fig. 18).  
Table 7 Exon/intron boundaries of the human S100A14 gene. The exon and 
intron sequences are shown in upper- and lowercase letters, respectively. Splice 
acceptor and donor sequences are shown in boldface type. 
Exon cDNA 
position 
(bp) 
Exon 
size 
(bp) 
3' splice acceptor 
(intron/exon) 
5' splice donor 
(exon/intron) 
Intron size
(bp) 
1 1-30 30  GCCAACAG/gtaaggaa 358 
2 31-138 108 ctaagcag/ATCATGAG ACGCAGAG/gtgggctc 447 
3 139-285 147 gccctcag/GATGCTCA TCATGCCG/gtatggac 212 
4 286-1067 782 cccctcag/AGCAACTG 
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Fig. 18 Southern blot analysis of the S100A14 gene in lung cancer cell lines. 
Southern blot analysis of the representative S100A14-positive (2078, 9442, H2170) 
and S100A14-negative (Colo 677, H209, Colo 668, H157, N417, A427, H526) cell 
lines. Genomic DNA (30 µg) isolated from 25 lung tumour cell lines was digested with 
SacI and EcoRI (300 U). The 1628-bp (SacI) and 500-bp (EcoRI) bands were 
detected in digests of all examined cell lines. S100A14 cDNA sequence that covers 
the protein coding region was 32P-labelled and was used as a probe for hybridization. 
Next, the three PAC clones were used to determine the chromosomal localization 
of S100A14 by fluorescence in situ hybridization (FISH) on normal human 
metaphase chromosomes. All clones revealed a strong signal at chromosome 
band 1q21 with the clone I22230 being the most specific (Fig. 19). 
1q21
 
Fig. 19 Chromosomal localization of S100A14 by FISH. The FISH analysis was 
performed on metaphases of normal human lymphocytes using biotin-16-dUTP-
labelled genomic PAC clone I22230. White arrowheads indicate the specific signal on 
chromosome 1q21. 
Clones A12752 and D11609 showed additional weaker signals on other different 
chromosomes. Due to the presence of these signals the mapping result was 
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confirmed and refined by hybridizing the S100A14 cDNA to the established 6 Mb 
YAC contig and to the genomic restriction map of region 1q21 (Marenholz et al., 
1996, 2001). The specific probe detected two of the 24 YACs of the contig, 
100_f_3 and 950_e_2, which were already known to contain several other genes 
of the S100 gene cluster in chromosomal region 1q21 (Schäfer et al., 1995, 
Marenholz et al., 1996) (Fig. 20A). S100A14 was mapped on the same SalI 
fragment as S100A1 and S100A13, the most telomeric genes of the established 
S100 cluster (Fig. 20B).  
 
Fig. 20 S100A14 is localized within the S100 gene cluster on human 
chromosome 1q21. A Southern blot that contains SalI-digested DNA of 24 YACs 
covering chromosomal region 1q21 was hybridized with the 32P-labelled S100A14 
cDNA. A: Four YACs of the contig that cover the distal S100 genes including the 
adjacent regions, are shown. Two YACs were positive for the S100A14-specific probe 
(right) that detected the same restriction fragments as the S100A1 probe (left). The 
second fragment identified in YAC 100_f_3 is probably due to an additional, 
rearranged clone in the original YAC culture. B: SalI restriction map of YAC 100_f_3. 
A vertical bar represents the YAC. Boxes represent SalI restriction fragments that 
were detected by the genes above. The order of genes has been resolved previously 
(South et al., 1999). The position of S100A14 relative to S100A13 and S100A1 could 
not be resolved. C: Ideogram of human chromosome 1. 
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We additionally confirmed localization of the gene in the region 1q21 on the 
genomic restriction map of the H2LCL cell line (Marenholz et al., 1996), on which 
the S100A14 probe detected the same NotI-, NruI-, MluI-, and BsiWI-fragments as 
the adjacent S100 genes (data not shown). 
3.5 Identification and Characterization of the Promoter for the S100A14 
Gene 
To further investigate the reasons for deregulated S100A14 expression in 
tumours, we examined regulation of its putative promoter. As cell model system 
we chose HEK 293 cells, which do not express endogenous S100A14, and Lovo 
cells, which express the gene at a high level. 
Isolation of S100A14 genomic DNA provided 511 bp of the 5’ upstream 
region of the major transcription initiation site of the gene. In order to identify 
potential regulatory sequences within this region, a panel of deletion mutants, 
covering the region of 495-bp immediately adjacent to the transcription start site, 
was generated and linked to a promoterless luciferase reporter gene. The 
presence of endogenous SacI and PstI sites was used to aid the subcloning. The 
p500-luc luciferase reporter driven by the longest promoter fragment showed a 
significant luciferase activity in extracts from HEK 293 and Lovo cells (Fig. 21A, B). 
Thus, we generated deletion mutants of this fragment to locate the minimal 
promoter region responsible for the observed activity. 
The p300-luc promoter construct that covers the proximal region of the 
promoter (-313/-12) conferred a 4-fold activation. The other promoter fragment 
(p250-luc) covering the -495/-313 region showed a very low level of activity, similar 
to the level obtained with the control vector pGL3 Basic. This indicated that the 
-313/-12 region of the S100A14 promoter is sufficient to induce a potent luciferase 
activity. Therefore, we investigated deletion mutants of this promoter fragment. 
p2A-luc and p2B-luc luciferase reporters showed activity at a level approximately 
equal to that of the control vector. On the contrary, transfection of a p2C-luc 
construct, covering the most proximal promoter fragment (-208/-12) of 196-bp, 
resulted in an enhanced luciferase activity that could be indicative of the presence 
of possible transcription factor binding sites.  
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Fig. 21 Transcription activities of S100A14 promoter constructs. A: Effects of 
deletions of putative cis-acting regulatory elements on luciferase activity in HEK 293 
cells. A series of 5’ deletion mutants were fused with the firefly luciferase reporter 
gene (black box) and analysed by transient transfection. Native restriction sites used 
for cloning are indicated. The relative sizes of the constructs are to scale. The 
numbers in parentheses indicate the position of the tested promoter region within the 
5’ upstream region of the S100A14 gene. Firefly luciferase activity was normalized to 
Renilla luciferase activity, which was measured to control for transfection efficiency. 
Means and standard deviations are indicated to the right. The data shown are 
representative of three experiments, each performed in triplicate. B: Transcription 
activities of the S100A14 promoter constructs in HEK 293 and Lovo cells. Relative 
luciferase activity is indicated ± the standard deviation. The mean values for Lovo cells 
were uniformly scaled by the factor 3 to allow comparison of the two cell lines. The 
results represent the mean of triplicate experiments. 
Results  77 
 
 
Computer-assisted analysis of the minimal promoter fragment revealed a TATA 
box, multiple potential transcription factor binding sites for Elk-1, and RFX-1, as 
well as single binding sites for SRF (serum response factor), AP-1, CEBP, CHOP, 
USF, NFκB, and N-myc.  
In search for conserved elements in the human S100A14 promoter, we 
retrieved 3460 bp in the sequence 5’ upstream of the mouse S100a14 gene. 
Comparison of the region with the 511 bp of the human S100A14 promoter 
revealed presence of two fragments immediately upstream of the transcription start 
site that were conserved in the human gene (Fig. 22). One of the fragments 
(-7/-48) showed 97% identity with the human counterpart and encompassed the 
TATA box. The other fragment (-76/-135) showed 89% identity with the human 
sequence and contained a CAAT sequence. This sequence, however, lacked 
significance to the consensus CCAAT box in our promoter prediction analysis. 
Within the conserved fragment from -76 to -135 bp two possible transcription 
factor binding sites for CEBP and C/EBP homologous protein (CHOP), also known 
as growth arrest- and DNA damage-inducible gene 153 (GADD153) were 
detected. Both of them belong to the CCAAT/enhancer binding protein (CEBP) 
family of transcription factors. 
Additionally, a potential NFκB consensus motif was conserved in the mouse 
and human DNA within the minimal promoter fragment but further upstream of the 
two strongly conserved promoter fragments. This putative consensus site was 
located in equivalent position in alignment between the two orthologous 
sequences. No significant homology of sequences further upstream could be 
detected.  
To determine if the potential NFκB binding site represents a functional NFκB 
response element, we examined it in more detail. Therefore, it was evaluated 
whether the S100A14 promoter was subjected to transactivation by wild type p65 
– the DNA binding subunit of NFκB. HEK 293 cells were co-transfected with 
p65/Flag and the p2C-luc luciferase reporter or with empty vectors. Measurement 
of luciferase activity revealed a weak decrease in the p2C-luc luciferase reporter 
activity following transient transfection with an empty vector for p65, indicating an 
inhibitory effect of pcDNA3/Flag vector (data not shown). Nevertheless, no 
increase of activity was detected upon co-transfection of HEK 293 with p65 
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compared with the co-transfection with the empty vector (data not shown). 
Treatment with TNF-α also did not induce any significant transactivation of the 
promoter in any concentration tested (5-25 ng/ml) thus confirming our Northern 
blot results (data not shown). 
mouse_ CCTTTCAACCTTTCATCTCTAGGCTGTCAGGACTGAGAGGCTTGACTCT-AGGTTTCAGC 59 
human_ CCAGGCAGGCTTGAGTGTCAG---TATCCAAGCTG---GGCCTGACTGGGAGAAGTGTGC 54 
       **   **  ***   * **     * **    ***   *** *****   **   *  ** 
 
mouse_ AGGCCCGAGTGATCCAAGCCAAATTAGCTCTAGTTGGAAGGGAGAGGAGAAGAGAGATGC 119
human_ GTGTGCGTGTGTGTGTGTGTGTGTGTGCACGTGA-GAGAGAGAGAGAGAGAGACAGACAG 113
         *  ** ***            *  ** *  *  *  ** *****    *** ***    
 
mouse_ CAAAGCACAGAGATCCATGGGCCTCGTTCAAGCTTCTCCTTCCATAAGCTTCCGTTGATC 179
human_ ACACACATGGAGGGTACAGAGGCTCCT----GCTTCTCCTTCCT--GGTCACAGAT--TC 165
         *  **  ***      * * *** *    ************    *   * * *  ** 
 
mouse_ AGCCCTTGCTTCTCTTTTGTCGACCCCCTCTGCTCCCCTGCATCATAGCTGCCTCAGGTT 239
human_ AGACCC--CCTCTCCTTCCCTGCCCTGCAGTTCGCCAGGGCCCTTCCACTTCCTAGGGTG 223
       ** **   * **** **    * **  *  * * **   **       ** ***  ***  
 
mouse_ CTTACCCTCCTAGCTAAGATCCCCTCTGCATCTCCCTAGCTTT-TCTTTTTCCTCTCCCT 298
human_ AC--CCCATGAGGTCTCGAAGTCCTCTCTGTCTCCCCAGCCTTCTCGCTTCTCTTTCTCT 281
           ***     *    **   *****   ****** *** ** **  **  ** ** ** 
 NFκB Elk-1 RFX-1     SRF 
mouse_ GTGACTCTGTAAGGTGATCTTGCGCCAGGGGCATCCCGTACCCAGCCCTCCACGGCTTCC 358
human_ GTGACTCTGCATGCTGATCGGAGGCCAGGGGTTTCCCAGCCCCAGCCCTCTGTGGCTCCC 341
       ********* * * *****    ********  ****   **********   **** ** 
 N-myc USF AP-1    RFX   Elk-1 
mouse_ TCCTCATGATAGGGGTGGGGACTGACTCTAGAGCT-------GTAGAGGGTGGGGCTCAT 411
human_ TCCTCGTGGCAGGG-TCATGGTAGGCTCTGGAACTCTGGCCAGCGGAGGGTGGGGCCCAT 400
       ***** **  **** *   *   * **** ** **       *  *********** *** 
     CEBP  CHOP 
mouse_ AAAGCTGGCTCCCAGCCCAGGAGGCTGCAATAGCTGGGGTGGCTGAGGGATAAGGCCCTG 471
human_ AAAGCTGGCTCATAGCCCAGGCTGCTGCAATAGCAGGGGTGGCTTAGG--------CCCA 452
       ***********  ********  *********** ********* ***        **   
 
mouse_ GCCCTGCCCCGTCTCCCCTCCCTTCCCCCAGGTATAAGAGCAGAGCTCAGGTGAGCTGGC 531
human_ GCCC---CCTGCCTCCCCTCCCTTCCCCCAGGTATAAGAGCTGAGCTCAGGTGAGCTGGC 512
       ****   ** * ***************************** ******************  
 
mouse_ TCCTCCATCCTGTCT 546 
human_ TCCTCCTGTCTTGTC 527 
       ******   **  
  
Fig. 22 Comparison of nucleotide sequence and potential regulatory elements 
of the S100A14 promoter fragment in mouse and human genomic DNAs. The 
consensus sequences of the potential transcription factor-binding sites are underlined 
or in bold. Nucleotide identities are indicated by asterisks. The predicted TATA box 
and CAAT sequence are represented by shading the consensus sequence. The major 
transcription initiation site identified in the human S100A14 is indicated by boxes. 
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3.6 ERBB Ligands Induce S100A14 Expression at the Transcriptional Level 
in 9442 Cells 
Preliminary experiments with H322 lung tumour cells revealed that stimulation of 
the cells with serum induced S100A14 transcript (Fig. 23). Furthermore, our initial 
analysis by immunohistochemistry of breast tumours demonstrated a significant 
correlation between a high S100A14 level and ERBB2 overexpression (p = 0.04). 
This prompted us to investigate whether S100A14 could be subjected to epidermal 
growth factor (EGF) regulation. 
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Fig. 23 Up-regulation of S100A14 expression in H322 cells after stimulation 
with serum. Northern blot analysis of S100A14 expression in H322 cells was 
performed after stimulation with 20% serum for the indicated times. S100A14 cDNA 
sequence that covers the protein coding region was 32P-labelled and used as a probe 
for hybridization. 18S RNA was assayed as a loading control. 
Eight human cell lines were treated with recombinant human EGF and S100A14 
mRNA expression was measured by Northern blot analysis. The eight cell lines 
included immortalized bronchial epithelial cells (9442) and immortalized mammary 
epithelial cells (HMEB), which express S100A14 as well as six S100A14-negative 
tumour cell lines: three breast (SK-BR-3, MCF-7, MDA-MB-231) and three lung 
(H157, DMS-114, A549) tumour cell lines. Expression of endogenous S100A14 
mRNA was remarkably induced by EGF in S100A14-positive 9442 and HMEB 
cells, but not in S100A14-negative tumour cell lines (Fig. 24).  
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Fig. 24 Treatment of 9442 and HMEB cells with EGF leads to the induction of 
S100A14. 9442 and HMEB cells were grown for 3 days in regular culture medium and 
then treated for 12 hours with 50 ng/ml of EGF without medium change. 10 µg of total 
RNA was size-fractionated followed by Northern blot analysis. S100A14 cDNA 
sequence was applied as a probe for hybridization. 18S RNA was used as a loading 
control. 
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Based on this result, we decided to further characterize regulation of the gene by 
EGF using 9442 cells as a cell model. The 9442 (BET-1A) cells are derived from 
normal human bronchial epithelial cells that were immortalized with the SV40 early 
region and represent non-tumorigenic cells. 
First, we determined the kinetics of S100A14 induction by EGF in 9442 cells. 
Following the growth factor treatment, S100A14 levels were induced at 3 hours 
post-treatment and then gradually increased, reaching a maximal level at 12 hours 
(Fig. 25). The observed sustained response remained for up to 24 hours, with a 
subsequent gradual decrease to slightly above pre-stimulation level. These results 
clearly demonstrated an EGF-dependent induction of endogenous S100A14 
expression and indicated that S100A14 is an EGF target gene. 
S100A14
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Fig. 25 S100A14 is induced by EGF in a time-dependent manner in 9442 cells. 
9442 cells were grown for 3 days in regular culture medium and then treated for the 
indicated times with 50 ng/ml of EGF without medium change. Northern blot analysis 
was performed using specific 32P-labelled S100A14 cDNA probe for the detection. 
18S RNA was used to correct for equal loading. 
Next, we examined the dose dependency of the S100A14 mRNA induction in 9442 
cells. The response appeared to be maximal at a concentration of 50 to 100 ng/ml 
of EGF (Fig. 26). Therefore, 50 ng/ml of EGF treatment for 12 hours was used in 
this study. 
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Fig. 26 Induction of S100A14 is EGF dose-dependent. 9442 cells were grown for 
3 days in regular culture medium and then treated with 1-100 ng/ml of EGF for 
12 hours without medium change. S100A14 was detected by Northern blot analysis 
using a specific 32P-labelled cDNA probe. 18S RNA was used as a loading control. 
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Treatment of the cells with transforming growth factor-α (TGF-α), another ERBB 
receptor ligand, also resulted in an increase of the S100A14 transcript level 
(Fig. 27). The kinetics of the TGF-α-induced response was similar for the EGF and 
TGF-α ligands with a delayed time course relative to the EGF-induced response. 
The induction was transient, starting at 6 hours post-treatment, reaching maximal 
levels 12 hours post-stimulation and remaining for up to 48 hours, with levels 
returning to basal by 72 hours. 
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Fig. 27 TGF-α induces S100A14 mRNA in 9442 cells. 9442 cells were grown for 
3 days in regular culture medium and then treated for the indicated times with 
20 ng/ml of TGF-α without medium change. 10 µg of total RNA was size-fractionated 
followed by Northern blot analysis. S100A14 cDNA sequence was 32P-labelled and 
used as a probe for hybridization. 18S RNA was used as a loading control. 
S100A14 was also induced in response to fresh medium or “stimulation medium” 
showing a maximal level at 6 hours (Fig. 28). Notably, the induction was less 
potent than in response to EGF. 
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Fig. 28 Up-regulation of S100A14 expression in 9442 cells after stimulation 
with fresh medium. 9442 cells were grown for 3 days in regular culture medium and 
then incubated for the indicated times with fresh medium. Northern blot analysis was 
performed using 32P-labelled S100A14 cDNA probe for the detection. 18S RNA was 
used to correct for equal loading. 
It was of interest to determine whether the minimal positive promoter element, 
which we identified, confers EGF responsiveness to the luciferase reporter gene. 
Treatment of the p2C-luc-transfected HEK 293 and Lovo cells with EGF revealed 
no significant induction of the promoter fragment (data not shown). 
The up-regulation of S100A14 by EGF was examined at the protein level by 
Western blotting of the whole cell lysates. The cells were collected 24 hours after 
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stimulation with EGF. We did not, however, detect any substantial changes in 
S100A14 protein level even after increasing the EGF concentration (Fig. 29). 
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Fig. 29 S100A14 protein is not induced following treatment with EGF. 9442 
cells were grown for 3 days in regular culture medium and then treated with 1-100 
ng/ml of EGF for 24 hours without medium change. 10 µg of whole protein extracts 
were subjected to SDS-PAGE followed by Western blot analysis using anti-S100A14 
antibody. β-actin was used as a loading control. 
3.6.1 Effects of Signalling Pathways Inhibition on Activation of S100A14 by 
EGF 
The major downstream signalling pathways triggered by activated ERBB receptors 
are ERK1/2 mitogen-activated protein kinase (MAPK), stress-activated protein 
kinase/c-JUN NH2-terminal kinase (SAPK/JNK), p38 MAPK, and 
phosphatidylinositol 3’-kinase (PI3K) pathways. To assess which signalling 
pathway(s) mediated the stimulatory effect of EGF on S100A14 we applied several 
pharmacological agents to inhibit these pathways.  
First, kinetics of the growth factor-induced response was determined for the 
three MAPK signalling pathways (ERK1/2, p38, JNK) and the PI3K cascade in 
order to establish the stimulation efficacy and the optimal treatment time. Immuno-
blotting with the respective antiphospho antibodies revealed that growth factor 
stimulation caused a significant increase in ERK1/2 activation which remained on 
a steady level over a period of 120 min (Fig. 30A). The p38 signalling pathway was 
also markedly activated reaching a maximal induction level between 5 and 30 min 
after treatment with levels returning to basal by 120 min (Fig. 30B). Mitogen 
exposure also enhanced the phoshorylation and activation of the JNK MAPK 
cascade in these cells with maximal response at 5 to 15 min after stimulation 
(Fig. 30C). Remarkably, growth factor treatment had no effect on the activation of 
AKT suggestive of a constitutive activation of the PI3K pathway in these cells 
(Fig. 30D).  
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Fig. 30 Kinetics of the growth factor-induced response for the ERK1/2, p38, 
and JNK MAPK pathways and the PI3K cascade. 9442 cells were grown for 3 days 
in regular culture medium. The medium was then replaced with the medium that was 
supplemented with a double set of growth factors (referred to as “stimulation medium”; 
MS). The cells were cultured for the indicated times and harvested. 20 µg of whole 
protein extracts were subjected to SDS-PAGE followed by Western blot analysis using 
A: anti-phospho ERK1/2, B: anti-phospho p38, C: anti-phospho SAPK/JNK, and D: 
anti-phospho AKT antibodies. β-actin, p38, SAPK/JNK, and AKT were used as loading 
controls, respectively. 
Next, we examined the inhibitory efficacy of various pharmacological agents on 
activation of the intracellular signalling pathways triggered in response to EGF. 
U0126 (MEK1 and MEK2 inhibitor) markedly suppressed growth factors-induced 
ERK1/2 activation in 9442 cells (Fig. 31A). AG1478 (ERBB receptor tyrosine 
kinase inhibitor) also markedly attenuated ERK1/2 phosphorylation (Fig. 31B). The 
suppressive efficacy of SB203580 (p38 kinase inhibitor) on the p38 MAPK 
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pathway and SP600125 (JNK kinase inhibitor) on the JNK pathway was confirmed 
by the ability to block the activation of their downstream targets: HSP27 and 
c-JUN, respectively. This was determined by immunoblotting with the respective 
antiphospho antibodies (Fig. 31C, D). Pretreatment with LY294002 (a PI3K 
inhibitor) only partially inhibited the response to growth factors (Fig. 31E). 
Increasing concentration of the inhibitor failed to alter the inhibitory response in 
these cells. 
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Fig. 31 The inhibitory efficacy of various pharmacological agents on activation 
of the ERK1/2, p38, and JNK MAPK pathways and the PI3K cascade. 9442 cells 
were grown in regular medium for 3 days and then preincubated for 1 hour with 
A: 20 µM U0126, B: 10 µM AG1478, C: 40 µM SB203580, D: 40 µM SP600125, and 
E: 40 µM LY294002, respectively, without medium change. Next, the cells were 
stimulated with the medium that was supplemented with a double set of growth factors 
(referred as “stimulation medium”; MS) for 10 min (A), 10 min (B), 5 min (C), 5 min (D), 
and 10 min (E). As negative controls, cells were treated with the vehicle: DMSO (A, B, 
C, D) or ethanol (E). 20 µg of whole protein extracts were subjected to SDS-PAGE 
followed by Western blot analysis using anti-phospho ERK1/2 (A, B), anti-phospho 
HSP27 (C), anti-phospho c-JUN (D), and anti-phospho AKT (E) antibodies. β-actin, 
p38, c-JUN, and AKT were assayed as loading controls. 
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To delineate the pathways involved in S100A14 mRNA induction we treated 9442 
cells with the MAPK and the PI3K pathway inhibitors prior to EGF stimulation. 
Treatment with LY294002 does not abrogate growth factor-dependent induction of 
S100A14 mRNA (Fig. 32A). Its expression was also unaffected by SB203580 and 
SP600125 inhibitors. In contrast with this result, U0126 completely abrogated 
EGF-induced S100A14 mRNA expression at the time of optimal gene induction 
(after 12 hours) and this treatment reduced mRNA levels to those seen in 
unstimulated cells (Fig. 32B). To examine whether the intact tyrosine kinase 
activity of the EGF receptor was necessary for the EGF-induced S100A14 
expression, cells were preincubated with AG1478. AG1478 completely prevented 
EGF-induced S100A14 up-regulation (Fig. 32B). None of the concentrations of the 
inhibitors that were used in this study caused cell detachment or cell death.  
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Fig. 32 ERK1/2 MAPK signalling pathway determines S100A14 induction 
following stimulation with EGF. 9442 cells were grown in regular medium for 3 days 
and then preincubated for 1 hour with A: 40 µM SP600125, 40 µM SB203580, 40 µM 
LY294002, B: 20 µM U0126, and 10 µM AG1478, respectively, without medium 
change. As negative controls, cells were treated with the vehicle: DMSO or ethanol. 
Next, the cells were stimulated with 50 ng/ml of EGF for 12 hours and harvested. 
10 µg of total RNA was size-fractionated followed by Northern blot analysis using 
32P-labelled S100A14 cDNA probe for the detection. 18S RNA was used to correct for 
equal loading. 
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These results demonstrated that ERK1/2 MAPK signalling plays a prominent role 
in regulation of S100A14 transcript in response to growth factors.  
No inhibition of S100A14 protein was detected following treatment with the 
U0126 and AG1478 inhibitors (data not shown). Experiments included both whole 
cell lysates as well as subcellular fractionated lysates (membrane and soluble 
fraction). Similarly, no shift in the S100A14 subcellular localization was observed 
and S100A14 remained compartmentalized to crude membrane and soluble 
fractions upon induction by EGF, as determined by Western blotting with anti-
S100A14 antibody (data not shown). 
3.6.2 EGF-Induced S100A14 Gene Expression is Dependent on de novo 
Protein Synthesis  
To further investigate the mechanisms of EGF-mediated S100A14 transcriptional 
activation, we employed cycloheximide (CHX) – an inhibitor of protein synthesis. 
Pretreatment of cells with CHX led to a partial reduction in the EGF-induced 
S100A14 mRNA levels in a dose-dependent manner (Fig. 33). Based on this 
result, we concluded that the induction of S100A14 following EGF treatment 
requires a new protein synthesis. Therefore, S100A14 is likely to be an indirect 
transcriptional target of EGF signalling and it is conceivable that the synthesis of 
other protein(s) is involved in its transcriptional activation. 
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Fig. 33 EGF-induced S100A14 expression is dependent on de novo protein 
synthesis. 9442 cells were grown in regular medium for 3 days and then 
preincubated for 1 hour with 2, 5, and 10 µg/ml of cycloheximide (CHX), respectively, 
without medium change. As negative controls, cells were treated with the vehicle 
DMSO. Next, the cells were stimulated with 50 ng/ml EGF for 12 hours and harvested. 
10 µg of total RNA was size-fractionated followed by Northern blot analysis using 
32P-labelled S100A14 cDNA probe for the detection. 18S RNA was used as a loading 
control. 
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PMA induced S100A14 mRNA in 9442 cells reaching a maximal level by 12 
hours and returning to a level slightly above basal by 24 hours (Fig. 34A). The 
kinetics of this response paralleled the time course of the EGF effect, although 
PMA was less potent than EGF in inducing S100A14. 
3.7 Transcriptional Induction by Protein Kinase C 
Screening for transcriptional modulators of S100A14 revealed phorbol ester 
12-myristate 13-acetate (PMA) as a potential activator of the gene. PMA acts as a 
specific agonist of both conventional and novel protein kinase C (PKC) 
isoenzymes activation. The phospholipase Cγ – PKC pathway is well known to be 
coupled to activation of ERBB receptors and PKC has often been implicated as a 
mediator of ERBB receptor transactivation. The involvement of PKC was therefore 
investigated to determine whether PKC could mediate S100A14 mRNA induction.  
To confirm that S100A14 induction in response to PMA was PKC-dependent, 
we tested the ability of the PKC inhibitor bisindolylomaleimide I to block PMA-
stimulated S100A14 induction. As demonstrated in Fig. 34B, bisindolylomaleimide 
I (5 µM) did not abrogate S100A14 induction in response to PMA.  
The ability of PMA to cause the phosphorylation and activation of ERK1/2 
MAP kinases is well established and has been shown to depend upon PKC-
mediated activation of upstream elements of the ERK1/2 MAPK pathway, 
including RAS and RAF-1. We therefore addressed the question whether PMA 
had the capacity to activate the ERK1/2 MAPK pathway in 9442 cells. PMA 
induced a rapid increase in the amount of phospho-ERK1/2 in 9442 cells and this 
activation continued for at least 60 min (Fig. 34C). To determine whether the PMA-
induced increase in S100A14 mRNA also depends upon the activation of ERK1/2, 
we stimulated 9442 cells with PMA and tested by Northern blot analysis the ability 
of U0126 to inhibit S100A14 mRNA. In the presence of U0126, the S100A14 
mRNA level decreased to slightly above pre-stimulation level (Fig. 34B). 
The ability of both EGF and PMA to stimulate ERK1/2 activity in 9442 cells 
could suggest that the capacity of EGF to stimulate S100A14 might be PKC-
dependent. We therefore tested the effect of the PKC inhibitor on S100A14 
induction in response to EGF. Pretreatment of cells with bisindolylmaleimide I did 
not significantly influence S100A14 up-regulation in response to EGF suggesting 
that the induction is not mediated by PKC (Fig. 34D).  
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Fig. 34 PMA exerts stimulation of S100A14 via PKC activation. 9442 cells were 
grown for 3 days in regular culture medium. A: The cells were then treated without 
medium change with 100 nM of PMA for the indicated times and harvested for 
Northern blot analysis. B: The cells were preincubated for 1 hour with 5 µM of 
bisindolylomaleimide I (BIS) or 20 µM of U0126, respectively, without medium change. 
As negative controls, cells were treated with the vehicle DMSO. Next, the cells were 
stimulated with 100 nM of PMA for 12 hours and harvested. 10 µg of total RNA was 
size-fractionated followed by Northern blot analysis using 32P-labelled S100A14 cDNA 
probe for the detection. 18S RNA was used as a loading control. C: The cells were 
stimulated without medium change with 10 and 100 nM of PMA for the indicated times 
and harvested. 20 µg of whole protein extracts were subjected to SDS-PAGE followed 
by Western blot analysis using anti-phospho ERK1/2 antibody. β-actin was used as a 
loading control. D: The cells were preincubated for 1 hour with 5 µM of 
bisindolylomaleimide I (BIS) without medium change. Next, the cells were stimulated 
with 100 nM of PMA or 50 ng/ml of EGF, respectively, for 12 hours and harvested. As 
negative controls, cells were treated with the vehicle DMSO. Northern blot analysis 
was performed using 32P-labelled S100A14 cDNA probe for the detection. 18S RNA 
was used as a loading control. 
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4 Discussion  
4.1 Identification of the S100A14 cDNA  
This study was undertaken in order to identify tumour-associated genes with 
potential application in the detection or treatment of the disease. For this purpose, 
suppression subtractive hybridization (SSH) was performed using cDNA 
synthesized from normal human bronchial epithelial cells and cells derived from a 
metastatic small cell lung carcinoma (Difilippantonio et al., 2003). 
SSH was developed by Diatchenko and colleagues (Diatchenko et al., 1996) 
providing a powerful approach for identification of genes differentially expressed in 
one cell population compared to another. The technique has been successfully 
used in many experimental settings and two important applications are differential 
gene expression in multiple tumour systems and identification of tumorigenesis 
relevant genes. Although cDNA microarrays are increasingly used for the global 
analysis of gene expression, SSH is still widely applied. It not only permits 
identification of tumour-associated genes with known function but also unbiased 
isolation of novel sequences that are not yet available on microchips. Moreover, it 
enables the recovery of abundant as well as low-copy-number mRNA transcripts.  
Using this approach, we recovered a set of genes differentially expressed in 
lung tumour cells compared to normal lung cells. These genes then provided the 
groundwork for identifying unknown transcripts with diagnostic and prognostic 
value for cancer. In this set of cDNAs, it was then confirmed that one of the under-
represented transcripts, with no homology to any known gene, was differentially 
expressed in a panel of lung tumour cell lines. Hence, we decided to analyse this 
transcript more extensively.  
The isolated full-length cDNA is 1067 bp in length and encodes a putative 
protein of 104 amino acids. The predicted protein contains the S100-specific EF-
hand calcium-binding domain and shares the highest sequence homology with 
S100A13. We therefore assigned this unknown transcript as a novel member of 
the S100 gene family and designated it S100A14 (Pietas et al., 2002).  
The S100 protein family forms a growing subfamily of proteins related by 
Ca2+-binding motifs to the EF-hand Ca2+-binding protein superfamily. The 
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members of this family are involved in Ca2+-, Zn2+-, and Cu2+-dependent regulation 
of many cellular processes, including tumour development and acquisition of 
metastatic phenotype (Donato, 2001; Heizmann et al., 2002). The homology to the 
protein family known to be associated with tumorigenesis prompted us to 
investigate the involvement of S100A14 in tumour biology. 
Further analysis of the cDNA sequence revealed that the S100-specific 
N-terminal EF-hand of S100A14 consists of 13 amino acids. This is in contrast 
with the 14 amino acid loop characteristic for the S100 family. However, it should 
still be a functional calcium-binding domain since the critical Glu45 is present 
(Kawasaki et al., 1998). The carboxyl terminal canonical EF-hand, also referred to 
as the high affinity calcium-binding site, seems to be mutated as only 2 out of 6 
conserved amino acid residues are present. The presence of the N-myristoylation 
site at the N-terminus of S100A14 poses the possibility of an interaction with a 
membrane receptor or with the lipid bilayer itself. In contrast to other S100 protein 
family members the deduced protein contains an extended hydrophilic loop at the 
N-terminus spanning at least 17 amino acids. The calculated molecular weight and 
isoelectric point for the S100A14 protein are in accordance with characteristic 
features of the S100 family as small acidic proteins. Also the structural 
organization of the protein based on hydropathy plots is similar to other members 
of the family. 
4.2 S100A14 is Differentially Expressed in Human Tumours 
Expression of S100A14 was found in epithelial cells of a variety of tissues 
including colon, thymus, kidney, liver, small intestine, lung, breast, cervix, ovary, 
uterus, pancreas, prostate, rectum, stomach and thyroid gland, most of them 
having mainly an epithelial-parenchymal phenotype. In contrast, most 
mesenchymal-stromal tissues like skeletal muscle, white blood cells and spleen 
are negative (Fig. 5). This is largely consistent with our database searches 
indicating many S100A14-related ESTs present in libraries of normal as well as 
tumour tissue such as squamous cell carcinoma of the skin, colon, stomach and 
pancreas adenocarcinoma as well as uterus and lung cancers. Normal tissues 
were additionally represented by head and neck as well as placenta. In contrast, 
we did not observe detectable mRNA expression in placenta even after prolonged 
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exposure indicating that the expression level of the protein must be very low (data 
not shown). We found mouse S100a14 transcript mainly in libraries of embryonal 
origin. 
We were primarily interested in identifying transcripts differentially expressed 
in a wide range of tumours. Differential expression of S100A14 was therefore 
confirmed by Northern blot analysis of various immortalized and tumour cell lines 
from different tissues. S100A14 was abundantly expressed in cells cultured from 
normal human epithelial cells, moderately expressed in immortalized epithelial 
cells, and absent from most of the examined tumour cell lines. The relatively high 
S100A14 expression in most of the colon tumour cell lines could be due to its high 
basal expression level in normal colon tissue. These results indicate that altered 
S100A14 expression occurs in most of the human tumour cell lines. Therefore, we 
hypothesized that its expression might be also suppressed in primary tumour 
tissue.  
Using the BD Biosciences array with 241-matched tumour/normal cDNA 
samples from individual patients we determined the expression status of S100A14 
in 10 different human tumour types. The gene is preferentially overexpressed in 
ovary, breast, and uterus tumours, and mainly underexpressed in kidney, rectum, 
and colon tumours. Most notably, increased rather than decreased expression of 
S100A14 has been found in lung tumours. The reason for this discrepancy is 
unclear, although it may be due to differences between the cell model system and 
the primary tissue. This highlights the need to supplement cell culture-derived 
transcript abundance data with transcriptional or immunohistochemical analysis of 
primary material. Thus, using immunohistochemistry, we sought to determine 
S100A14 protein expression in lung tumour specimens. Additionally, we examined 
breast tumour samples since this tumour type showed significant S100A14 
overexpression in our transcriptional analysis.  
Whilst normal lung and breast epithelial cells express S100A14 at a low level, 
we observed strong tumour cell-localized cytoplasmic and membranous S100A14 
protein expression in over 60% of the analysed tumour samples. Thus, our 
analysis on the expression of S100A14 in primary tumours differs from the cell 
culture data by demonstrating a consistent and strong overexpression of this gene 
in multiple lung and breast tumour samples. We therefore speculated that the 
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expression of the gene might be modulated by extrinsic factors or by the 
microenvironment in which the cancer cells reside.  
The influence of cell culture conditions on gene expression patterns of 
cultured cell lines is a longstanding concern. Cells grown in culture have unlimited 
access to nutrients under conditions most favourable for growth and proliferation 
and only little exposure to extrinsic factors that modulate growth and 
differentiation, e.g. cytokines. In contrast, cells in a tumour growing in a host tissue 
environment face conditions with more limited nutrients and oxygen and are 
subjected to or benefit from a wide variety of host factors. Recently, global gene 
expression profiling of tumour cells grown in vitro versus the same cells 
transplanted into an in vivo environment (nude mice) have been performed 
(Creighton et al., 2003). This revealed specific up-regulation of one set of genes 
related to cell growth and proliferation when in culture and a different set of genes 
related to cell adhesion, extracellular matrix, growth substances, and 
neovascularization when developing as an in vivo tumour.  
Our expression analysis of nine S100A14-negative lung tumour cell lines 
transplanted into immunodeficient mice as well as spheroides of 2 ovary tumour 
cell lines did not reveal a general re-expression of the gene (Fig. 12). Thus, our 
results cannot imply an essential physiological role of the tumour environment for 
S100A14 expression. The interpretation of this finding remains to be elucidated.  
Our expression analysis also suggests that up-regulation of S100A14 is not a 
universal feature of epithelial cell tumours. A potential mechanism for the 
apparently contradictory role of S100A14 in renal, colon and rectum cancer could 
be context-dependent. Since most genes act within networks, differences in 
S100A14 expression pattern may arise from differences in the expression profile 
of its interacting proteins as well as differential availability of signalling pathways 
involved in its regulation in various cell types. A growing number of genes 
regulated by the relative contributions of specific signalling pathways in a particular 
cell type have been revealed in the recent years as exemplified by S100A2 and 
maspin. S100A2 was found to be frequently down-regulated early in lung cancer 
development (Feng et al., 2001). Supporting these data, a number of expression 
studies implicated this gene as a breast tumour suppressor gene (Liu et al., 2000; 
Wicki et al., 1997). However, contrary to the proposed role of S100A2 as a tumour 
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suppressor protein, it was found to be overexpressed in gastric and ovarian 
tumours (El-Rifai et al., 2002; Hough et al., 2001). 
Maspin (SERPIN B5) was also found to be down-regulated in breast and 
prostate cancer and was suggested to be a suppressor of metastasis (Seftor et al., 
1998). Paradoxically, it was reported that the gene was strongly expressed relative 
to normal tissue in pancreatic tumours (Maas et al., 2001) and lung tumours 
(Heighway et al., 2002). The seemingly contradictory results of S100A14, S100A2 
and maspin suggest that these and other genes perhaps not only behave 
differently in particular tumours, but also that they may play different roles in 
various tissue types and perhaps even within distinct components of a tissue. 
Significant up-regulation of S100A14 in lung and breast tumours directed our 
attention towards its clinical significance in these tumours. Most interestingly, we 
found that S100A14 overexpression was significantly associated with ERBB2 
overexpression in breast tumours.  
The ERBB family of receptor tyrosine kinases (RTKs) couples binding of 
extracellular growth factor ligands to intracellular signalling pathways regulating 
diverse biologic responses, including proliferation, differentiation, cell motility, and 
survival (reviewed in Prenzel et al., 2001; Olayioye et al., 2000; Marmor et al., 
2004). It consists of four receptors: ERBB1 (also called epidermal growth factor 
receptor – EGFR or HER1), ERBB2 (HER2/neu), ERBB3 (HER3), and ERBB4 
(HER4). All the family members have in common an extracellular ligand-binding 
domain, a single membrane-spanning region and a cytoplasmic tyrosine kinase 
domain. A family of ERBB ligands, the EGF-related peptide growth factors, have 
been characterized, including epidermal growth factor (EGF), transforming growth 
factor-α (TGF-α), amphiregulin, heparin-binding EGF-like growth factor, 
betacellulin, epiregulin, and neuroregulins (NRG-1,-2,-3,-4). The binding affinity of 
the EGF-like ligands to various ERBB receptors differs as is their potency to 
induce signalling. No direct ligand for ERBB2 has yet been discovered. However, 
increasing evidence suggests that the primary function of ERBB2 is as a co-
receptor. In fact, ERBB2 is the preferred heterodimerization partner for all other 
ERBB family members and plays a role in the potentiation of ERBB receptor 
signalling. 
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The ERBB RTKs have a broad expression pattern on epithelial, mesenchymal, 
and neuronal cells. Signalling through these receptors plays a critical 
developmental role in inductive cell fate determination in many organ systems. 
This is exemplified by the perinatal (ERBB1) or early embryonic lethality (ERBB2, 
-3, and -4) of knock-out mice as a result of insufficient heart and nervous system 
development (Burden and Yarden, 1997). Furthermore, ERBB RTKs are involved 
in mammary gland development during puberty and pregnancy.  
Ligand binding drives receptor dimerization leading to the formation of both 
homo- and heterodimers. Dimerization consequently stimulates the intrinsic 
tyrosine kinase activity of the receptors and triggers autophosphorylation of 
specific tyrosine residues within the cytoplasmic domain. Each ERBB receptor 
displays a distinct pattern of C-terminal autophosphorylation sites. These 
phosphorylated residues serve as docking sites for signalling effector molecules 
containing Src homology 2 (SH2) or phosphotyrosine binding (PTB) domains. 
Examination of the binding preferences of different effector proteins revealed a 
great deal of overlap in the signalling pathways activated by the four ERBB 
receptors. All ERBB family members apparently utilize the mitogen-activated 
protein (MAP) kinase pathways as the major signalling routes.  
A wealth of clinical data demonstrates the importance of ERBB receptors, in 
particular ERBB1 and ERBB2, in multiple human cancers, including lung, colon, 
breast, prostate, brain, head and neck, thyroid, ovarian, bladder, gliomas, and 
renal carcinoma (Yarden and Sliwkowski, 2001). Several phenomena are 
resposible for hyperactivation of ERBB receptors in tumours, including 
overexpression, amplification, and constitutive activation of mutant receptors or 
autocrine growth factor loops. Most notably, ERBB2 is overexpressed in 20-30% 
of breast and ovarian tumours and its overexpression correlates with tumour 
chemoresistance and poor patient prognosis, yielding a median survival of 
3 years, compared with 6-7 years when unassociated with ERBB2 (Miles et al., 
1999; Witton et al., 2003).  
Due to their frequent overexpression in various cancers and their high 
signalling capacity ERBB receptors are promising targets for therapeutic 
intervention in human cancers. Monoclonal antibodies raised against several 
epitopes of the ERBB1 and ERBB2, as well as EGF and TGF-α blocking 
Discussion  95 
 
 
antibodies, have been validated in the clinic as an ERBB-directed therapeutic 
approach. Herceptin, a monoclonal antibody that targets the extracellular domain 
of ERBB2, was the first target-selective drug raised against an oncogenic cell 
surface receptor and therefore represents the first example of a new era of anti-
cancer therapy. This antibody is now applied in the treatment of metastatic breast 
cancer patients. 
The immunohistochemical detection of ERBB2 in our study (29.3%) is in 
keeping with the reported frequency of the protein overexpression in breast 
cancer. In contrast to a number of previous reports, however, ERBB2 expression 
was not related to oestrogen receptor negativity in our study. 
Immunohistochemical analysis of primary lung and breast tumours revealed 
a significant association between the subcellular distribution of S100A14 and the 
protein abundance. The majority of S100A14-overexpressing tumours displayed 
both plasma membrane and cytoplasmic localization of S100A14 relative to low-
expressing tumours showing predominantly cytoplasmic staining. Also, there was 
a significant correlation between higher-grade (grade 3) lung tumours and 
S100A14 cytoplasmic and plasma membrane localization. Moreover, subcellular 
distribution of S100A14 was related to lung tumour histology. Both cytoplasmic 
and plasma membrane-localized staining were associated with squamous cell 
carcinomas compared to adenocarcinomas detecting cytoplasmic-only S100A14. 
In contrast to this tumour cell plasma membrane localization, normal human 
breast and lung epithelial cells showed exclusively diffuse cytosolic S100A14 
expression (Fig. 8 and Fig. 11). These data suggest that translocation of S100A14 
to the plasma membrane could be unique to cancer cells over normal lung and 
breast epithelial cells and could represent the disease-associated state. 
Many S100 proteins translocate to different cellular compartments in 
response to elevated intracellular Ca2+ and Zn2+ level and this process was shown 
to be cell type specific (Hsieh et al., 2004). Exposure of several different cell lines 
to elevated Ca2+ and Zn2+ level did not affect the subcellular localization of 
S100A14 in our study, suggesting that fluctuations of divalent cations do not 
regulate S100A14 protein distribution. The prevalence and the clinical relevance of 
the plasma membrane relative to cytoplasmic S100A14 distribution remains to be 
established in other tumour types. It is conceivable that the subset of lung and 
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breast cancers that show both plasma membrane and cytoplasmic localization 
define a molecularly different mechanism of regulation on the protein. 
Analysis of cultured cells demonstrated predominantely plasma membrane-
localized endogenous S100A14 (Fig. 14). Most notably, prominent staining at cell 
junctions was detected in several tumour cell lines suggesting a potential role in 
establishing cell-cell contacts. Cellular fractionation of 9442 cells and testing the 
different fractions with anti-S100A14 antibody confirmed the immunofluorescence 
data. S100A14 can be detected in both membrane-bound and soluble forms, 
although the soluble protein is present only in very small amounts (Fig. 15). 
Analysis of cells transiently transfected with epitope-tagged protein showed 
predominantely cytoplasmic and perinuclear localization of the S100A14 protein 
(Fig. 13). This result, however, requires further confirmation by cellular 
fractionation. A challenge of future investigations will be to address whether the 
sites of action of S100A14 are in the cytosol or in membranes.  
4.3 Identification and Characterization of the Genomic Locus of S100A14  
Numerous studies have described frequent alterations of the chromosomal region 
1q21 in tumours where the human S100 gene cluster is located. In order to 
elucidate the rationale for the differential S100A14 expression in tumours, we 
defined its chromosomal localization as well as the nature of its genomic locus in 
size, structure, and sequence of its introns and exons. Furthermore, we analysed 
its immediately upstream regulatory region to get some insights into the regulation 
of the gene. 
The human S100 gene family encodes a set of structurally related proteins 
sharing a common genomic organization of three exons and two introns, with the 
first exon being short and untranslated and the second and third exons containing 
the coding sequence (Fig. 35). Exceptions are S100A5 consisting of four exons 
with exon three and four being the coding ones, S100A4 containing an additional 
alternatively spliced untranslated exon, S100A11 with the coding sequence 
beginning already in the first exon, and S100A16, which is composed of four 
exons and three introns with coding sequence in the third and fourth exon and the 
first and second exon being alternatively transcribed.  
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Unlike other S100 genes, S100A14 contains an additional intron that interrupts the 
sequence encoding the N-terminal part of the protein. Lack of nucleotide sequence 
homology to any of the S100 family members and lack of strong conservation of 
the genomic structure may indicate that S100A14 is less closely related to other 
members of the S100 family.  
S100A1
S100A4
S100A5
S100A11
S100A14
 
Fig. 35 Generic S100 gene structure. A typical S100 gene, e.g. S100A1 is 
composed of three exons (boxes) with exon 1 being not translated (open boxes) and 
exons two and three containing the coding region (black boxes). Exceptions to this 
general rule are depicted below with straight lines in S100A4 indicating alternative 
splicing and arrows indicating the translational start. 
An Alu element belonging to the “young” Alu subfamily (AluY) was identified in the 
direct proximity of the polyadenylation signal in the 3’ UTR reaching beyond the 
genomic locus of S100A14. This family of repetitive DNA has been implicated in 
the stimulation of homologous and non-homologous recombination and triggering 
chromosomal rearrangements (Deininger and Batzer, 1999). The frequent 
involvement of the highly conserved 26-bp core sequence of Alu elements in gene 
rearrangements suggested that this sequence might represent a recombinational 
hotspot (Rüdiger et al., 1995). The Alu element present in the genomic locus of 
S100A14 contains the 26-bp core sequence and therefore might contribute 
specifically to gene rearrangements.  
We mapped S100A14 to the chromosome band 1q21 where 16 other S100 
genes are tightly clustered (Heizmann et al., 2002). This region is known to be 
involved in structural and numerical aberrations in various human tumours 
(Weterman et al., 1996; Gendler et al., 1990). Our Southern blot analysis of 
S100A14-negative as well as S100A14-positive lung cancer cell lines, however, so 
far indicates that the S100A14 gene itself is not affected by rearrangements. 
S100A14 was present in all tumour cell lines examined and showed no detectable 
Discussion  98 
 
 
deletions or gross rearrangements (Fig. 18). Thus, it seems likely that the 
differential expression observed in tumour cell lines is not driven by dramatic gene 
deletions or gross rearrangements. This, however, does not completely rule out a 
possible correlation of S100A14 expression with the frequently observed 
chromosome 1q21 rearrangements in solid tumours.  
It has been previously shown that the chromosome region 1q21-q22 contains 
extended regions of high CpG island density (Wright et al., 2001). Consistent with 
this observation are reports of site-specific methylation associated with 
transcriptional repression in the promoter region of S100A2 in tumorigenic cells 
(Wicki et al., 1997; Lee et al., 1992). Examination of the 5’ upstream region as well 
as introns of S100A14 did not reveal any CpG island. Similarily, we did not 
observe re-expression of the gene in eight lung cancer cell lines on treatment with 
5-aza-2'-deoxycytidine as determined by Northern blot and RT-PCR analysis (data 
not shown). 
In the course of our studies on the genomic organization of S100A14, we 
identified the S100A14 promoter fragment, located within 511 bp upstream of the 
transcription initiation site, and containing constitutive promoter elements (TATA 
box) that might support basal transcription at this promoter. 
The primary aim of our promoter analysis was to determine whether the 
aberrant regulation of S100A14 at the promoter level might be responsible for its 
altered expression in tumours. Therefore, we chose for the transient expression 
analysis HEK 293 cells, which are well established in promoter assays but do not 
express endogenous S100A14, and Lovo cells, which have a high level of 
S100A14 mRNA. Another reason for selecting these cell lines was the high 
transfection efficiency with standard procedures. Using a luciferase reporter 
system, a panel of deletion mutants covering the entire putative promoter fragment 
was constructed in the promoterless pGL3 Basic vector. 
Transient luciferase expression experiments indicated the presence of a core 
promoter located within 196 bp immediately upstream of the major transcription 
initiation site (Fig. 21). The 4.5-fold activation of the promoter fragment in HEK 293 
and Lovo cells compared with the control vector-transfected cells is in accord with 
many previously published promoter analyses supporting the significance of our 
data (Perrais et al., 2002; Nichols et al., 2003; Diaz-Guerra et al., 1997; Bordonaro 
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et al., 2002). Besides a TATA box and an incomplete CCAAT box, consensus 
motifs for transcription factors located within the promoter region included Elk-1, 
RFX-1, SRF, AP-1, CEBP, CHOP, USF, NFκB, and N-myc, many of which are 
associated with proliferative response.  
Site conservation is a good indicator of its functional importance and 
comparative genome sequence analysis (phylogenetic footprinting) can eliminate 
up to 90% of false binding-site predictions (Wasserman and Sandelin, 2004). 
Therefore, we compared the region immediately upstream of the mouse 
orthologue with the 511-bp fragment of the human S100A14 promoter. The 
analysis revealed the presence of two fragments immediately upstream from the 
transcription start site that were conserved in the mouse and the human gene 
(Fig. 22). They encompassed the TATA box and the CAAT sequence. Additionally, 
a potential NFκB consensus motif was conserved in the mouse and the human 
DNA within the minimal promoter fragment but further upstream of the two highly 
conserved promoter fragments. No other sequences matching the further 
upstream consensus transcription factor binding sites related to mitogenic 
response could be detected. 
Thus, the strong conservation between the mouse and the human S100A14 
promoter fragment concerns only constitutive promoter elements that probably 
contribute to the basal activity of the promoter. It is therefore conceivable that the 
respective homologous promoter fragment is present further upstream in the 
mouse promoter or that the regulation of the mouse S100a14 is different from the 
regulation of the human counterpart. 
A potential NFκB transcription factor binding site was conserved in the 
mouse and the human promoter fragment. NFκB has been reported to be involved 
in TNF-α-induced expression of other S100 genes (Joo et al., 2003). Therefore, 
we have analysed the potential role of NFκB in the regulation of the S100A14 
transcription. We found that NFκB could not transactivate S100A14 by co-
transfection experiments with the NFκB subunit p65 and the S100A14 luciferase 
reporter. Similarly, treatment of cells with TNF-α, which induces degradation of IκB 
and translocation of NFκB to the nucleus, did not enhance the S100A14 promoter-
driven reporter gene transcription. Moreover, TNF-α did not induce S100A14 
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expression at the mRNA level in Northern blot analysis. Thus, we found no 
evidence that NFκB transactivates the S100A14 promoter fragment.  
Taken together, our analysis of two cell lines although differing in S100A14 
expression yielded the same activation pattern of the analysed promoter fragment. 
This means that the transcription regulatory region that we identified is most 
probably not the critical determinant of S100A14 expression in tumours. Based on 
these findings, we suggest that a further distal promoter or enhancer confers 
induction to S100A14 and possibly influences its expression in tumours. 
4.4 Oncogenic Signalling Pathways Mediate S100A14 Transcriptional 
Induction 
S100A14 is differentially expressed in many human tumours and its expression is 
enhanced in lung and breast tumours (Pietas et al., 2002). No data pertinent to the 
molecular mechanisms responsible for the regulation of the S100A14 gene are 
available. 
Based on our initial finding that serum stimulation enhanced S100A14 
expression in H322 cells, we reasoned that this effect could be mediated by 
growth factors. In this context, the additional finding of positive correlation with 
ERBB2 overexpression in breast tumours raised the possibility that epidermal 
growth factor (EGF) might function as a positive regulator of the gene. To 
elucidate mechanisms whereby S100A14 expression is enhanced in lung tumours, 
we studied the effects of EGF on S100A14 expression in 9442 human 
immortalized bronchial epithelial cells as well as the signal transduction pathways 
that trigger its expression.  
EGF induced a significant increase in S100A14 mRNA expression in a time- 
and dose-dependent manner in 9442 cells but not in S100A14-negative cell lines 
(Fig. 25 and Fig. 26). This result implies that a low EGF concentration in culture 
media cannot account for the absence of S100A14 transcript in the examined 
negative cell lines. The EGF effects on S100A14 expression were also detected in 
another cell line examined in this study – HMEB, indicating similar transcriptional 
regulation in immortalized breast epithelial cells (Fig. 24).  
Moreover, treatment of 9442 cells with transforming growth factor-α (TGF-α), 
a member of the EGF ligand family that binds to and activates the ERBB receptor, 
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also enhanced S100A14 transcript with similar kinetics to EGF, thus confirming the 
involvement of ERBB receptor signalling in growth factor-induced S100A14 
expression (Fig. 27).  
TGF-α is an essential mediator of oncogenesis and malignant progression. 
Its overexpression in transgenic mice leads to hyperplasia as well as malignancy 
in pancreas and breast tissues (Sandgren et al., 1990). TGF-α also acts as a 
strong collaborator in promoting carcinogenesis by other oncogenes (Sandgren et 
al., 1993) and chemical carcinogens (Takagi et al., 1993). Among the ERBB family 
members, TGF-α binds only to the ERBB1 receptor and is best known as an 
autocrine stimulatory growth factor (Riese et al., 1996). Strong expression of 
TGF-α has been found in 67% of pulmonary adenocarcinomas (Tateishi et al., 
1991) pointing to an important role in non-small cell lung cancer (Rusch et al., 
1997; Fontanini et al., 1998). 
S100A14 was also induced in response to fresh medium or “stimulation 
medium” showing, however, an earlier and less potent maximal response relative 
to the response induced by EGF (Fig. 28). The less potent response in 
comparison to that induced by stimulation with EGF could be due to the lower EGF 
concentration present in the medium than the concentration applied in our EGF-
stimulation experiments (50 ng/ml). In addition, other unknown growth factors 
could contribute to this more rapid stimulation. 
Regulatory promoter regions responsive to EGF or PMA could not be 
identified in this study, neither in the 511-bp fragment nor in the minimal S100A14 
upstream regulatory fragment. This suggests the existence of other cooperative 
elements present at more distant site or in the intervening sequences of the 
S100A14 gene. 
The analysis of S100A14 expression at the protein level did not reveal any 
induction following EGF treatment (Fig. 29). Moreover, treatment with U0126 and 
AG1478 inhibitors also had no impact on the S100A14 protein level as determined 
by Western blotting of whole cell- and fractionated cell-extracts. These findings 
raise the possibility of an additional post-transcriptional regulation of the gene. 
Regulatory elements modulating mRNA half-life are often found within 
3' untranslated regions (3' UTR) (Chen et al., 1995; Hollams, 2002). They include 
AU-rich elements (AREs) that are associated with stabilization-destabilization of 
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the mRNA or hairpin (stem-loop) structure. Binding of a trans-acting factor to these 
elements influences the turnover of the mRNA or its translational efficiency (Baker 
et al., 2000; Ranganathan et al., 2000). AREs are found in the 3' UTR of many 
mRNAs that code for proto-oncogenes, nuclear transcription factors, and cytokines 
e.g. COX-2, p21Waf1, TNF-α, interferon-β, GM-CSF, c-myc, and c-fos (Dixon et al., 
2000; Giles et al., 2003; Wang et al., 1997; Kruys et al., 1989; Han et al., 1990; 
Levine et al., 1993). The 644-bp 3' UTR of S100A14 accounts for over 60% of the 
transcript length suggesting that it might be a target of post-transcriptional 
regulation. 
Although, long tracts of the highly conserved AREs could not be found in the 
3’ UTR of S100A14, we cannot exclude that the few poorly conserved AREs found 
in the 3’ UTR of S100A14 confer post-transcriptional control to its mRNA. 
Moreover, it is possible that sequestration of some factors involved in translation 
that are present in limiting amounts may be responsible for the observed inhibition 
of translation of the S100A14 mRNA. 
The development of efficient and selective inhibitors against protein kinases 
involved in signalling has made significant progress. These inhibitors provide a 
suitable alternative to transfection experiments using dominant-negative mutants 
of protein kinases, in particular for cells which cannot be transfected efficiently in 
culture with standard procedures. In the present study, we used several inhibitors 
to characterize the signalling events involved in EGF-induced expression of 
S100A14 (Fig. 36).  
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Fig. 36 Pharmacological modulation of the ERBB-induced signalling pathways 
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In order to determine the effects of the inhibitors on the signalling cascades we 
first carried out an analysis of the kinetics of the mitogen-induced response for the 
three MAPK signalling pathways (ERK1/2, p38, JNK) and the PI3K cascade in 
9442 cells.  
Growth factor stimulation caused a significant increase in phosphorylation 
and activation of ERK1/2, p38, and JNK kinases but had no effect on the activation 
of AKT, suggestive of a constitutive activation of the PI3K pathway in these cells 
(Fig. 30). The EGF-induced S100A14 expression was inhibited by mitogen-
activated protein (MAP) kinase kinase (MEK) inhibitor U0126 but not by p38, JNK, 
and PI3K pathway inhibitors (Fig. 32). Inhibition of ERBB receptor tyrosine kinase 
activity by AG1478 inhibitor also resulted in a reduction of S100A14 mRNA levels 
to those seen in unstimulated cells, thus confirming the results obtained with the 
MEK1/2 inhibitor. Taken together, these inhibitor studies demonstrate that the 
activation of ERBB tyrosine kinase by its ligands EGF and TGF-α, leads to the 
synthesis of S100A14 mRNA via the activation of the RAS-RAF-MEK-ERK 
signalling pathway. 
The importance of constitutively activated mitogenic signalling pathways in 
oncogenesis is well established. Binding of extracellular growth factor ligands 
couples the ERBB family of receptor tyrosine kinases to intracellular signalling 
pathways regulating diverse biologic responses including proliferation, 
differentiation, cell motility, and survival, all of them implicated in tumorigenesis. 
The RAS-RAF-MEK-ERK pathway is at the heart of signalling networks that 
govern these processes. It may be noted that about 30% of human tumours carry 
RAS gene mutations that may prolong the activation of mitogenic signalling 
pathways (Khosravi-Far and Der, 1994). Of the three genes in this family 
(composed of KRAS, NRAS, and HRAS), KRAS is the most frequently mutated 
member in human tumours, including adenocarcinoma of the pancreas (~70-90% 
incidence), colon (~50%), and lung (~25-50%) (Pellegata et al., 1994; Bos et al., 
1987; Mills et al., 1995). 
Thus, multiple components of mitogenic signal transduction pathways are 
either overexpressed (ERBB receptor family and ligands, and cyclin D1) or 
mutated (KRAS) in cancer, leading to excessive activation of these important 
growth-modulating cascades. We therefore suggest that the involvement of ERBB 
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receptor signalling and the RAS-RAF-MEK-ERK pathway in S100A14 transcript 
regulation links the gene to oncogenic signalling pathways in cancer. Identification 
of target genes of ERBB signalling such as S100A14 may, therefore, prove 
important for a clearer understanding of the output of the ERBB module and 
consequently contribute to future ERBB-directed approaches that are more 
beneficial for cancer treatment. 
S100 family members have been specifically related to the ERBB status in 
breast tumorigenesis including S100A4 and S100P (Perou et al., 2000; Rudland et 
al., 2000; Sorlie et al., 2001; Mackay et al., 2003). S100A4 is a direct target of 
ERBB2 signalling in medulloblastoma cells and levels of ERBB2 and S100A4 are 
tightly correlated in samples of primary medulloblastoma (Hernan et al., 2003). 
The induction involves phosphatidylinositol 3-kinase, AKT and ERK1/2 kinase. 
In this context, it should be noted that signalling by ERBB receptors is 
accompanied in many cell types by a transient increase in the cytosolic 
concentration of Ca2+. This process is mediated by phospholipase Cγ-protein 
kinase C (PLCγ-PKC) pathway (Marmor et al., 2004). PLCγ phosphorylation by 
ERBB1 and ERBB2 results in its activation. PLCγ hydrolyzes phosphatidylinositol 
4,5-biphosphate to generate the second messengers diacylglycerol and inositol 
triphosphate. Binding of inositol triphosphate to receptors on the endoplasmic 
reticulum results in Ca2+ release, which lead to the activation of calcium/ 
calmodulin-dependent protein kinases and phosphatases, including Pyk2 and 
calcineurin. Furthermore, Ca2+ and diacylglycerol activate protein kinase C (PKC), 
resulting in the phosphorylation of a large variety of substrates. PKC also mediates 
a feedback attenuation of the signalling by ERBB receptors due to its capacity to 
phosphorylate ERBBs and to inhibit the receptor’s tyrosine kinase activity (Welsh 
et al., 1991).  
ERBB receptors also play an important role in the regulation of cell motility 
and cytoskeletal reorganization mainly by the recruitment of Ca2+ and 
phosphatidylinositol 4,5-biphosphate (Feldner and Brandt, 2002). Many 
experimental data support the notion that PLCγ is the most important molecule in 
the ERBB2-mediated migratory/invasive ability of certain tumour cells (Brandt et 
al., 1999). Interestingly, ERBB1 homodimers and ERBB1:ERBB2 heterodimers 
differentially modulate the time course of PLCγ activation thereby generating 
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different patterns of oscillations in Ca2+ level (Dittmar et al., 2002). EGF-induced 
breast tumour cell migration was attributed to a transient, rather than sustained, 
activation of PLCγ due to ERBB2 signalling. 
There are multiple ways how EGF signalling could have an effect on the 
expression level of S100A14: 1) direct transcriptional regulation, 2) influence on 
the mRNA stability or 3) indirectly through other transcription factors/signalling 
pathways. We wished to determine which of these mechanisms is responsible for 
EGF-mediated S100A14 transcriptional activation. Although the effect of EGF on 
the stability of S100A14 mRNA was not examined in this study, cycloheximide – 
an inhibitor of protein synthesis – partially blocked S100A14 induction by EGF, 
indicating requirement for de novo protein synthesis (Fig. 33). Therefore, we 
suggest that S100A14 is an indirect transcriptional target of EGF signalling. 
Treatment with the phorbol ester PMA enhanced S100A14 expression in 
9442 cells (Fig. 34A). PMA is a potent tumour promoter as well as a growth 
regulator of many different cell types (Hunter and Karin, 1992). It activates protein 
kinase C (PKC), a ubiquitous family of serine/threonine kinases. These kinases 
play key regulatory roles in a multitude of cellular processes, including 
proliferation, apoptosis, differentiation, cell migration, and adhesion (Mellor and 
Parker, 1998; Lafon et al., 2000; Zhao et al., 2000). The PKC family consists of at 
least 11 isoforms. Specific isoforms are activated, depending on isoform, by Ca2+, 
phospholipids or diacylglycerol generated by phospholipase Cγ (PLCγ) or 
phospholipase D (PLD) from phosphatidylinositol 4,5-biphosphate. 
We used bisindolylomaleimide I which acts as a competitive inhibitor for the 
ATP-binding site of PKC to inhibit PKC in 9442 cells. Bisindolylmaleimide I shows 
high selectivity for PKC-α, -β1, -β2, -γ, -δ, and -ε isozymes with a ranked order of 
potency α>β1>ε>δ (Martiny-Baron et al., 1993). Pretreatment with the inhibitor did 
not significantly affect PMA-induced S100A14 expression in 9442 cells (Fig. 34B). 
The reason for this is unclear considering that the concentration of the inhibitor we 
applied was shown by others to block completely the activity of PKCs in bronchial 
epithelial cells (Reibman et al., 2000; Graness et al., 2002). Furthermore, the 
range of phorbol ester-sensitive isoforms of PKC (PKC-α, -β1, -β2, -γ, -δ, -ε, -η, -θ) 
virtually matches that of isoforms inhibited by bisindolylmaleimide I. Nevertheless, 
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we cannot exclude that the PKC isotypes that are not inhibited or only weakly 
inhibited by the inhibitor are responsible for S100A14 induction.  
We next examined whether EGF-induced stimulation of S100A14 was 
mediated by PKC. Preincubation of cells with bisindolylomaleimide I does not 
prevent the EGF-induced stimulation of S100A14 indicating that this induction is 
not mediated by PKC, in agreement with the finding that EGF activates the 
ERK1/2 cascade in a PKC-independent manner, via the RAS-dependent pathway 
(Boulikas, 1995), see Fig. 34D. 
Previous studies have demonstrated that acute treatment with phorbol esters 
leads to a rapid activation of ERK MAPK in most cell types (Rossomando et al., 
1989). Since PKC is the major target for these tumour promoters, it has been 
implicated in the activation of the ERK MAPK pathway and the consequent 
triggering of cellular responses such as differentiation and proliferation (Mischak et 
al., 1993; Murray et al., 1993). Accordingly, it has been demonstrated that 
members of all three groups of PKC isoforms (conventional, novel, and atypical) 
are able to activate upstream elements of the ERK MAPK pathway, including RAS 
and RAF-1, and the mechanism of activation shows some isotype specificity 
(Schönwasser et al., 1998; Marais et al., 1998). 
We found that PMA indeed induces activation of the ERK1/2 signalling 
pathway in 9442 cells (Fig. 34C). Moreover, MEK1/2 inhibitor – U0126 inhibited 
PMA-induced S100A14 expression indicating that the ERK1/2 MAPK pathway is 
the signalling pathway that targets S100A14 expression in response to PMA 
(Fig. 34B). 
Protein kinase C overexpression is associated with increased tumorigenicity 
and metastatic potential in several experimental models, and its activity is 
increased in tumours of breast and lung as compared with their normal counter-
parts (Blobe et al., 1994; O’Brian et al., 1989; Clegg et al., 1999). The essential 
role of PKC in processes relevant to neoplastic transformation and tumour 
invasion renders it a potentially suitable target for anticancer therapy (Basu, 1993). 
PKC-α, an important tumour-promoting factor is currently being studied as a target 
in treating patients with cancer.  
In summary, our results demonstrate that PMA exerts stimulation of S100A14 
via PKC activation in 9442 cells. We also show that the PMA-induced S100A14 
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expression in 9442 cells requires activation of the ERK1/2 MAPK pathway. 
Overexpression of PKC in lung and breast tumours could therefore contribute to 
the enhanced expression of S100A14 in these tumours. Our data also indicate that 
both PKC- and ERBB-dependent signalling converge on the ERK1/2 cascade to 
regulate the expression of S100A14 and are probably necessary for its full activity 
(Fig. 37). 
PKCRAF
ERK1/2
MEK1/2
RAS
S100A14
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Fig. 37 Schematic representation of the signalling pathways leading to 
S100A14 up-regulation in response to EGF and PMA in 9442 cells 
A recent study of the protein arylation targets in human bronchial epithelial cells 
dosed with 1,4-benzoquinone (BQ) and 1,4-naphthoquinone (NQ), common 
tobacco smoke and environmental pollutants, revealed that the S100A14 protein 
was one of the major cellular targets (Lamé et al., 2003). 
Many quinonoid compounds are reactive electrophiles capable of causing 
cellular injury by two mechanisms: 1) direct disruption of the function of critical 
proteins or regulatory pathways, or 2) secondary activation of the immune system 
by the modified protein. For quinonoid compounds, a third mechanism might be 
considered where the adducted protein acts as a platform for quinone redox 
cycling producing reactive oxygen species that in turn damage the protein and its 
surrounding environment, including oxidative DNA damage. The toxicity of 
arylating quinones can be magnified by the redox cycling properties of quinone 
metabolites, e.g. glutathione (GSH) conjugates. 
Specifically, Lamé and his collegues, found that S100A14 protein formed 
substantial amounts of adducts with BQ and NQ, as well as with GSH-BQ on two 
cysteine containing peptides (residues 1-5 and 68-78), providing evidence for a 
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cycle of oxidation of the resulting BQ-GSH conjugate metabolite followed by 
attachment to the protein. Formation of such protein adducts is expected to 
increase the residence time of redox cycling substances and therefore induce 
single and double strand breaks in DNA.  
The finding of the modification of S100A14 protein by quinones is the first 
report, to our knowledge, implicating one of the putative functions of this protein. 
Future research aimed at identifying target proteins of S100A14 needs to be done 
to determine further functions of this novel gene and elucidate its role in neoplastic 
transformation.  
 
 
In summary, by analysing a human lung tumour cell line subtraction cDNA library, 
we have identified and characterized a novel member of the human S100 gene 
family that we designated S100A14. It encodes an mRNA that is ubiquitously 
expressed in normal human tissues of epithelial origin. We demonstrated that 
S100A14 transcript is down-regulated in many immortalized and tumour cell lines 
from different tissues. In contrast, studies on human primary tumours, including 
lung and breast, revealed predominantly up-regulation of the gene at the mRNA 
and protein level.  
We mapped the S100A14 gene to a region of chromosomal instability on 
human chromosome 1q21 and subsequently resolved the gene structure of 
S100A14 in human by demonstrating its organization of four exons and three 
introns spanning a total of 2165 bp of genomic sequence. By analysing the 
5’ upstream proximal region of the S100A14 gene, we identified and characterized 
the minimal promoter fragment of the gene. 
Studies on regulation of S100A14 in 9442 immortalized bronchial epithelial 
cells identified it as a growth factor-inducible gene that is induced by epidermal 
growth factor (EGF) and transforming growth factor-α (TGF-α). EGF-mediated 
transcriptional induction of S100A14 depends on extracellular signal-regulated 
kinase (ERK1/2) signalling and requires de novo protein synthesis. In support of 
these findings, we demonstrated co-existence of ERBB2 overexpression and 
S100A14 protein accumulation in primary breast tumours. 
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Further studies identified phorbol ester 12-myristate 13-acetate (PMA) as an 
activator of S100A14 in 9442 cells suggesting regulation by protein kinase C 
(PKC). The PMA-induced S100A14 expression is mediated by activation of the 
ERK1/2 signalling cascade indicating that both PKC- and ERBB-dependent 
signalling converge on the ERK1/2 cascade to regulate the expression of 
S100A14. Considering the frequent incidence of aberrant activation of the ERK1/2 
and PKC signalling pathways in tumours as well as their oncogenic potential we 
suggest that it is the impaired regulation of these signalling cascades that couples 
S100A14 to malignant transformation. 
The challenge of future investigations will be to define the binding partners of 
S100A14 to determine the function of this novel gene in cancer, and to further 
elucidate the functional importance of ERBB- and PKC-dependent signalling for 
the S100A14 gene regulation. 
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